NATIONAL CANCER REGISTRY
السجل الوطني للسرطان

Cancer in Lebanon: 2005 - 2007

تقرير السرطان في لبنان: ٢٠٠٥ - ٢٠٠٧

Ministry of Public Health
Directorate of Prevention
Epidemiological Surveillance Program

National Cancer Registry - Report 2005-2007

Introduction

In Lebanon, cancer diseases constitute a major health burden. The national annual incidence rate is among the highest in the EMR0 region, and is rather similar to the rates in industrialized countries.

Given its importance, the information provided by the National Cancer Registry (NCR) helps improving our knowledge on cancer occurrence and characteristics, guides prioritizing public health measures, monitoring trends, and enables us to evaluate the control programs.

This report is the Ministry of Public Health's third official NCR report covering the years 2005, 2006, and 2007.

In the future, it is recommended that more surveillance activities be conducted, such as mapping cancer cases and conducting survival analysis for priority cancer sites.

Finally, I would like to commend the efforts of the NCR committee chaired by the Director General, and the work of the Epidemiological Surveillance Program; and to thank all health professionals working in hospitals, laboratories, funding agencies and scientific societies, who contributed to this national endeavor as well as the WHO and the Italian Cooperation for their valuable support.

The Minister of Public Health

Ali Hassan Khalil

Acknowledgments

ITALIAN COOPERATION IN LEBANON

LEBANESE SOCIETY OF MEDICAL ONCOLOGY

LEBANESE SOCIETY OF PATHOLOGY

LEBANESE SOCIETY OF HEMATOLOGY

LEBANESE CANCER SOCIETY

LEBANESE EPIDEMIOLOGICAL ASSOCIATION

Contributors

NCR committee

Dr Walid Ammar (Chairman)
By alphabetical order
Dr Miguel Abboud
Dr Salim Adib
Dr Ali Bazarbachi
Dr Antoine Checrallah
Dr Michel Daher
Dr Azzam Dandachi
Dr Fadia Elias
Dr Marwan Ghosn
Dr Nada Ghosn
Dr Rasha Hamra
Dr Rahif Jalloul
Dr Oussama Jaradi
Dr Joseph Kattan
Dr Assaad Khoury
Dr Alissar Rady
Dr Ali Shamseddine

Capture system:

MOPH/Quarantina Drug Center: Dr Khitam Chehadeh & team
MOPH/Drug Committee: Dr Fadia Elias
MOPH-WHO/Quarantina Database: Mr Houssam Shammaah

Recapture system: (*by alphabetical order)*

Dr Akram Ahdab Laboratory
Dr Abdul Rahman Annous Laboratory
Dr Fadi Assy Laboratory
American University Hospital
Bahman Hospital
Beirut Governmental Hospital / Rafic Hariri University Hospital
Dr Abdel Magid Chehal Laboratory
Dr Mohamed Charafeddine Laboratory
Clemenceau Medical Center
Dar Amal Hospital
Hammoud Hospital
Dr Khalid Habib Laboratory
Ragheb Harb Hospital
Hopital Hotel Dieu de France
Institut National de Pathologie
Dr Nawaf Jurdi Laboratory
Khoury General Hospital (Zahleh)
Hopital Libano-Français
Makassed General Hospital
Mutuelle des Fonctionnaires de l'Etat
Hopital Notre Dame du Liban
Hopital Notre Dame du Secours
Rassoul Azam Hospital
Riyak Hospital
Hopital Rizk
Sahel General Hospital

Hopital Saint-Georges Orthodoxe
Tel Chiha Hospital
Zahraa Hospital

NCR/MOPH team:
Dr Nada Ghosn (team leader)
Dr Houeida Amine
Mr Wissam Nasser
Ms Majd Saleh
Mr Ahmad Saleh
Ms Joumana Mansour
Ms Iman Chamas
Mrs Chirine Hassounah
Mrs Olga Irani
Mrs Nathalie Melhem
Mrs Rana Ghosn

Report Preparation:
Dr Nada Ghosn
Dr Salim Adib
Mr Wissam Nasser
Ms Majd Saleh

Table of contents

1. Historical background 1
2. Definitions and Objectives 1
3. Methods 1
3.1 Event case definition 1
3.2 Data collection 2
3.2.1 The capture system 2
3.2.2 The recapture system 2
3.2.3 Reporting form 2
3.3 Medical coding 2
3.3.1 General coding 2
3.3.2 Pediatric cancers 4
3.4 National Database 4
3.5 Data validation 5
3.5.1 Duplicates 5
3.5.2 Missing data 5
3.5.3 Detecting and correcting inconsistent data 5
3.6 Denominators for rate estimation 5
3.6.1 Data sources 5
3.6.2 Final denominator estimates for the NCR 6
3.7 Data analysis 6
3.7.1 Formula for the annual crude incidence rate 6
3.7.2 Formula for annual age and gender-specific incidence rate 6
3.7.3 Formula for annual age standardized incidence rate (ASR) 7
3.7.4 Target tables for all ages 8
3.7.5 Target tables for pediatric cases 8
3.8 Dissemination of data 8
3.8.1 Electronic reports 8
3.8.2 Annual reports 8
4. Results 9
4.1 Sources of cancer data 9
4.2 Total counts 9
4.3 Completeness of data 9
4.4 Distribution by gender and age group 9
4.5 Crude incidence rates 9
4.6 Age-specific incidence rates 10
4.7 Age-standardized incidence rate 10
4.8 Anatomical cancer sites for males 10
4.9 Anatomical cancer sites for females 10
4.10 Demographic and morphological characteristics for major cancer sites 10
4.10.1 Stomach (C16) 10
4.10.2 Colon-rectum (C18-C20) 10
4.10.3 Liver (C22) 11
4.10.4 Pancreas (C25) 11
4.10.5 Trachea, Bronchus and Lung (C33-34) 11
4.10.6 Breast (C50) 11
4.10.7 Cervix Uteri (C53) 12
4.10.8 Ovary (C56) 12
4.10.9 Prostate (C61) 12
4.10.10 Kidney (C64) 12
4.10.11 Bladder (C67) 12
4.10.12 CNS (C70) 13
4.10.13 Thyroid (C73) 13
4.10.14 Leukemia 13

4.10.15 Lymphoma 13
4.11 Pediatric cases 13
4.12 Non-melanoma skin cancers 14
4.13 In situ cancers 14
5. Conclusion 14

List of figures 16

Figure 1: *Distribution of incident cancer cases by age group among males, Lebanon, 2005-2007* 16
Figure 2: *Distribution of incident cancer cases by age group among females, Lebanon, 2005-2007* 16
Figure 3: *Annual cancer incidence rates, Lebanon, 2003-2007, all cancers* 17
Figure 4: *Annual cancer incidence rates, Lebanon, 2003-2007, all cancers excluding non-melanoma skin cancer* 17
Figure 5: *Age-specific cancer incidence rates among males, Lebanon, 2005-2007* 18
Figure 6: *Age-specific cancer incidence rates among females, Lebanon, 2005-2007* 18
Figure 7: *Distribution of cancer by primary site among males, Lebanon, 2005-2007* 19
Figure 8: *Annual cancer incidence rates by primary site among males, Lebanon, 2005-2007* 20
Figure 9: *Distribution of cancer by primary site among females, Lebanon, 2005-2007* 21
Figure 10: *Annual cancer incidence rates by primary site among females, Lebanon, 2005-2007* 22
Figure 11: *Age-specific incidence rates by age group and gender for stomach cancer, Lebanon, 2005-2007* 23
Figure 12: *Age-specific incidence rates by age group and gender for colo-rectal cancer, Lebanon, 2005-2007* 24
Figure 13: *Age-specific incidence rates by age group and gender for liver cancer, Lebanon, 2005-2007* 25
Figure 14: *Age-specific incidence rates by age group and gender for pancreas cancer, Lebanon, 2005-2007* 26
Figure 15: *Age-specific incidence rates by age group and gender for trachea, bronchus and lung cancer, Lebanon, 2005-2007* 27
Figure 16: *Age-specific incidence rates by age group in females for breast cancer, Lebanon, 2005-2007* 28
Figure 17: *Age-specific incidence rates by age group in females for cervical cancer, Lebanon, 2005-2007* 28
Figure 18: *Age-specific incidence rates by age group in females for ovary cancer, Lebanon, 2005-2007* 29
Figure 19: *Age-specific incidence rates by age group in males for prostate cancer, Lebanon, 2005-2007* 29
Figure 20: *Age-specific incidence rates by age group and gender for kidney cancer, Lebanon, 2005-2007* 30
Figure 21: *Age-specific incidence rates by age group and gender for bladder cancer, Lebanon, 2005-2007* 31
Figure 22: *Age-specific incidence rates by age group and gender for CNS cancer, Lebanon, 2005-2007* 32
Figure 23: *Age-specific incidence rates by age group and gender for thyroid cancer, Lebanon, 2005-2007* 33
Figure 24: *Age-specific incidence rates by age group and gender for leukemia, Lebanon, 2005-2007* 34
Figure 25: *Age-specific incidence rates by age group and gender for lymphoma, Lebanon, 2005-2007* 35
Figure 26: *Age-specific incidence rates by age group and gender for non-melanoma skin cancer, Lebanon, 2005-2007* 36
Figure 27: *Estimated Global Age-Standardized Rate for cancer among males, Globocan 2008* 37
Figure 28: *Estimated Global Age-Standardized Rate for cancer among females, Globocan 2008* 38
Figure 29: *Estimated EMR Age-Standardized Rate for cancer among males, Globocan 2008* 39
Figure 30: *Estimated EMR Age-Standardized Rate for cancer among females, Globocan 2008* 40

List of tables 41

Denominators
Table 1: *Population estimates (including Palestinian camps) by age group and gender, Lebanon, 2005* 41
Table 2: *Population estimates (including Palestinian camps) by age group and gender, Lebanon, 2006* 41
Table 3: *Population estimates (including Palestinian camps) by age group and gender, Lebanon, 2007* 42
Summary
Table 4: *Annual cancer distribution, by gender, Lebanon, 2003-2007* 42
Table 5: *Completeness of core variables in NCR database, Lebanon, 2005-2007* 43
Table 6: *Distribution of incident cancer cases among males by age group, Lebanon, 2005-2007* 43
Table 7: *Distribution of incident cancer cases among females by age group, Lebanon, 2005-2007* 44
Table 8: *Mean age of incident cancers by gender, Lebanon, 2005-2007* 44
Table 9: *Cancer crude incidence rates per 100,000 by gender, Lebanon, 2003-2007* 45
Table 10: *Age-specific cancer incidence rates per 100,000 by gender, Lebanon, 2005-2007* 45
Table 11: *Age-standardized cancer incidence rates (ASR) per 100,000 by gender, Lebanon, 2003-2007* 46
Table 12: *Distribution of cancer cases by primary site, males, Lebanon, 2005-2007* 46
Table 13: *Crude (CR) and age-standardized (ASR) cancer incidence rates per 100,000 by primary site, males, Lebanon, 2005-2007* 47

Table 14: *Distribution of cancer cases by primary site, females, Lebanon, 2005-2007* 48
Table 15: *Crude (CR) and age-standardized (ASR) cancer incidence rates per 100,000 by primary site, females, Lebanon, 2005-2007* 49
Stomach cancer
Table 16: *Distribution of stomach cancer by gender and age group, Lebanon, 2005-2007* 50
Table 17: *Annual incidence rates per 100,000 of stomach cancer, Lebanon 2003-2007* 50
Table 18: *Age-specific, crude and age-standardized incidence rates for stomach cancer, Lebanon, 2005-2007* 51
Table 19: *Distribution of stomach cancer by histological group, Lebanon, 2005-2007* 51
Colon-rectum cancer
Table 20: *Distribution of colo-rectal cancer by gender and age group, Lebanon, 2005-2007* 52
Table 21: *Annual incidence rates per 100,000 of colo-rectal cancer, Lebanon 2003-2007* 52
Table 22: *Age-specific, crude and age-standardized incidence rates for colo-rectal cancer, Lebanon, 2005-2007* 53
Table 23: *Distribution of colo-rectal cancer by histological group, Lebanon, 2005-2007* 53
Liver cancer
Table 24: *Distribution of liver cancer by gender and age group, Lebanon, 2005-2007* 54
Table 25: *Annual incidence rates per 100,000 of liver cancer, Lebanon 2003-2007* 54
Table 26: *Age-specific, crude and age-standardized incidence rates for liver cancer, Lebanon, 2005-2007* 55
Table 27: *Distribution of liver cancer by histological group, Lebanon, 2005-2007* 55
Pancreas cancer
Table 28: *Distribution of pancreas cancer by gender and age group, Lebanon, 2005-2007* 56
Table 29: *Annual incidence rates per 100,000 of pancreas cancer, Lebanon 2003-2007* 56
Table 30: *Age-specific, crude and age-standardized incidence rates for pancreas cancer, Lebanon, 2005-2007* 57
Table 31: *Distribution of pancreas cancer by histological group, Lebanon, 2005-2007* 57
Trachea, bronchus, and lung cancer
Table 32: *Distribution of pulmonary cancer by gender and age group, Lebanon, 2005-2007* 58
Table 33: *Annual incidence rates per 100,000 of pulmonary cancer, Lebanon 2003-2007* 58
Table 34: *Age-specific, crude and age-standardized incidence rates for pulmonary cancer, Lebanon, 2005-2007* 59
Table 35: *Distribution of pulmonary cancer by histological group, Lebanon, 2005-2007* 59
Breast cancer
Table 36: *Distribution of breast cancer by gender and age group, Lebanon, 2005-2007* 60
Table 37: *Annual incidence rates per 100,000 of breast cancer, Lebanon 2003-2007* 60
Table 38: *Age-specific, crude and age-standardized incidence rates for breast cancer, Lebanon, 2005-2007* 61
Table 39: *Distribution of breast cancer by histological group, Lebanon, 2005-2007* 61
Cervix uteri cancer
Table 40: *Distribution of cervical cancer by age group, Lebanon, 2005-2007* 62
Table 41: *Annual incidence rates per 100,000 of cervical cancer, Lebanon 2003-2007* 62
Table 42: *Age-specific, crude and age-standardized incidence rates for cervical cancer, Lebanon, 2005-2007* 63
Table 43: *Distribution of cervical cancer by histological group, Lebanon, 2005-2007* 63
Ovary cancer
Table 44: *Distribution of ovary cancer by age group, Lebanon, 2005-2007* 64
Table 45: *Annual incidence rates per 100,000 of ovary cancer, Lebanon 2003-2007* 64
Table 46: *Age-specific, crude and age-standardized incidence rates for ovary cancer, Lebanon, 2005-2007* 65
Table 47: *Distribution of ovary cancer by histological group, Lebanon, 2005-2007* 65
Prostate cancer
Table 48: *Distribution of prostate cancer by age group, Lebanon, 2005-2007* 66
Table 49: *Annual incidence rates per 100,000 of prostate cancer, Lebanon 2003-2007* 66
Table 50: *Age-specific, crude and age-standardized incidence rates for prostate cancer, Lebanon, 2005-2007* 67
Kidney cancer
Table 51: *Distribution of kidney cancer by gender and age group, Lebanon, 2005-2007* 68
Table 52: *Annual incidence rates per 100,000 of kidney cancer, Lebanon 2003-2007* 68
Table 53: *Age-specific, crude and age-standardized incidence rates for kidney cancer, Lebanon, 2005-2007* 69
Table 54: *Distribution of kidney cancer by histological group, Lebanon, 2005-2007* 69
Bladder cancer
Table 55: *Distribution of bladder cancer by gender and age group, Lebanon, 2005-2007* 70
Table 56: *Annual incidence rates per 100,000 of bladder cancer, Lebanon 2003-2007* 70

Table 57: *Age-specific, crude and age-standardized incidence rates for bladder cancer, Lebanon, 2005-2007* 71
Table 58: *Distribution of bladder cancer by histological group, Lebanon, 2005-2007* 71
Central Nervous System (CNS)
Table 59: *Distribution of CNS cancer by gender and age group, Lebanon, 2005-2007* 72
Table 60: *Annual incidence rates per 100,000 of CNS cancer, Lebanon 2003-2007* 72
Table 61: *Age-specific, crude and age-standardized incidence rates for CNS cancer, Lebanon, 2005-2007* 73
Table 62: *Distribution of CNS cancer by histological group, Lebanon, 2005-2007* 73
Thyroid cancer
Table 63: *Distribution of thyroid cancer by gender and age group, Lebanon, 2005-2007* 74
Table 64: *Annual incidence rates per 100,000 of thyroid cancer, Lebanon 2003-2007* 74
Table 65: *Age-specific, crude and age-standardized incidence rates for thyroid cancer, Lebanon, 2005-2007* 75
Table 66: *Distribution of thyroid cancer by histological group, Lebanon, 2005-2007* 75
Leukemia
Table 67: *Distribution of leukemia by gender and age group, Lebanon, 2005-2007* 76
Table 68: *Annual incidence rates per 100,000 of leukemia, Lebanon 2003-2007* 76
Table 69: *Age-specific, crude and age-standardized incidence rates for leukemia, Lebanon, 2005-2007* 77
Table 70: *Distribution of leukemia by histological group, Lebanon, 2005-2007* 77
Lymphoma
Table 71: *Distribution of lymphoma by gender and age group, Lebanon, 2005-2007* 78
Table 72: *Annual incidence rates per 100,000 of lymphoma, Lebanon 2003-2007* 78
Table 73: *Age-specific, crude and age-standardized incidence rates for lymphoma, Lebanon, 2005-2007* 79
Table 74: *Distribution of lymphoma by histological group, Lebanon, 2005-2007* 79
Table 75: *Distribution of lymphoma by site, Lebanon, 2005-2007* 80
Pediatric cancer
Table 76: *Reported pediatric cases by main ICCC-3 groups (age<20) - Lebanon 2005-2007* 81
Table 77: *Reported pediatric cases by ICCC-3 subgroups (age<20) - Lebanon 2005-2007* 82
Non-melanoma skin cancer
Table 78: *Distribution of non-melanoma skin cancer by gender and age group, Lebanon, 2005-2007* 86
Table 79: *Annual incidence rates per 100,000 of non-melanoma skin cancer, Lebanon 2005-2007* 86
Table 80: *Age-specific, crude and age-standardized incidence rates for non-melanoma skin cancer, Lebanon, 2005-2007* 87
Table 81: *Distribution of non-melanoma skin cancer by histological group, Lebanon, 2005-2007* 87
In-situ tumors
Table 82: *Distribution of in-situ tumors by site and year, Lebanon, 2005-2007* 88
General tables per year
Table 83: *Frequency of incident cases by primary site & age group, Lebanon, 2005* 89
Table 84: *Frequency of incident cases by primary site & age group, males, Lebanon, 2005* 90
Table 85: *frequency of incident cases by primary site & age group, females, Lebanon, 2005* 91
Table 86: *Relative proportions of cases by primary site & age group, males, Lebanon, 2005* 92
Table 87: *Relative proportions of cases by primary site & age group, females, Lebanon, 2005* 93
Table 88: *Incidence rates per 100,000 by primary site & age group, males, Lebanon, 2005* 94
Table 89: *Incidence rates per 100,000 by primary site & age group, females, Lebanon, 2005* 95
Table 90: *Frequency of incident cases by primary site & age group, Lebanon, 2006* 96
Table 91: *Frequency of incident cases by primary site & age group, males, Lebanon, 2006* 97
Table 92: *Frequency of incident cases by primary site & age group, females, Lebanon, 2006* 98
Table 93: *Relative proportions of cases by primary site & age group, males, Lebanon, 2006* 99
Table 94: *Relative proportions of cases by primary site & age group, females, Lebanon, 2006* 100
Table 95: *Incidence rates per 100,000 by primary site & age group, males, Lebanon, 2006* 101
Table 96: *Incidence rates per 100,000 by primary site & age group, females, Lebanon, 2006* 102
Table 97: *Frequency of incident cases by primary site & age group, Lebanon, 2007* 103
Table 98: *Frequency of incident cases by primary site & age group, males, Lebanon, 2007* 104
Table 99: *Frequency of incident cases by primary site & age group, females, Lebanon, 2007* 105
Table 100: *Relative proportions of cases by primary site & age group, males, Lebanon, 2007* 106
Table 101: *Relative proportions of cases by primary site & age group, females, Lebanon, 2007* 107
Table 102: *Incidence rates per 100,000 by primary site & age group, males, Lebanon, 2006* 108
Table 103: *Incidence rates per 100,000 by primary site & age group, females, Lebanon, 2007* 109

Acronyms 110

References 111

Appendix I: Reporting system 112
Appendix II: Hospital reporting system 113
Appendix III: NCR committee 114
Appendix IV: NCR form 115

1. Historical background

The National Cancer Registry (NCR) was established in Lebanon in 1995, and its first committee was formed according to Decision 1/1222 as a program at the Ministry of Public Health (MOPH).

Shy progress was observed from 1995 till 2002 due to organizational problems.

In 2002, the NCR became operational and incident cancer notification became mandatory according to MOPH Decision 1/511 (Appendix I). With the collaboration of WHO, the first NCR report "Cancer in Lebanon 2002" was released and was based on passive reporting of cancer cases "capture system".

In 2005, data collection activities received a new boost following MOPH Decision 1/230 (Appendix I). The "Cancer in Lebanon 2003" report was released and included cancer cases both from passive (capture) and active (recapture) reporting.

In July 2007, the NCR was integrated in the Epidemiological Surveillance Program at the MOPH. The third annual report "Cancer in Lebanon 2004; With an update of Cancer 2003" was released in 2008. This report is available on-line at www.moph.gov.lb.

In 2009, the NCR committee was modified according to Decision 1/994 (Appendix III).

During the years 2008 and 2009, data for years 2005-2007 were cleaned and analyzed. In this report, the results of these three years are presented.

NCR activities in Lebanon are largely supported by the Italian Cooperation and the WHO Representation Office in Beirut.

2. Definitions and Objectives

A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place. The purpose of the cancer registry is to provide regular data necessary for the control and prevention of cancer.

The general objectives of the Lebanese National Cancer Registry are:

- To measure cancer incidence and age-specific incidence rates.
- To describe cancer by time, place, persons and disease.
- To provide a national database for further epidemiological research.

3. Methods

3.1 Event case definition

Target cases are:

- Incident cases by year of diagnosis
- Malignant tumors, excluding in-situ tumors as confirmed by histopathology and/or hematology findings
- Cancers of all sites excluding non-melanoma skin cancers

In-situ tumors are analyzed in separate chapters, as well as non-melanoma skin cancers.

3.2 Data collection

Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).

3.2.1 The capture system

The capture system is based on physician's routine reporting of cancer cases. Physician's complete and send NCR form (Appendix III):

1. Directly from their clinic; or
2. Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients

Public social funds: National Social Security Fund, the medical services of the Armed Forces, the Mutuelle des Fonctionnaires, etc … are also required and actually report cases to the NCR.

3.2.2 The recapture system

The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
In 2004, 17 reporting sites were listed for the recapture system.

3.2.3 Reporting form

The reporting form is divided into 4 parts: patient information, tumor registry information, treatment information, and physician information (Appendix IV).

The patient information part asks about the patient's full name, gender, date of birth, place of residence, and place of birth. Nominal reporting is confidential but necessary to avoid duplicate recording. There are no unified ID number in Lebanon which can be used as substitute for names.

The tumor registry information asks about the primary cancer site, its laterality, date of diagnosis, morphology, TNM classification, stage, grade, and whether it is a new or a relapse case.

Treatment information asks about the final treatment type, if there was previous chemotherapy, and the type of treatment planned.

Physician's information are also obtained to allow the registry staff to contact the treating physician when necessary to complete missing data.

3.3 Medical coding

3.3.1 General coding

The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).

The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor [formula 1].

Formula 1: General Structure of ICD-O, 3rd edition

Topography		Morphology		
C_ _.	_	M _ _ _ _	_	_
Site	Subsite	Histology	Behavior	Grade

Source: WHO. International Classification of Diseases for Oncology, third edition. ICD-O-3

3.3.1.1 Topography

It is the code indicating the site and subsite of the cancer case. For example, for lung cancer of the lower lobe, the lung site is coded as 34 and the lower lobe subsite is coded as 3 [Formula 2].

Formula 2: Structure of ICD-O, 3rd edition

Topography		Example on topography	
C_ _.	_	C 34.	3
Site	Subsite	lung	Lowerlobe

Source: WHO. International Classification of Diseases for Oncology, third edition. ICD-O-3

The topography codes are similar to those of the ICD-10 codes with some differences regarding:

- Leukemias, which are coded C42.1 with ICD-O-3
- Lymphomas, which are coded C77 in ICD-O-3
- Mesotheliomas, which are coded according to their topography (pleural or peritoneal...)
- Melanomas, which are coded C42 as skin cancer

3.3.1.2 Morphology

It is a 5 digit code which indicates the histology of a given cancer. The morphology code also specifies the behavior and the grade of the tumor.

3.3.1.3 Behavior

This variable describes the way the cancer behaves in the body, that is whether it is benign (coded 0), uncertain (coded 1), in situ (coded 2), malignant (coded 3), malignant metastatic (coded 6), or malignant uncertain if primary or metastatic (coded 9).

3.3.1.4 Grade

This variable indicates (when relevant) how well differentiated is the cancer: grade I well differentiated (coded 1), grade II moderately differentiated (coded 2), grade III poorly differentiated (coded 3), grade IV undifferentiated (coded 4), and grade not determined (coded 9).

For an adenocarcinoma in situ, well differentiated, in the lower lobe of the lung, the final code is C34.3 M8140/21 [formula 3].

Formula 3: General Structure of ICD-O, 3rd edition

Topography		Morphology		
C34.	3	M 8140	2	1
Site	Subsite	Histology	Behavior	Grade

Source: WHO. International Classification of Diseases for Oncology, third edition. ICD-O-3

3.3.2 Pediatric cancers

For pediatric cancers, the classification is done using the International Classification of Childhood Cancer, third edition ICCC-3. Pediatric cancer cases are classified according to their morphology (histopathology) rather than primary site, as is done for adults.

The classification includes malignant and benign tumors.

There are three hierarchical classifications for coding: level 1 comprising 12 main diagnostic groups, level 2 comprising 47 diagnostic subgroups, and level 3 is an extended and optional division.

The 12 main diagnostic groups in level 1 are:

1. Leukemias, myeloproliferative diseases, and myelodysplastic diseases.
2. Lymphomas and reticuloendothelial neoplasms
3. Central Nervous System (CNS) and miscellaneous intracranial and intraspinal neoplasms
4. Neuroblastomas and other peripheral nervous cell tumors
5. Retinoblastomas
6. Renal tumors
7. Hepatic tumors
8. Malignant bone tumors
9. Soft tissue and other extraosseous sarcomas
10. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads
11. Other malignant epithelial neoplasms and malignant melanomas
12. Other and unspecified malignant neoplasms

Pediatric ages extend from birth to 15. However, in this report, pediatric analysis has also included cases up to age 19. This was done in response to demands from oncologists who are increasingly treating the 15-19 age-groups with the same protocols as younger cases, and finding better results than with adult protocols.

3.4 National Database

All notified cancer cases are entered in the national database regardless of whether the cancer is benign, malignant, in-situ, metastatic, a duplicate, or a same case with multiple sites.

The Lebanese NCR data are entered using Epidata. A special application allows search of duplicates and the generation of automatic descriptive outputs. The files are later exported to Excel, STATA, and SPSS for further analysis.

The architecture of the database is based on the International Agency for Research on Cancer (IARC) CanReg4 variables and format. CanReg4 is a software program released in 2001, and is special for population-based cancer registries to use for data entry and analysis. Its direct use in Lebanon was not possible because of the Arabic formatting of some variables. The application developed for the NCR allows the conversion of ICD-O-3 codes into ICD-10 and ICCC-3 codes for the purposes of the final reporting.

Codes for place of birth and residence are obtained from the Central Administration for Statistics (CAS) in Lebanon.

3.5 Data validation

Data validation encompasses three methods: finding and removing duplicates, finding and completing missing information, and finding information inconsistent with logical or range values and correcting them.

3.5.1 Duplicates

A duplicate is a case with the same primary cancer site entered into the database more than once.
Finding duplicates takes place in two ways:

1. Searching for duplicates before data are entered within the same year, and,
2. Finding duplicates comparing with the previous years before analyzing the data.
   This second verification is to ensure cases entered in one given year are really incident cases.

In historical duplicate cases, the first record is kept and if needed completed with data from later years.

3.5.2 Missing data

Missing information on age, gender, and place of residence, are completed using information from the MOPH-DDC database, which holds a copy of users ID cards.

The missing "age" variable is a limitation of the age-standardization procedure. Should "age" remain missing after all possible remedies have been used, a proxy approach is used to avoid losing data in the standardization. Cases with unspecified ages are distributed among all age groups according to the proportion of cases with known ages, in that same year.

3.5.3 Detecting and correcting inconsistent data

Inconsistent information are detected by cross tabulating:

- topography versus morphology,
- topography versus gender,
- and topography versus age.

3.6 Denominators for rate estimation

3.6.1 Data sources

a) National population estimates

The official source of population estimates for the Republic of Lebanon is the Central Administration for Statistics (CAS). CAS provides official population estimates episodically.
The latest available estimates are those of 2004 and 2007. The population was estimated then at 3,755,034 for 2004 and 3,759,136 for 2007 [Table 1].
These figures do not include the population residing in Palestinian camps. Palestinians residing outside the camps within the Lebanese population are included.
The age and gender profiles of the Lebanese population are derived from CAS figures of 2004 and 2007.

b) National population growth

Population estimates for the intervening years 2005 and 2006 are generated using national growth rates applied to the estimates starting from 2004.
National growth rates for 2004-2005 and 2005-2006 are measured using a baseline growth rate from 1997 CAS survey with a decrement every 5 years. Those figures are provided by the Department of Statistics at the MOPH.

Accordingly, the population estimates (excluding camps population) were 3,810,758 in 2005 and 3,867,500 inhabitants in 2006 [Table 2].

c) UN statistics for the Palestinian population in Lebanon

Statistics related to Palestinians residing inside camps are provided by the UNRWA official annual reports for the mid-year.

The Palestinian population living in camps was reported at 211,593 in 2005, 214,736 in 2005 and 217,441 in 2007 [Table 3]. These numbers are included in the population denominator used by NCR, as those Palestinians are long-term permanent residents in Lebanon.

d) Demographic profile by age and gender

The age and gender profile of the Lebanese population is derived from CAS national surveys of 2004 and 2007 [Table 4].

3.6.2 Final denominator estimates for the NCR

Population estimates with figures per gender and age groups are generated using the above mentioned sources. The population estimates (including camps) used in the NCR report are 4,022,351 in 2005, and 4,082,236 in 2006 and 3,976,577 in 2007. The distribution by age-groups and gender for each year are provided in tables 5, 6 and 7. The decrease in population estimates in 2007 is attributed by CAS to a more accurate counting process, and larger migration of adults in reproductive ages.

3.7 Data analysis

3.7.1 Formula for the annual crude incidence rate

The crude rate is prepared after obtaining the number of new cases for each year, and the total population at risk in that same year.

Formula 4: Crude incidence rate per year

$$\text{Crude Rate CR} = \frac{\text{Number of new cancer cases in one year}}{\text{Population at risk in the same year}} \times 100{,}000$$

The confidence interval is computed using a risk error of 0.05 assuming a Poisson distribution to calculate the variance.

Formula 5: Variance of crude incidence rate

$$\text{Estimated Variance} = \frac{\text{Observed number of new cancer cases in one year}}{(\text{Population at risk in the same year})2}$$

3.7.2 Formula for annual age and gender-specific incidence rate

The age-specific rate is the number of new cases for a specific age-group over the size of that age-group.

Formula 6: Age-specific incidence rate per year

$$\text{Age specific rate} = \frac{\text{Number of new cancer cases for a specific age group, in one year}}{\text{Population for a specific age group at risk in the same year}} \times 100{,}000$$

The gender-specific rate is the number of new cases for a specific gender over the population at risk also for that same gender.

Formula 7: Gender-specific incidence rate per year

$$\text{Gender specific rate} = \frac{\text{Number of new cancer cases for a specific gender, in one year}}{\text{Population for a specific gender at risk in the same year}} \times 100{,}000$$

3.7.3 Formula for annual age standardized incidence rate (ASR)

The direct standardized method is applied.

The WHO-standard world population of 100,000 inhabitants is used with its specific distribution by age-groups. For that standard population, numbers of expected cases for each age-group are computed using the age-specific incidence rates observed in Lebanon. The numbers of expected cases are summed and the total number of expected cases (for all ages) represents the ASR. An example of computation is shown in formula 8.

Formula 8: Computation of age standardized incidence rates (stomach cancer, Denmark, males, 1993-1997)

Age group	Nb of cases	Person-years at risk	Age-specific incidence (per 105 years)	Standard world population	Expected cases in standard population
(i)	d_i	y_i	$10^5(d/y_i)$	w_i	$d_i w/y_i$
0 - 4	0	863,799	0.00	12000	0.00
5 - 9	0	765,274	0.00	10000	0.00
10 - 14	0	710,183	0.00	9000	0.00
15 - 19	1	824,459	0.12	9000	0.01
20 - 24	1	946,843	0.11	8000	0.01
25 - 29	4	1,034,977	0.39	8000	0.03
30 - 34	10	1,040,497	0.96	6000	0.06
35 - 39	16	958,241	1.67	6000	0.10
40 - 44	36	942,690	3.82	6000	0.23
45 - 49	67	1,013,068	6.61	6000	0.40
50 - 54	113	902,693	12.52	5000	0.63
55 - 59	142	691,196	20.54	4000	0.82
60 - 64	197	583,101	33.78	4000	1.35
65 - 69	238	525,292	45.31	3000	1.36
70 - 74	307	455,623	67.38	2000	1.35
75 - 79	262	330,900	79.18	1000	0.79
80 - 84	235	209,558	112.14	500	0.56
85+	126	126,826	99.35	500	0.50
Total	1,755	12,925,220	13.58	100,000	8.19

Source: Bray F.

The final formula is shown below:

Formula 9: Age standardized incidence rate per year

Age standardized rate ASR per 100,000 per annum = $\Sigma\, d_i\, w_i / y_i$

The confidence interval is calculated for a risk error of 0.05 and a variance assuming the Poisson distribution.

Formula 10: Variance of age standardized incidence rate

Estimated Variance of ASR = $\Sigma\, d_i\, (w_i / y_i)^2$

3.7.4 Target tables for all ages

Tables for all ages are prepared based on the cancer primary sites (topography) codes using the ICD-10, and grouped according to IARC methodology.

Metastatic tumors with unknown primary site are coded as unspecified cancer site.

Data are presented by gender and age-groups.

3.7.5 Target tables for pediatric cases

Tables for pediatric cases (<20y) are prepared based on the histopathology (morphology) of ICCC-3. Data are displayed by age-groups.

3.8 Dissemination of data

3.8.1 Electronic reports

Tables on cancer epidemiology are uploaded as soon as available on the MOPH website:
www.moph.gov.lb (→ Prevention → surveillance unit → cancer).

3.8.2 Annual reports

Annual reports can be found on the same website link, and as hard copies at the Ministry of Public Health, Epidemiological Surveillance Program-Central Unit.

The website is www.moph.gov.lb (→ Prevention → surveillance unit → cancer).

The address of the Epidemiological Surveillance Program is: Lebanese Ministry of Public Health, second building (behind the French embassy), 3rd floor. Beirut, Lebanon.

Tel: +961.1.614194
Fax: +961.1.610920
Email: esumoh@moph.gov.lb

4. Results

4.1 Sources of cancer data

For years 2005-2007, 29 sites participated in the data collection process. The total number of records including duplicates entered annually were 9889, 11641, and 13195 respectively. Two sites did not participate in the data collection.

4.2 Total counts

After removal of duplicates, the total number of incident cancer cases excluding non-melanoma skin cancers, was 7406 in 2005, 7969 in 2006, and 8913 cases in 2007 [Table 4].

4.3 Completeness of data

For years 2005-2007, the data completeness was as follows [Table 5]:

- Age: from 91% to 93%
- Gender: from 99%
- District of residence: from 16% to 21%
- Topography of the primary site: from 97% to 98%
- Histology: from 95% to 97%

Lower completeness on residence is associated with the recapture system which provides data from the histology and hematology laboratories. Those laboratories do not usually require place of residence in the request form and do not include it in the laboratory report. Existing data on place of residence are obtained only from the capture system, where patients and physicians fill the NCR reporting form.

4.4 Distribution by gender and age group

The distribution of males to females throughout the years shows an approximately even distribution [Table 4].

For males, the distribution by age shows a consistent progressive increase starting at age 40-45 years, peaking at 65-69 years [Table 6, Figure 1].

For females, there is a rapid increase of the distribution of cases starting 35-39, reaching a plateau in the older age-groups [Table 7, Figure 2].

The mean ages at diagnosis throughout the three years for men and women are relatively stable. In any given year, women had a consistently and significantly younger mean age at diagnosis (mid-fifties) than men (early sixties) [Table 8].

4.5 Crude incidence rates

For all cancer sites (excluding non-melanoma skin cancers), the annual crude incidence rate per 100,000 was 184 in 2005, 195 in 2006 and 224 in 2007 [Table 9].
For males, the increase of the annual crude incidence rate per 100,000 was from 181 in 2005, to 195 in 2006, reaching 227 in 2007.
For females, the annual crude incidence rate per 100,000 was 187 in 2005, 195 in 2006 and 220 in 2007.

4.6 Age-specific incidence rates

Age-specific annual incidence rates increase with age for both genders. The slope of the increase is more rapid in males than in females [Table 10, Figures 5, 6].

4.7 Age-standardized incidence rate

For all cancer sites (excluding non-melanoma skin cancer cases), the annual age-standardized incidence rate per 100,000 was 182 in 2005, 193 in 2006, and 199 in 2007 [Table 11].

4.8 Anatomical cancer sites for males

The three most frequent primary sites in males were: prostate, bladder and bronchus/lung. They represented together 46-49% of all cancers among males. In 2007, the prostate site was observed for 19% of cases, bladder for 16.5% and lung for 14%. The proportion of cancers of unknown sites was 2-3% [Table 12, Figure 7].
In 2007, the highest site-specific incidence rates in 2007 were 43/100,000 for prostate cancer, 37/100,000 for bladder cancer, and 31.5/100,000 for bronchus/lung cancer [Table 13, Figure 8].
From 2005 to 2007, a slight increase was observed for the three top sites. For example, bronchus/lung cancer had an annual incidence rate at 25/100,000 in 2005, 29/100,000 in 2006, and 31.5/100,000 in 2007.
Less frequent yet present are the colorectum cancer (9% in 2007), Non-Hodgkin Lymphoma NHL (6% in 2007), and leukemia (4% in 2007) [Table 12, Figure 7].

4.9 Anatomical cancer sites for females

Breast cancer remained the most relatively frequent cancer throughout the years (42-43%). The annual incidence rate for breast cancer has been increasing from 72/100,000 in 2005, to 87/100,000 in 2007 [Tables 14 & 15, Figures 9 & 10].
Following breast cancer, colorectum (7% in 2007), NHL (6% in 2007), bronchus/lung (6% in 2007) and ovary appeared as most frequent.

4.10 Demographic and morphological characteristics for major cancer sites

Particular analyses were conducted for selected cancers either because of their major case-load (such as breast, bladder, lymphomas), and/or their potential for prevention and early detection (such as colorectum, cervix, larynx, liver) and/or in their local or regional epidemiological particularities (such as ovary, thyroid and kidney).

4.10.1 Stomach (C16)

The number of reported cases of stomach cancer was 229 in 2005, 210 in 2006, and 276 in 2007. In any given year, there were more cases among males, and their age distribution increased dramatically from age 60. The mean age at diagnosis across years was 64 years for males, and varied from 59 to 63 years for females [Table 16].
The annual incidence rate was 5-7 per 100,000. The age-standardized rate was 5-6 per 100,000 [Table 17].
Age-specific incidence rates start increasing from age 35 years [Table 18, Figure 11].
The most frequent histological type was stomach adenocarcinoma (84%) [Table 19].

4.10.2 Colon-rectum (C18-C20)

The number of reported cases of colon and rectum cancers was 583 in 2005, 646 in 2006 and 680 in 2007, with a slight male dominance (55%) and an increasing frequency after age 60. The mean age varied between 61-64 years, with no difference by gender [Table 20].

The annual incidence rate per 100,000 varied between 14.5-17, while the age-standardized rate varied between 14-16 [Table 21].
The age-specific incidence rates for males showed a slight increase starting the age of 30-34 years and accelerated starting the age 50-54 years. For females, the slight increase started at 30-34 years [Table 22, Figure 12].
The most frequent histological type was colo-rectal adenocarcinoma (91%) [Table 23].

4.10.3 Liver (C22)

The number of reported liver cases was 84 in 2005, 97 in 2006 and 123 in 2007, with a slight male dominance (54-66%) and most occurring after age 50. The mean age varied between 59-63 years for males and 58-65 years for females [Table 24].

The annual incidence rate per 100,000 was 2-3. The age-standardized rate per 100,000 was 2-3 [Table 25].
The age-specific incidence rates showed an increase starting the 50-54 age-group [Table 26, Figure 13].
The most frequent histological types were cholangiocarcinoma (69%), followed by hepatocellular carcinoma (26%) [Table 27].

4.10.4 Pancreas (C25)

The number of reported pancreas cancer cases was 143 in 2005, 132 in 2006 and 118 in 2007, equally distributed by gender, and mostly distributed after age 50. The mean age varied between 62-63 years [Table 28].
The annual incidence rate per 100,000 was 3-4. The age-standardized rate was 3-4 [Table 14].
The age-specific incidence rates showed an increase starting the 50-55 age-group [Table 30, Figure 14].
The most frequent histological type of pancreas cancer was adenocarcinoma (91%) [Table 31].

4.10.5 Trachea, Bronchus and Lung (C33-34)

The number of reported lung, bronchus and trachea cases was 702 in 2005, 823 in 2006 and 856 in 2007, predominantly in males (71-72%), with a distribution increasing after 55. The mean age varied between 64-66 years for males and 62-63 years for females [Table 32].
The crude incidence rate per 100,000 varied between 25-31.5 for males, and 9-12 for females.
The age-standardized incidence varied between 25-29 for males, and 10-12 for females [Table 33].
The age-specific incidence rates for males start to increase at age 40-44 years and reach 100 around 60 years. For females, the age-specific rates start to increase around 50 years and continue to increase slowly with age [Table 34, Figure 15].
Non-small cell carcinoma was the most frequent type of lung cancer (85%) [Table 35].

4.10.6 Breast (C50)

The number of reported breast cancer cases was 1466 in 2005, 1641 in 2006 and 1776 in 2007, of which 99% of cases were females. The mean age was 54-55 years for females [Table 36].
The crude incidence rate per 100,000 inhabitants was 72-87 for females, and 1 for males. For females, the rates increased from 2005 to 2007. The age-standardized incidence rate per 100,000 inhabitants was 71-79 for females, and 1 for males [Table 37].

Age-specific incidence rates for females start to increase at 30-35 years, and reach a plateau starting 45-49 years with rates exceeding 200/100,000 [Table 38, Figure 16].
The infiltrating duct adenocarcinomas was the most frequent histological type (62%) [Table 39].

4.10.7 Cervix Uteri (C53)

The number of reported cervical cancer cases was 82 in 2005, 76 in 2006 and 100 in 2007. The mean age was around 53-55 years [Table 40].
The annual incidence rate per 100,000 was 4-5. The age-standardized rate was 4 [Table 41].
The age-specific incidence rates showed a slight increase starting 30-34 age-group, which accelerates starting the 50-54 age-group [Table 42, Figure 17].
Cases are predominantly epidermoid squamous cell carcinomas (60%) [Table 43].

4.10.8 Ovary (C56)

The number of reported ovarian cancer cases was 182 in 2005, 153 in 2006 and 187 in 2007.
The mean age was 54-57 years [Table 44].
The crude incidence rate per 100,000 was 7-9. The age-standardized incidence rate was 7-9 [Table 45].
Age-specific incidence rates increased progressively starting the age of 40-44 age-group [Table 46, Figure 18].
Adenocarcinomas was the most frequent histological type (78%) [Table 47].

4.10.9 Prostate (C61)

The number of reported prostate cancer cases was 607 in 2005, 744 in 2006 and 841 in 2007. The mean age varied around 70 years [Table 48].
The annual incidence rate per 100,000 varied between 30-43, and the age-standardized rate between 29-35 [Table 49].
The age-specific incidence rates showed an acceleration starting the age of 50-54 years [Table 50, Figure 19].

4.10.10 Kidney (C64)

The number of reported kidney cancer cases was 111 in 2005, 123 in 2006 and 142 in 2007, of which 69-75% were male cases. The mean age was 56-59 years for males and 46-58 for females [Table 51].
The annual incidence rate per 100,000 was 3-4, the age-standardized rate was 3 [Table 52].

The age-specific incidence rates showed an acceleration starting 35-39 age-group for males, and 50-54 age-group for females [Table 53, Figure 20].
The most frequent histological type was renal cell carcinomas (75.5%) [Table 54].

4.10.11 Bladder (C67)

The number of bladder cancer cases is 689 in 2005, 726 in 2006 and 910 in 2007, predominantly in males (81-82%). The mean age was 66-68 years with no significant differences by gender [Table 55].
The crude incidence rate increased from 28 to 37 per 100,000 for males, whereas it was 6-9 for females. The age-standardized incidence rate was 28-32 for males, and 6-7 for females [Table 56].
For males, the age-specific rates started to increase from 35-39 age-group and reached 100/100,000 in the 60-64 age-group. Age-specific incidence rates for females started to increase from 40-44 age-group, and showed a progressive increase at later age [Table 57, Figure 21].
In any given year, the majority of cases were transitional cell carcinoma (93%) [Table 58].

4.10.12 CNS (C70)

The number of reported cases of central nervous system cancer was 175 in 2005, 134 in 2006 and 193 in 2007, with a male majority. The mean age varied between 39-42 years for males and 38-46 for females [Table 59].
The annual incidence rate per 100,000 varied between 3-5. The age-standardized rate varied between 3-5 [Table 60].
The age-specific incidence rates showed an increase starting 35-39 age-group [Table 61, Figure 22].
The most frequent CNS cancer type was astrocytic tumor (51%) [Table 62].

4.10.13 Thyroid (C73)

The number of incident cases was 142 in 2005, 178 in 2006 and 212 in 2007, of whom 73-80% of cases are females. The mean age was 45-46 years [Table 63].
The crude incidence rate per 100,000 was 2-3 for males, and 5-8 for females. The age-standardized incidence rate per 100,000 inhabitants was 2-3 for males, and 5-7 for females [Table 64].
Age-specific incidence rates for males, started to increase from 40-44 age-group. For females, the age-specific rates started to increase from 25-29 age-group [Table 65, Figure 23].
The histological findings pointed out the papillary adenocarcinomas as the most frequent (84%) [Table 66].

4.10.14 Leukemia

The number of reported cases of leukemia was 296 in 2005, 345 in 2006 and 333 in 2007. Of these, 56-59% were diagnosed in males. The mean age was 44-46 years for males and 41-49 years for females [Table 67].
The annual incidence rate was 7-8 per 100,000. The age-standardized rate was 8 per 100,000 [Table 68].
The age-specific incidence rates showed a first peak under 5 years, then a relative absence of cases until the age of 30 [Table 69, Figure 24].
The histology patterns showed the following distribution: AML (27%), ALL (23.5%), CLL (20%), and CML (15%) [Table 70].

4.10.15 Lymphoma

The number of incident cases of lymphoma was 660 in 2005, 666 in 2006 and 691 in 2007. Of those, 53-54% were diagnosed in males. The mean age was 50-51 [Table 71].
The crude incidence rate was 18-19 per 100,000 for males, and 15-16 for females. The age-standardized incidence rate was 18 per 100,000 for males, and 14 for females [Table 72].
Age-specific incidence rates started to increase from 20-25 age-group, and continued to increase progressively over age [Table 73, Figure 25].
The histological findings pointed out that 46% of lymphomas were Non Hodgkin Lymphoma, whereas 29% were unspecified lymphomas [Table 74].
As for the site, the most frequent sites were lymph nodes (61%), followed by the digestive organs (11%) [Table 75].

4.11 Pediatric cases

Cases recorded in patients under 20 years of age were 292, 287 and 294 in 2005, 2006 and 2007, respectively [Tables 76 and 77].
The category "Leukemia and myeloproliferative and myelodysplastic diseases" represented about 28% of those pediatric cases in any given year, with an annual average of 84 new cases.
The most frequent types were: lymphoid leukemia (19%), followed by acute myeloid leukemia (5%).
In second position, lymphomas and reticuloendothelial neoplasms represented 20% of pediatric cases.
The annual average was 59 cases. The 3 main types were:

- Hodgkin Lymphoma (10%)
- Non-Hodgkin Lymphoma (5%)
- Burkitt Lymphoma (2%).

In third position, malignant bone tumors represented 12% of cases, with an annual average of 34 cases. Two types were dominant:

- Osteosarcomas (4%)
- Ewing and Askin tumors (4%).

4.12 Non-melanoma skin cancers

The number of reported non-melanoma skin cancer cases was 508 in 2005, 522 in 2006 and 639 in 2007, with a male predominance (60-66%). More than 50% of cases were diagnosed from age 65. The mean age was 68-69 years for males and 63-65 for females [Table 78].
The annual incidence rate was 13-16 per 100,000. The age-standardized rate was 12-13 per 100,000 [Table 79].
The age-specific incidence rates for males, and females, showed a slight increase starting the age of 30-34 years and accelerated starting the age 55-59 years [Table 80, Figure 26].
The specific histological types were basal cell carcinoma (66%) and squamous cell carcinoma (31%) [Table 81].

4.13 In situ cancers

In situ cancers were analyzed separately. They accounted for 75, 104 and 112 cases in 2005, 2006 and 2007, respectively [Table 82].
Breast cancer represented 45% of all in situ cases, followed by bladder (14%), skin (12%) and cervix uteri (7%).

5. Conclusion

With this report, the National Cancer Registry (NCR) has now reported 5 consecutive years of cancer data (2003-2007) in Lebanon. The number of incident cases recorded has been increasing steadily, from just about 7000 cases in 2003 to almost 9000 in 2007. The overall cancer incidence rates have also increased from180 new cases per 100,000 in 2004 to almost 200 by 2007. These trends largely reflect the worldwide situation in cancer incidence.Increases in incidence rates most probably reflect a reality linked to the ageing of the Lebanese population andthe worsening environmental and behavioral risk factors since the 1980s. The age-standardized cancer incidence rate in Lebanon is very likely the highest reported in Arab countriesfor both males and females.

In addition to real worsening cancer dynamics in Lebanon, the upward trends can be partly attributed to improved NCR recording capacity, as increasingly more cancer sites have contributed data to the Registry.

While completeness of recording has improved, so has data quality. One good indicator of data quality is the fact that cancers with "unknown primary sites" have decreased to less than 3% by 2007. Efforts will continue to improve the reporting of cases' demographic and clinical characteristics, with better collaboration required from data providers.

As incident cancer cases have been increasing, so have the numbersregistered with the MOPH Drug Dispensing Center. The average number of prevalent patients receiving drugs for free has exceeded 20,000 per year. The gap between incident and prevalent case-loads suggests that cancer treatment in Lebanon continues to be largely beneficial to patients whose survival is being prolonged hopefully with a final positive outcome. However, this assertion can only verified if NCR is linked to the national mortality statistics, which would allow a quantification of the national survival rates for each type of cancer in particular and for all cancers in general.

Among men, three sites remain in competition for the three most frequent positions, depending on years. These are bladder, lung and prostate cancers. These three sites together compose annually almost 50% of the case-load in men, followed by colorectal cancer and NH lymphoma. In women, breast accounts for about 40% of all cases in any given year, followed by colorectal cancer, NH lymphoma, lung and ovary. The implications of these findings for cancer prevention and early detection should be considered by all stakeholders concerned with cancer prevention and control.

Another important finding with serious preventive implications is the age at which most cancer cases are diagnosed. The number of pediatric cases remained largely constant over a 5-year period, hovering slightly under 300 cases per year. Similarly, cancer in persons aged 70 and beyond composed about 27% of the total case-load in any given year. Consequently, the bulging case-load of incident cancer cases is occurring between ages 21 and 69, which remain the years of productive life for most people. This poses a serious public health challenge which has to be addressed in a global way in the context of a National Cancer Control Program for Lebanon.

Figure 1: Distribution of incident cancer cases by age group among males, Lebanon, 2005-2007



Figure 2: Distribution of incident cancer cases by age group among females, Lebanon, 2005-2007



Figure 3: Annual cancer incidence rates, Lebanon, 2003-2007, all cancers



Figure 4: Annual cancer incidence rates, Lebanon, 2003-2007, all cancers excluding non-melanoma skin cancer



Figure 5: Age-specific cancer incidence rates among males, Lebanon, 2005-2007



Figure 6: Age-specific cancer incidence rates among females, Lebanon, 2005-2007



Figure 7: Distribution (%) of cancer by primary site among males, Lebanon, 2005-2007



Figure 8: Annual cancer incidence rates by primary site among males, Lebanon, 2005-2007



Figure 9: Distribution (%) of cancer by primary site among females, Lebanon, 2005-2007



Figure 10: Annual cancer incidence rates by primary site among females, Lebanon, 2005-2007



Figure 11: Age-specific incidence rates by age group and gender for stomach cancer, Lebanon, 2005-2007





Figure 12: Age-specific incidence rates by age group and gender for colo-rectal cancer, Lebanon, 2005-2007





Figure 13: Age-specific incidence rates by age group and gender for liver cancer, Lebanon, 2005-2007





Figure 14: Age-specific incidence rates by age group and gender for pancreas cancer, Lebanon, 2005-2007





Figure 15: Age-specific incidence rates by age group and gender for trachea, bronchus and lung cancer, Lebanon, 2005-2007





Figure 16: Age-specific incidence rates by age group in females for breast cancer, Lebanon, 2005-2007



Figure 17: Age-specific incidence rates by age group in females for cervix uteri cancer, Lebanon, 2005-2007



Figure 18: Age-specific incidence rates by age group in females for ovary cancer, Lebanon, 2005-2007



Figure 19: Age-specific incidence rates by age group in males for prostate cancer, Lebanon, 2005-2007



Figure 20: Age-specific incidence rates by age group and gender for kidney cancer, Lebanon, 2005-2007





Figure 21: Age-specific incidence rates by age group and gender for bladder cancer, Lebanon, 2005-2007





Figure 22: Age-specific incidence rates by age group and gender for CNS cancer, Lebanon, 2005-2007





Figure 23: Age-specific incidence rates by age group and gender for thyroid cancer, Lebanon, 2005-2007





Figure 24: Age-specific incidence rates by age group and gender for leukemia, Lebanon, 2005-2007





Figure 25: Age-specific incidence rates by age group and gender for lymphoma, Lebanon, 2005-2007





Figure 26: Age-specific incidence rates by age group and gender for non-melanoma skin cancer, Lebanon, 2005-2007





Figure 27: Estimated Global Age-Standardized Rate for cancer among males, Globocan 2008



Figure 28: Estimated Global Age-Standardized Rate for cancer among females, Globocan 2008



Figure 29: Estimated EMR Age-Standardized Rate for cancer among males, Globocan 2008



Figure 30: Estimated EMR Age-Standardized Rate for cancer among females, Globocan 2008



Denominators

Table 1: Population estimates (including Palestinian camps) by age-group and gender, Lebanon, 2005

Age-group	Males		Females		Total	
	n	%	n	%	n	%
0-4	168,939	8.40%	148,827	7.40%	317,766	7.90%
5-9	189,050	9.40%	172,961	8.60%	362,012	9.00%
10-14	213,185	10.60%	201,118	10.00%	414,302	10.30%
15-19	205,140	10.20%	193,073	9.60%	398,213	9.90%
20-24	205,140	10.20%	193,073	9.60%	398,213	9.90%
25-29	152,849	7.60%	164,916	8.20%	317,766	7.90%
30-34	144,805	7.20%	148,827	7.40%	293,632	7.30%
35-39	124,693	6.20%	148,827	7.40%	273,520	6.80%
40-44	120,671	6.00%	148,827	7.40%	269,498	6.70%
45-49	98,548	4.90%	108,603	5.40%	207,151	5.10%
50-54	88,492	4.40%	88,492	4.40%	176,983	4.40%
55-59	70,391	3.50%	76,425	3.80%	146,816	3.70%
60-64	64,358	3.20%	72,402	3.60%	136,760	3.40%
65-69	60,335	3.00%	60,335	3.00%	120,671	3.00%
70-74	48,268	2.40%	44,246	2.20%	92,514	2.30%
75-79	28,156	1.40%	28,156	1.40%	56,313	1.40%
80-84	16,089	0.80%	16,089	0.80%	32,179	0.80%
85+	4,022	0.20%	4,022	0.20%	8,045	0.20%
Total	2,003,131	100.00%	2,019,220	100.00%	4,022,351	100.00%

Source: MOPH, ESP

Table 2: Population estimates (including Palestinian camps) by age-group and gender, Lebanon, 2006

Age-group	Males		Females		Total	
	n	%	n	%	n	%
0-4	171,454	8.40%	151,043	7.40%	322,497	7.90%
5-9	191,865	9.40%	175,536	8.60%	367,401	9.00%
10-14	216,359	10.60%	204,112	10.00%	420,470	10.30%
15-19	208,194	10.20%	195,947	9.60%	404,141	9.90%
20-24	208,194	10.20%	195,947	9.60%	404,141	9.90%
25-29	155,125	7.60%	167,372	8.20%	322,497	7.90%
30-34	146,960	7.20%	151,043	7.40%	298,003	7.30%
35-39	126,549	6.20%	151,043	7.40%	277,592	6.80%
40-44	122,467	6.00%	151,043	7.40%	273,510	6.70%
45-49	100,015	4.90%	110,220	5.40%	210,235	5.10%
50-54	89,809	4.40%	89,809	4.40%	179,618	4.40%
55-59	71,439	3.50%	77,562	3.80%	149,002	3.70%
60-64	65,316	3.20%	73,480	3.60%	138,796	3.40%
65-69	61,234	3.00%	61,234	3.00%	122,467	3.00%
70-74	48,987	2.40%	44,905	2.20%	93,891	2.30%
75-79	28,576	1.40%	28,576	1.40%	57,151	1.40%
80-84	16,329	0.80%	16,329	0.80%	32,658	0.80%
85+	4,082	0.20%	4,082	0.20%	8,164	0.20%
Total	2,032,954	100.00%	2,049,282	100.00%	4,082,236	100.00%

Source: MOPH, ESP

Table 3: Population estimates (including Palestinian camps) by age-group and gender, Lebanon, 2007						
Age-group	**Males**		**Females**		**Total**	
	n	**%**	**n**	**%**	**n**	**%**
0-4	144,461	7.40%	132,097	6.60%	276,558	7.00%
5-9	171,863	8.70%	163,475	8.10%	335,337	8.40%
10-14	195,722	10.00%	180,033	9.00%	375,755	9.40%
15-19	206,565	10.50%	179,598	8.90%	386,163	9.70%
20-24	202,805	10.30%	187,117	9.30%	389,922	9.80%
25-29	154,869	7.90%	166,799	8.30%	321,668	8.10%
30-34	141,277	7.20%	150,892	7.50%	292,170	7.30%
35-39	119,515	6.10%	147,133	7.30%	266,648	6.70%
40-44	108,020	5.50%	139,615	6.90%	247,635	6.20%
45-49	101,185	5.10%	118,645	5.90%	219,830	5.50%
50-54	87,485	4.50%	98,762	4.90%	186,247	4.70%
55-59	71,470	3.60%	79,314	3.90%	150,784	3.80%
60-64	67,384	3.40%	79,097	3.90%	146,481	3.70%
65-69	63,408	3.20%	67,167	3.30%	130,575	3.30%
70-74	55,237	2.80%	55,020	2.70%	110,257	2.80%
75-79	39,113	2.00%	35,354	1.80%	74,468	1.90%
80-84	23,425	1.20%	23,425	1.20%	46,849	1.20%
85+	11,495	0.60%	7,736	0.40%	19,231	0.50%
Total	1,965,299	100.00%	2,011,278	100.00%	3,976,577	100.00%
Source: MOPH, ESP						

Summary tables

Table 4: Annual cancer distribution, by gender, Lebanon, 2003-2007					
Year	**Males**		**Females**		**Total***
2003	3565	(49.9%)	3577	(50.1%)	7142
2004	3586	(49.8%)	3606	(50.1%)	7197
2005	3622	(48.9%)	3780	(51%)	7406
2006	3965	(49.8%)	3999	(50.2%)	7969
2007	4471	(50.2%)	4428	(49.7%)	8913
** Number do not add up because of some missing data.* *Excluding non-melanoma skin and all in-situ cancers* *Source : MOPH, ESP*					

Table 5: Completeness of core data in NCR database, Lebanon, 2005-2007			
Variable	**2005 (N=7920)**	**2006 (N=8500)**	**2007 (N=9554)**
	% of completeness	% of completeness	% of completeness
Age	91.30%	92.40%	92.90%
Gender	99.90%	99.90%	99.80%
Residence	20.80%	21.00%	16.20%
Topography	97.00%	97.70%	97.40%
Histology	95.50%	94.90%	96.80%

Including non-melanoma skin and all in-situ cancers
Source: MOPH, ESP

Table 6: Distribution of incident cancer cases among males by age-groups, Lebanon, 2005-2007			
Age group	**Year**		
	2005	**2006**	**2007**
0-4y	0.80%	1.00%	0.90%
5-9y	1.00%	0.80%	0.60%
10-14y	1.40%	0.90%	1.00%
15-19y	1.30%	1.40%	1.30%
20-24y	1.50%	1.50%	1.40%
25-29y	1.20%	1.50%	1.30%
30-34y	2.10%	1.60%	2.00%
35-39y	2.70%	2.30%	2.10%
40-44y	3.60%	3.50%	3.20%
45-49y	5.10%	4.60%	5.00%
50-54y	6.20%	6.40%	6.40%
55-59y	8.00%	8.80%	8.70%
60-64y	11.00%	10.70%	11.00%
65-69y	14.50%	14.50%	13.50%
70-74y	13.40%	13.00%	13.90%
75+y	18.60%	20.50%	21.30%
Unsp.	7.60%	7.20%	6.40%
Total %	100%	100%	100%
Total n	3623	3965	4471

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 7: Distribution of incident cancer cases among females by age-group, Lebanon, 2005-2007

Age group	Year		
	2005	2006	2007
0-4y	1.10%	0.60%	0.50%
5-9y	0.60%	0.60%	0.60%
10-14y	0.70%	0.90%	0.70%
15-19y	0.90%	1.00%	1.00%
20-24y	1.20%	0.80%	1.10%
25-29y	1.70%	1.80%	1.50%
30-34y	3.00%	2.50%	2.60%
35-39y	5.60%	5.30%	5.50%
40-44y	9.80%	8.40%	9.10%
45-49y	9.20%	10.00%	9.70%
50-54y	10.60%	9.80%	10.80%
55-59y	9.30%	11.10%	10.70%
60-64y	10.60%	9.60%	9.90%
65-69y	9.30%	10.60%	9.10%
70-74y	8.60%	8.70%	9.70%
75+y	11.40%	12.40%	12.10%
Unsp.	6.30%	6.00%	5.40%
Total %	100%	100%	100%
Total n	3780	3999	4428

Excluding non-melanoma skin and all in-situ cancers

Source : MOPH, ESP

Table 8: Mean age of incident cancers by gender, Lebanon, 2005-2007

Gender	2005		2006		2007	
	Mean	95%CI	Mean	95%CI	Mean	95%CI
Males	60.5	[59.9-61.1]	61.5	[60.9-62.0]	61.8	[61.3-62.3]
Females	55.2	[54.6-55.7]	56.1	[55.6-56.7]	56.3	[55.8-56.7]
Both	57.8	[57.4-58.2]	58.8	[58.4-59.2]	59.1	[58.7-59.4]
p-value	≤ 0.05		≤ 0.05		≤ 0.05	

Excluding non-melanoma skin and all in-situ cancers
Source: MOPH, ESP

Table 9: Crude cancer incidence rates per 100,000 by gender, Lebanon, 2003-2007

Year	Males	Females	Total
2003	200 [193-207]	197 [196-203]	198 [194-202]
2004	183 [177-189]	181 [176-187]	182 [178-186]
2005	180.8 [174.9-186.7]	187.2 [181.2-193.2]	184 [179.8-188.2]
2006	195 [189.0-201.1]	195.1 [189.1-201.2]	195.1 [190.8-199.4]
2007	227.4 [220.8-234.1]	220.2 [213.7-226.6]	223.8 [219.1-228.4]

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 10: Age-specific cancer incidence rates per 100000, by gender, Lebanon, 2005-2007

Age group	Males			Females		
	2005	2006	2007	2005	2006	2007
0-4y	18	25	28	30	18	17
5-9y	20	18	18	14	14	16
10-14y	25	18	25	15	18	19
15-19y	25	28	28	19	22	25
20-24y	29	30	33	26	18	28
25-29y	30	40	41	42	45	42
30-34y	57	45	66	81	71	80
35-39y	84	76	81	150	149	175
40-44y	116	121	137	265	234	304
45-49y	202	196	234	340	386	382
50-54y	274	301	345	484	465	514
55-59y	449	524	582	492	610	629
60-64y	670	704	787	588	554	588
65-69y	943	1009	1019	620	737	634
70-74y	1086	1141	1211	791	822	829
75+y	1523	1798	1385	961	1082	862
All ages	181	195	227	187	195	220

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 11: Age-standardized cancer incidence rates per 100,000 [and 95% confidence interval] by gender, Lebanon, 2003-2007.

Year	Males	Females	Both
2003	191 [185-197]	191 [185-197]	191 [187-195]
2004	179 [173-185]	180 [174-186]	180 [176-184]
2005	179.8 [173.7-186.0]	184.7 [178.6-190.8]	182.3 [177.9-186.6]
2006	193.9 [187.5-200.3]	192.5 [186.3-198.6]	193.2 [188.8-197.6]
2007	201.4 [195.0-207.7]	196.6 [190.6-202.6]	199 [194.6-203.4]

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 12: Distribution of cancer cases by primary site, males, Lebanon, 2005-2007

Primary site	N			%		
	2005	2006	2007	2005	2006	2007
Prostate	607	744	841	16.80%	18.80%	18.80%
Bladder	558	595	736	15.40%	15.00%	16.50%
Lung	502	582	620	13.90%	14.70%	13.90%
Colorectum	318	349	383	8.80%	8.80%	8.60%
Non-Hodgkin	281	278	280	7.80%	7.00%	6.30%
Leukemia	165	204	195	4.60%	5.10%	4.40%
Stomach	124	129	144	3.40%	3.30%	3.20%
Larynx	97	118	131	2.70%	3.00%	2.90%
Brain & nervous	90	84	115	2.50%	2.10%	2.60%
Hodgkin disease	76	84	89	2.10%	2.10%	2.00%
Kidney	77	79	89	2.10%	2.00%	2.00%
Liver	45	52	81	1.20%	1.30%	1.80%
Testis	62	49	66	1.70%	1.20%	1.50%
Bone	53	41	62	1.50%	1.00%	1.40%
Multiple Myeloma	62	47	60	1.70%	1.20%	1.30%
Pancreas	70	72	57	1.90%	1.80%	1.30%
Thyroid	32	36	57	0.90%	0.90%	1.30%
Lip, Oral cavity	34	51	51	0.90%	1.30%	1.10%
Gallbladder	29	22	31	0.80%	0.60%	0.70%
Melanoma	34	32	29	0.90%	0.80%	0.60%
Pharynx	25	34	21	0.70%	0.90%	0.50%
Oesophagus	17	22	17	0.50%	0.60%	0.40%
Other specified	162	173	206	4.50%	4.40%	4.60%
Unspecified	102	88	109	2.80%	2.20%	2.40%
Total	3622	3965	4470	100.00%	100.00%	100.00%

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 13: Annual cancer crude (CR) and age-standardized (ASR) incidence rates per 100,000 by primary site, males, Lebanon, 2005-2007

Primary site	CR			ASR		
	2005	2006	2007	2005	2006	2007
Prostate	30.3	36.6	42.8	29.1	34.7	34.1
Bladder	27.9	29.3	37.4	27.7	28.6	32.1
Lung	25.1	28.6	31.5	25.3	29.1	27.8
Colorectum	15.9	17.2	19.5	16	17	16.9
Non-Hodgkin	14	13.7	14.2	14.1	13.8	13.3
Leukemia	8.2	10.1	9.9	8.3	10.3	9.5
Stomach	6.2	6.3	7.3	6.2	6.4	6.4
Larynx	4.8	5.8	6.7	5	5.9	6.1
Brain & nervous	4.5	4.1	5.9	4.6	4.4	6
Hodgkin disease	3.8	4.1	4.5	3.5	3.9	4.3
Kidney	3.8	3.9	4.5	4	4	4.5
Liver	2.2	2.6	4.1	2.3	2.7	3.7
Testis	3.1	2.4	3.4	2.9	2.3	3.2
Bone	2.6	2	3.2	2.5	1.9	3
Multiple Myeloma	3.1	2.3	3.1	3	2.4	2.8
Pancreas	3.5	3.5	2.9	3.6	3.6	3
Thyroid	1.6	1.8	2.9	1.6	1.7	2.9
Lip, Oral cavity	1.5	2.3	2.7	1.9	2.5	2.5
Gallbladder	1.4	1.1	1.6	1.4	1	1.3
Melanoma	1.7	1.6	1.5	1.6	1.5	1.4
Pharynx	1.2	1.6	1.1	1.3	1.7	1.2
Oesophagus	0.8	1.1	0.9	0.8	1.1	0.8
Other specified	7.8	8.2	10.7	8.1	8.6	9.5
Unspecified	5.1	4.3	5.5	5.1	4.4	5.1
Total	180.1	194.5	227.8	179.9	193.5	201.4

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 14: Distribution of cancer cases by primary site, females, Lebanon, 2005-2007

Primary site	N			%		
	2005	2006	2007	2005	2006	2007
Breast	1451	1617	1747	41.60%	43.20%	42.20%
Colorectum	265	297	296	7.60%	7.90%	7.20%
Lung	198	241	234	5.70%	6.40%	5.70%
Non-Hodgkin lymphoma	236	248	234	6.80%	6.60%	5.70%
Ovary	182	153	187	5.20%	4.10%	4.50%
Corpus uteri	120	147	179	3.40%	3.90%	4.30%
Bladder	130	130	174	3.70%	3.50%	4.20%
Thyroid	110	142	154	3.20%	3.80%	3.70%
Leukemia	130	141	136	3.70%	3.80%	3.30%
Stomach	105	81	130	3.00%	2.20%	3.10%
Cervix uteri	82	76	100	2.40%	2.00%	2.40%
Hodgkin disease	67	54	85	1.90%	1.40%	2.10%
Brain & nervous system	85	50	78	2.40%	1.30%	1.90%
Pancreas	73	60	61	2.10%	1.60%	1.50%
Multiple Myeloma	49	48	59	1.40%	1.30%	1.40%
Gallbladder	30	34	50	0.90%	0.90%	1.20%
Bone	28	34	43	0.80%	0.90%	1.00%
Kidney	24	37	43	0.70%	1.00%	1.00%
Liver	39	45	42	1.10%	1.20%	1.00%
Melanoma	30	40	38	0.90%	1.10%	0.90%
Lip, Oral cavity	25	38	30	0.70%	1.00%	0.70%
Larynx	21	22	25	0.60%	0.60%	0.60%
Oesophagus	7	10	11	0.20%	0.30%	0.30%
Other specified	164	145	168	4.70%	3.90%	4.10%
Unspecified	122	99	119	3.50%	2.60%	2.90%
Total	3487	3745	4136	100.00%	100.00%	100.00%

Excluding non-melanoma skin and all in-situ cancers

Source : MOPH, ESP

Table 15: Annual cancer crude (CR) and age-standardized (ASR) incidence rates per 100,000 by primary site, females, Lebanon, 2005-2007

Primary site	CR			ASR		
	2005	2006	2007	2005	2006	2007
Breast	71.9	78.9	86.9	71	78.2	78.8
Colorectum	13.1	14.5	14.7	12.7	14.1	12.7
Lung	9.8	11.8	11.6	9.8	11.6	10
Non-Hodgkin lymphoma	11.7	12.1	11.6	11.3	11.9	10.2
Ovary	9	7.5	9.3	9	7.4	8.3
Corpus uteri	5.9	7.2	8.9	6	7.2	7.9
Bladder	6.4	6.3	8.7	6.2	6.1	7.2
Thyroid	5.4	6.9	7.7	5.2	6.6	6.9
Leukemia	6.4	6.9	6.7	6.9	7.1	6.6
Stomach	5.2	4	6.5	5	3.7	5.5
Cervix uteri	4.1	3.7	5	4	3.7	4.5
Hodgkin disease	3.3	2.6	4.2	3	2.5	3.8
Brain & nervous system	4.2	2.4	3.9	4.4	2.5	3.6
Pancreas	3.6	2.9	3	3.6	2.9	2.6
Multiple Myeloma	2.4	2.3	2.9	2.3	2.3	2.6
Gallbladder	1.5	1.7	2.5	1.4	1.6	2
Bone	1.4	1.7	2.1	1.3	1.6	2.1
Kidney	1.2	1.8	2.1	1.3	1.8	1.9
Liver	1.9	2.2	2.1	1.9	2.3	1.8
Melanoma	1.5	2	1.9	1.4	1.9	1.6
Lip, Oral cavity	1.1	1.8	1.4	1.2	1.8	1.4
Larynx	1	1.1	1.2	1	1.1	1.2
Oesophagus	0.3	0.5	0.5	0.3	0.4	0.4
Pharynx	0.3	0.5	0.2	0.4	0.5	0.3
Other specified	7.9	6.6	8	8.5	6.8	7.5
Unspecified	6	4.8	5.9	5.9	4.9	5.1
Total	186.5	194.7	219.5	185	192.5	196.5

Excluding non-melanoma skin and all in-situ cancers
Source : MOPH, ESP

Table 16: Distribution of stomach cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	124	105	229	129	81	210	144	130	276
%	54%	46%	100%	61%	39%	100%	52%	47%	100%
Age									
Mean	64.1	58.6	61.6	63.9	63.2	63.6	64.2	59.6	62.0
Mean 95 % CI	[61.9-66.4]	[55.8-61.4]	[59.8-63.4]	[61.7-66.1]	[59.5-66.9]	[61.7-65.6]	[61.8-66.7]	[56.6-62.5]	[60.1-64]
Median	67	58	64	66	68	67	67	60	65
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	0	0	0
15-19y	0	0	0	0	1	0	1	0	0
20-24y	0	0	0	0	0	0	0	2	1
25-29y	0	1	0	1	1	1	3	4	3
30-34y	1	2	1	0	5	2	1	2	1
35-39y	3	8	5	2	6	4	1	4	2
40-44y	6	8	7	5	0	3	3	5	4
45-49y	2	10	6	9	5	8	6	8	7
50-54y	9	9	9	5	6	6	5	12	8
55-59y	9	11	10	7	9	8	8	8	8
60-64y	10	8	9	14	1	9	11	6	9
65-69y	19	7	14	17	17	17	14	11	12
70-74y	15	16	16	16	14	15	17	10	13
75+y	19	12	16	20	27	23	21	21	21
Unsp.	6	10	8	4	7	5	10	7	9
Total	100	100	100	100	100	100	100	100	100

Table 17: Incidence of stomach cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	**Male**	**Female**	**Both**	**Male**	**Female**	**Both**
2003	6.4	4.9		6.2	5.1	
2004	7.6	6.7		7.5	6.7	
2005	6.2	5.2	5.7	6.2	5.0	5.6
2006	6.3	4.0	5.1	6.4	3.7	5.1
2007	7.3	6.5	6.9	6.4	5.5	6.0

Table 18: Age-specific, crude and age-standardized incidence rates for stomach cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.0	0.0	0.0	0.0	0.5	0.2	0.5	0.0	0.3
20-24y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.8
25-29y	0.0	0.6	0.3	0.6	0.6	0.6	2.6	3.0	3.1
30-34y	0.7	1.3	1.0	0.0	2.6	1.3	0.7	2.0	1.4
35-39y	3.2	6.0	4.8	2.4	3.3	3.2	0.8	3.4	2.3
40-44y	5.8	6.0	5.9	4.9	0.0	2.2	3.7	5.7	4.8
45-49y	3.0	10.1	6.8	12.0	3.6	8.1	9.9	9.3	9.6
50-54y	13.6	11.3	12.4	7.8	5.6	7.2	9.1	16.2	12.9
55-59y	17.0	17.0	17.0	12.6	10.3	11.4	18.2	15.1	16.6
60-64y	21.8	12.4	16.8	29.1	1.4	14.4	26.7	11.4	17.7
65-69y	43.1	13.3	27.3	37.6	24.5	31.0	34.7	22.3	28.3
70-74y	41.4	42.9	42.2	42.9	26.7	35.1	48.9	25.4	37.2
75+y	51.8	29.0	40.4	55.1	49.0	52.1	44.6	43.6	44.1
Crude Rate	**6.2**	**5.2**	**5.7**	**6.3**	**4.0**	**5.1**	**7.3**	**6.5**	**6.9**
	[5.1-7.3]	[4.2-6.2]	[5-6.4]	[5.3-7.4]	[3.1-4.8]	[4.4-5.8]	[6.1-8.5]	[5.4-7.6]	[6.1-7.7]
ASR	**6.2**	**5.0**	**5.6**	**6.4**	**3.7**	**5.1**	**6.4**	**5.5**	**6.0**
	[5.1-7.2]	[4.1-6]	[4.9-6.3]	[5.3-7.5]	[2.9-4.5]	[4.4-5.8]	[5.3-7.5]	[4.5-6.5]	[5.2-6.7]

Table 19: Distribution of stomach cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
EPIDERMOID CARCINOMA	Squamous Cell Carcinoma	1	0.4%	0	0.0%	2	0.7%	3	0.4%
	Other Epidermoid Carcinoma	1	0.4%	0	0.0%	0	0.0%	1	0.1%
ADENOCARCINOMA	Adenocarcinoma NOS	138	60.3%	115	54.8%	138	50.0%	391	54.7%
	Adenocarcinoma Intestinal	20	8.7%	19	9.0%	48	17.4%	87	12.2%
	Carcinoma Diffuse Type	0	0.0%	0	0.0%	1	0.4%	1	0.1%
	Linitus Plastica	4	1.7%	2	1.0%	2	0.7%	8	1.1%
	Mucinous Adenocarcinoma	2	0.9%	1	0.5%	6	2.2%	9	1.3%
	Mucin Producing	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Signet Ring Adenocarcinoma	18	7.9%	19	9.0%	38	13.8%	75	10.5%
	Other Adenocarcinoma	2	0.9%	9	4.3%	9	3.3%	20	2.8%
OTHER CARCINOMA	Other Specified Carcinoma	3	1.3%	6	2.9%	2	0.7%	11	1.5%
	Unspecified Carcinoma NOS	26	11.4%	27	12.9%	20	7.2%	73	10.2%
SARCOMA AND OTHER SOFT TISSUE TUMOR		6	2.6%	5	2.4%	4	1.4%	15	2.1%
OTHER SPECIFIC TYPES		6	2.6%	3	1.4%	3	1.1%	12	1.7%
UNSPECIFIED		2	0.9%	4	1.9%	3	1.1%	9	1.3%
TOTAL		229	100.0%	210	100.0%	276	100.0%	715	100.0%

Table 20: Distribution of colo-rectal cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	318	265	583	349	297	646	383	296	680
%	55%	45%	100%	54%	46%	100%	56%	44%	100%
Age									
Mean	61.4	61.4	61.4	64.7	62.8	63.8	64.2	61.9	63.3
Mean 95 % CI	[59.7-63.1]	[59.5-63.2]	[60.2-62.7]	[63.2-66.2]	[61.2-64.5]	[62.7-65]	[62.7-65.7]	[60.1-63.6]	[62.1-64.4]
Median	63	64	63	67	64	66	66	64	65
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	0	0	0
15-19y	0	0	0	0	0	0	1	0	0
20-24y	1	2	1	0	0	0	1	1	1
25-29y	1	1	1	1	0	1	1	2	1
30-34y	2	2	2	1	3	2	3	1	2
35-39y	3	3	3	2	3	2	2	3	3
40-44y	5	7	6	5	3	4	2	5	3
45-49y	4	6	5	5	6	6	5	7	6
50-54y	8	6	7	7	8	7	8	9	8
55-59y	10	9	10	10	11	10	11	9	10
60-64y	13	15	14	9	11	10	13	14	13
65-69y	14	10	12	14	12	13	12	10	11
70-74y	12	14	13	9	12	10	14	10	13
75+y	18	18	18	29	21	25	26	21	24
Unsp.	8	8	8	8	9	9	4	7	5
Total	100	100	100	100	100	100	100	100	100

Table 21: Incidence of colo-rectal cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	15.7	8.3		15.4	14.7	
2004	15.8	14.2		15.5	14.2	
2005	15.9	13.1	14.5	16.0	12.7	14.3
2006	17.2	14.5	15.8	17.0	14.1	15.6
2007	19.5	14.7	17.1	16.9	12.6	14.8

Table 22: Age-specific, crude and age-standardized incidence rates for colo-rectal cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.5	0.5	0.5	0.5	0.5	0.5	1.0	0.6	0.8
20-24y	1.9	2.1	2.3	0.0	0.5	0.2	2.0	1.6	1.8
25-29y	2.6	1.2	2.2	2.6	0.6	1.6	1.9	3.0	2.8
30-34y	5.5	4.0	4.8	2.0	6.0	4.0	7.1	2.0	4.8
35-39y	8.8	5.4	6.9	6.3	6.6	6.1	6.7	6.8	6.8
40-44y	13.3	12.8	13.4	13.9	6.0	9.5	6.5	10.7	8.9
45-49y	14.2	14.7	14.5	18.0	19.1	18.6	18.8	18.5	18.2
50-54y	30.5	18.1	24.3	30.1	27.8	29.5	34.3	29.4	31.7
55-59y	48.3	35.3	41.5	51.8	46.4	49.0	60.2	36.6	47.8
60-64y	71.5	58.0	64.3	55.1	50.4	52.6	74.2	55.6	64.2
65-69y	79.6	48.1	63.8	86.6	65.3	75.9	77.3	49.1	62.8
70-74y	84.9	92.7	88.6	67.4	89.1	76.7	101.4	60.0	80.7
75+y	128.4	107.7	118.1	226.6	136.8	181.7	137.8	102.2	121.0
Crude Rate	**15.9**	**13.1**	**14.5**	**17.2**	**14.5**	**15.8**	**19.5**	**14.7**	**17.1**
	[14.1-17.6]	[11.5-14.7]	[13.3-15.7]	[15.4-19]	[12.8-16.1]	[14.6-17]	[17.5-21.4]	[13-16.4]	[15.8-18.4]
ASR	**16.0**	**12.7**	**14.3**	**17.0**	**14.1**	**15.6**	**16.9**	**12.6**	**14.8**
	[14.2-17.7]	[11.2-14.3]	[13.2-15.5]	[15.2-18.8]	[12.5-15.8]	[14.3-16.8]	[15.2-18.7]	[11.2-14.1]	[13.6-15.9]

Table 23: Distribution of colo-rectal cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
EPIDERMOID CARCINOMA	Squamous Cell Carcinoma	1	0.2%	5	0.8%	5	0.7%	11	0.6%
	Other Epidermoid Carcinoma	0	0.0%	1	0.2%	0	0.0%	1	0.1%
ADENOCARCINOMA	Adenocarcinoma NOS	455	78.0%	488	75.5%	549	80.7%	1492	78.2%
	Adenocarcinoma in Adenomatous Polyp	1	0.2%	0	0.0%	1	0.1%	2	0.1%
	Adenocarcinoma in Villous Adenoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Mucinous Adenocarcinoma	17	2.9%	15	2.3%	17	2.5%	49	2.6%
	Mucine Producing Adenocarcinoma	0	0.0%	1	0.2%	0	0.0%	1	0.1%
	Signet Ring Adenocarcinoma	3	0.5%	3	0.5%	2	0.3%	8	0.4%
	Other Adenocarcinoma	46	7.9%	65	10.1%	65	9.6%	176	9.2%
OTHER CARCINOMA	Neuroendocrine Carcinoid	3	0.5%	1	0.2%	0	0.0%	4	0.2%
	Other Specific Carcinoma	7	1.2%	3	0.5%	3	0.4%	13	0.7%
	Unspecified Carcinoma NOS	8	1.4%	10	1.5%	10	1.5%	28	1.5%
SARCOMA & OTHER SOFT TISSUE TUMOR		5	0.9%	1	0.2%	7	1.0%	13	0.7%
OTHER SPECIFIED TYPES		1	0.2%	0	0.0%	1	0.1%	2	0.1%
UNSPECIFIED		36	6.2%	53	8.2%	20	2.9%	109	5.7%
TOTAL		583	100.0%	646	100.0%	680	100.0%	1909	100.0%

Table 24: Distribution of liver cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	45	39	84	52	45	97	81	42	123
%	54%	46%	100%	54%	46%	100%	66%	34%	100%
Age									
Mean	58.8	65.0	61.6	59.3	57.9	58.6	62.6	62.1	62.4
Mean 95 % CI	[54.5-63.1]	[60.8-69.2]	[58.5-64.6]	[55.1-63.4]	[51.5-64.2]	[55-62.3]	[59.2-66]	[58.5-65.8]	[59.9-65]
Median	58	67	63	58	65	59	64	63	64
Age group (%)									
0-4y	0	0	0	2	7	4	0	0	0
5-9y	0	0	0	0	2	1	0	0	0
10-14y	0	0	0	0	0	0	1	0	1
15-19y	2	0	1	0	0	0	1	0	1
20-24y	0	0	0	0	2	1	0	0	0
25-29y	0	0	0	0	0	0	0	0	0
30-34y	2	0	1	4	0	2	1	0	1
35-39y	7	3	5	4	2	3	5	0	3
40-44y	2	3	2	0	4	2	1	10	4
45-49y	9	3	6	8	4	6	4	12	7
50-54y	9	15	12	12	7	9	12	5	10
55-59y	20	5	13	23	16	20	7	7	7
60-64y	9	10	10	8	0	4	16	19	17
65-69y	11	15	13	13	24	19	10	10	10
70-74y	13	8	11	12	7	9	10	21	14
75+y	11	28	19	12	16	13	26	12	21
Unsp.	4	10	7	4	9	6	5	5	5
Total	100	100	100	100	100	100	100	100	100

Table 25: Incidence of liver cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	1.9	1.4		1.8	1.5	
2004	2.9	2.1		2.9	2.1	
2005	2.2	1.9	2.1	2.3	1.9	2.1
2006	2.6	2.2	2.4	2.7	2.3	2.5
2007	4.1	2.1	3.1	3.7	1.8	2.7

Table 26: Age-specific, crude and age-standardized incidence rates for liver cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.6	2.0	1.2	0.0	0.0	0.0
5-9y	0.0	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.0
10-14y	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.3
15-19y	0.5	0.0	0.3	0.0	0.0	0.0	0.5	0.0	0.3
20-24y	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0
25-29y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
30-34y	0.7	0.0	0.3	1.4	0.0	0.7	0.7	0.0	0.3
35-39y	2.4	0.7	1.5	1.6	0.7	1.1	3.3	0.0	1.5
40-44y	0.8	0.7	0.7	0.0	1.3	0.7	0.9	2.9	2.0
45-49y	4.1	0.9	2.4	4.0	1.8	2.9	3.0	4.2	3.6
50-54y	4.5	7.9	6.2	6.7	3.3	5.6	12.6	2.0	7.0
55-59y	12.8	2.6	8.2	16.8	10.3	13.4	8.4	3.8	6.0
60-64y	6.2	5.5	6.6	6.1	0.0	2.9	20.8	10.1	15.0
65-69y	8.3	11.6	9.9	11.4	19.6	15.5	12.6	6.0	10.0
70-74y	12.4	6.8	10.8	12.2	6.7	10.7	14.5	16.4	16.3
75+y	10.4	24.9	17.6	12.2	16.3	14.3	29.7	7.5	19.2
Crude Rate	**2.2**	**1.9**	**2.1**	**2.6**	**2.2**	**2.4**	**4.1**	**2.1**	**3.1**
	[1.6-2.9]	[1.3-2.5]	[1.6-2.5]	[1.9-3.3]	[1.6-2.8]	[1.9-2.8]	[3.2-5]	[1.5-2.7]	[2.5-3.6]
ASR	**2.3**	**1.9**	**2.1**	**2.7**	**2.3**	**2.5**	**3.7**	**1.8**	**2.7**
	[1.6-3]	[1.3-2.5]	[1.7-2.5]	[1.9-3.4]	[1.6-2.9]	[2-3]	[2.8-4.5]	[1.3-2.4]	[2.2-3.2]

Table 27: Distribution of liver cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n**	**2005 %**	**2006 n**	**2006 %**	**2007 n**	**2007 %**	**2005-2007 n**	**2005-2007 %**
HEPATOCELLULAR CARCINOMA		15	17.9%	22	22.7%	42	34.1%	79	26.0%
CHOLANGIOCARCINOMA	Intrahepatic	6	7.1%	8	8.2%	14	11.4%	28	9.2%
	Other Cholangiosarcoma	32	38.1%	32	33.0%	41	33.3%	105	34.5%
	Other Specific Carcinoma	12	14.3%	16	16.5%	13	10.6%	41	13.5%
	Unspecified Carcinoma NOS	13	15.5%	12	12.4%	11	8.9%	36	11.8%
HEPATOBLASTOMA		0	0.0%	4	4.1%	0	0.0%	4	1.3%
SARCOMA	Hemangiosarcoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Sarcoma	4	4.8%	1	1.0%	2	1.6%	7	2.3%
OTHER SPECIFIC TYPES		0	0.0%	0	0.0%	0	0.0%	0	0.0%
UNSPECIFIED		2	2.4%	2	2.1%	0	0.0%	4	1.3%
TOTAL		84	100.0%	97	100.0%	123	100.0%	304	100.0%

Table 28: Distribution of pancreas cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	70	73	143	72	60	132	57	61	118
%	49%	51%	100%	55%	45%	100%	48%	52%	100%
Age									
Mean	61.7	60.5	61.1	62.2	61.6	61.9	58.9	66.2	62.7
Mean 95 % CI	[58.6-64.8]	[56.9-64.1]	[58.7-63.5]	[59-65.3]	[58.3-64.9]	[59.6-64.2]	[56-61.8]	[63.5-68.8]	[60.6-64.8]
Median	61.5	64	63	64	66	65	61	67	64
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	1	1	0	0	0	0	0	0
15-19y	0	1	1	0	2	1	0	0	0
20-24y	0	1	1	0	0	0	0	0	0
25-29y	0	1	1	0	0	0	0	0	0
30-34y	1	0	1	1	0	1	0	0	0
35-39y	3	0	1	6	5	5	4	0	2
40-44y	4	4	4	4	3	4	9	2	5
45-49y	9	5	7	8	5	7	9	3	6
50-54y	13	12	13	4	8	6	12	10	11
55-59y	7	7	7	6	12	8	11	11	11
60-64y	16	11	13	17	8	13	19	15	17
65-69y	14	19	17	15	20	17	14	18	16
70-74y	11	10	10	17	22	19	16	18	17
75+y	16	14	15	13	10	11	2	20	11
Unsp.	6	12	9	10	5	8	5	3	4
Total	100	100	100	100	100	100	100	100	100

Table 29: Incidence of pancreas cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	**Male**	**Female**	**Both**	**Male**	**Female**	**Both**
2003	3.3	2.8		3.4	2.9	
2004	3.0	2.9		3.0	2.9	
2005	3.5	3.6	3.6	3.6	3.6	3.6
2006	3.5	2.9	3.2	3.6	2.9	3.2
2007	2.9	3.0	3.0	3.0	2.6	2.8

Table 30: Age-specific, crude and age-standardized incidence rates for pancreas cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.0	0.5	0.3	0.0	0.5	0.2	0.0	0.0	0.0
20-24y	0.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0
25-29y	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0
30-34y	0.7	0.0	0.3	0.7	0.0	0.3	0.0	0.0	0.0
35-39y	1.6	0.0	0.7	3.2	2.0	2.9	1.7	0.0	0.8
40-44y	2.5	2.0	2.6	2.4	1.3	1.8	4.6	0.7	2.4
45-49y	6.1	4.6	5.3	7.0	2.7	4.8	4.9	1.7	3.2
50-54y	11.3	11.3	11.3	3.3	5.6	5.0	8.0	6.1	7.5
55-59y	7.1	7.9	7.5	5.6	9.0	8.1	8.4	8.8	9.3
60-64y	18.6	12.4	15.4	19.9	6.8	13.7	17.8	11.4	14.3
65-69y	18.2	26.5	22.4	19.6	21.2	20.4	12.6	16.4	15.3
70-74y	16.6	18.1	17.3	26.5	31.2	28.8	18.1	20.0	19.0
75+y	24.9	22.8	23.8	20.4	12.2	16.3	1.4	18.0	9.2
Crude Rate	**3.5**	**3.6**	**3.6**	**3.5**	**2.9**	**3.2**	**2.9**	**3.0**	**3.0**
	[2.7-4.3]	[2.8-4.4]	[3-4.1]	[2.7-4.4]	[2.2-3.7]	[2.7-3.8]	[2.1-3.7]	[2.3-3.8]	[2.4-3.5]
ASR	**3.6**	**3.6**	**3.6**	**3.6**	**2.9**	**3.2**	**3.0**	**2.6**	**2.8**
	[2.8-4.5]	[2.8-4.4]	[3-4.2]	[2.8-4.5]	[2.1-3.6]	[2.7-3.8]	[2.2-3.7]	[1.9-3.2]	[2.3-3.3]

Table 31: Distribution of pancreas cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
EPIDERMOID CARCINOMA		0	0.0%	0	0.0%	0	0.0%	0	0.0%
ADENOCARCINOMA	Adenocarcinoma NOS	116	81.1%	114	86.4%	100	84.7%	330	84.0%
	Papillary Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Mucinous Adenocarcinoma	6	4.2%	3	2.3%	1	0.8%	10	2.5%
	Mucin Producing Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Infiltrating Duct Carcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Adenocarcinoma	4	2.8%	6	4.5%	6	5.1%	16	4.1%
OTHER CARCINOMA	Islet Cell Carcinoma	1	0.7%	0	0.0%	0	0.0%	1	0.3%
	Other Carcinoma	10	7.0%	3	2.3%	5	4.2%	18	4.6%
	Unspecified Carcinoma NOS	4	2.8%	5	3.8%	4	3.4%	13	3.3%
SARCOMA AND OTHER SOFT TISSUE		2	1.4%	0	0.0%	1	0.8%	3	0.8%
OTHER SPECIFIC TYPES		0	0.0%	0	0.0%	0	0.0%	0	0.0%
UNSPECIFIED		0	0.0%	1	0.8%	1	0.8%	2	0.5%
TOTAL		143	100.0%	132	100.0%	118	100.0%	393	100.0%

Table 32: Distribution of pulmonary cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	502	198	702	582	241	823	620	234	856
%	72%	28%	100%	71%	29%	100%	72%	27%	100%
Age									
Mean	64.2	61.7	63.4	64.5	62.2	63.8	65.7	62.8	64.9
Mean 95 % CI	[63.1-65.2]	[59.9-63.6]	[62.5-64.4]	[63.5-65.4]	[60.5-63.8]	[63-64.6]	[64.8-66.6]	[61-64.6]	[64.1-65.8]
Median	66	63	65	65	64	65	67	63	66
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	0	0	0
15-19y	0	0	0	0	0	0	0	1	0
20-24y	0	0	0	0	0	0	0	0	0
25-29y	0	1	0	0	1	0	0	0	0
30-34y	1	1	1	1	2	1	1	0	1
35-39y	1	4	2	1	1	1	0	3	1
40-44y	3	4	3	2	5	3	1	5	2
45-49y	7	7	7	4	7	5	5	4	4
50-54y	6	9	7	8	7	7	6	11	7
55-59y	9	11	10	13	10	12	11	12	12
60-64y	14	19	15	15	13	15	13	12	13
65-69y	18	13	17	18	19	18	18	9	16
70-74y	13	7	12	15	10	14	16	16	16
75+y	20	18	19	17	16	17	21	18	20
Unsp.	6	8	6	7	8	7	7	8	7
Total	100	100	100	100	100	100	100	100	100

Table 33: Incidence of incident pulmonary cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	31.6	12.4		31.6	13.2	
2004	28.8	10.8		28.2	10.8	
2005	25.1	9.8	17.4	25.3	9.8	17.6
2006	28.6	11.8	20.2	29.1	11.6	20.4
2007	31.5	11.6	21.5	27.8	10.0	18.9

Table 34: Age-specific, crude and age-standardized incidence rates for pulmonary cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.6	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.4
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.5	0.0	0.3	0.5	0.0	0.2	0.5	1.1	0.8
20-24y	1.0	0.0	0.5	1.0	0.0	0.5	0.5	0.0	0.3
25-29y	0.7	1.2	0.9	0.6	1.2	0.9	0.6	0.0	0.3
30-34y	2.8	1.3	2.0	2.0	2.6	2.7	2.8	0.7	1.7
35-39y	4.8	5.4	5.1	3.2	2.0	2.9	1.7	6.1	4.1
40-44y	14.1	6.0	9.6	11.4	9.3	10.2	9.3	9.3	9.3
45-49y	35.5	13.8	24.1	24.0	18.1	20.5	29.6	8.4	18.2
50-54y	38.4	20.3	29.4	53.4	18.9	36.7	48.0	27.3	37.0
55-59y	69.6	30.1	49.0	113.4	34.8	73.2	106.3	39.1	71.0
60-64y	115.0	55.2	83.4	145.4	47.6	93.7	124.7	37.9	77.8
65-69y	162.4	46.4	104.4	179.6	80.0	129.8	189.3	35.7	110.3
70-74y	147.1	33.9	93.0	191.9	57.9	127.8	197.3	74.5	136.0
75+y	221.7	78.7	150.2	212.3	87.8	149.0	187.8	69.2	131.6
Crude Rate	**25.1**	**9.8**	**17.4**	**28.6**	**11.8**	**20.2**	**31.5**	**11.6**	**21.5**
	[22.9-27.3]	[8.4-11.2]	[16.1-18.7]	[26.3-31]	[10.3-13.2]	[18.8-21.5]	[29.1-34]	[10.1-13.1]	[20-22.9]
ASR	**25.3**	**9.8**	**17.6**	**29.1**	**11.6**	**20.4**	**27.8**	**10.0**	**18.9**
	[23.1-27.6]	[8.4-11.2]	[16.2-18.9]	[26.7-31.6]	[10.1-13.1]	[19-21.8]	[25.6-30.1]	[8.7-11.3]	[17.6-20.2]

Table 35: Distribution of pulmonary cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
CARCINOMA	Small Cell	109	15.5%	98	11.9%	88	10.3%	295	12.4%
	Non Smal Cell Squamous And Transitional	105	15.0%	110	13.4%	157	18.3%	372	15.6%
	Non Small Cell Adenocarcinoma	323	46.0%	371	45.1%	399	46.6%	1093	45.9%
	Large Cell	12	1.7%	6	0.7%	9	1.1%	27	1.1%
	Other Non Small Cell	137	19.5%	217	26.4%	180	21.0%	534	22.4%
SARCOMA		7	1.0%	4	0.5%	5	0.6%	16	0.7%
OTHER SPECIFIED		1	0.1%	0	0.0%	1	0.1%	2	0.1%
UNSPECIFIED		8	1.1%	17	2.1%	17	2.0%	42	1.8%
TOTAL		702	100.0%	823	100.0%	856	100.0%	2381	100.0%

Table 36: Distribution of breast cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	15	1451	1466	23	1617	1641	28	1747	1776
%	1%	99%	100%	1%	99%	100%	2%	98%	100%
Age									
Mean	63.3	53.9	54.0	57.3	54.6	54.6	64.4	54.9	55.0
Mean 95 % CI	[56.8-69.9]	[53.3-54.6]	[53.4-54.7]	[50.5-64.2]	[53.9-55.3]	[54-55.3]	[58.8-70]	[54.2-55.5]	[54.4-55.6]
Median	69	53	53	63	53	53	67	53	53
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	4	0	0
15-19y	0	0	0	4	0	0	0	0	0
20-24y	0	0	0	0	0	0	0	0	0
25-29y	0	1	1	0	1	1	0	0	0
30-34y	0	3	3	0	2	2	0	3	3
35-39y	0	7	7	9	8	8	0	6	6
40-44y	20	15	15	13	12	12	0	13	13
45-49y	0	12	12	9	15	15	4	14	14
50-54y	7	14	14	9	12	12	11	13	13
55-59y	7	10	10	4	12	12	11	12	12
60-64y	7	10	10	13	10	10	11	10	10
65-69y	13	8	9	17	9	9	18	8	8
70-74y	27	7	7	9	6	6	11	8	8
75+y	20	7	7	13	8	8	25	8	8
Unsp.	0	5	5	0	5	5	7	5	5
Total	100	100	100	100	100	100	100	100	100

Table 37: Incidence of breast cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003		71.8			78.3	
2004		69.5			69.2	
2005	0.7	71.9	36.4	0.7	71.0	35.8
2006	1.1	78.9	40.2	1.2	78.2	39.7
2007	1.4	86.9	44.6	1.3	78.8	40.0

Table 38: Age-specific, crude and age-standardized incidence rates for breast cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3
10-14y	0.0	0.0	0.0	0.0	0.5	0.2	0.5	0.0	0.3
15-19y	0.0	1.6	0.8	0.5	0.5	0.5	0.0	0.0	0.0
20-24y	0.0	0.5	0.3	0.0	1.5	0.7	0.0	1.6	0.8
25-29y	0.0	9.7	5.0	0.0	9.0	4.7	0.0	4.2	2.2
30-34y	0.0	31.6	16.0	0.0	27.1	13.8	0.0	35.8	18.5
35-39y	0.0	75.3	40.9	1.6	86.1	47.6	0.0	80.9	44.6
40-44y	2.5	149.8	83.9	2.4	136.4	76.4	0.0	171.2	96.5
45-49y	0.0	175.9	92.2	2.0	226.8	119.9	1.0	213.2	115.5
50-54y	1.1	246.3	123.7	2.2	222.7	112.5	3.4	246.0	132.6
55-59y	1.4	202.8	106.3	1.4	264.3	138.3	4.2	271.1	144.6
60-64y	1.6	207.2	110.4	4.6	231.4	124.6	4.5	227.6	125.6
65-69y	3.3	215.5	109.4	6.5	238.4	122.5	7.9	209.9	111.8
70-74y	8.3	226.0	112.4	4.1	236.1	115.0	5.4	258.1	131.5
75+y	6.2	217.5	111.9	6.1	289.9	148.0	10.8	225.5	112.4
Crude Rate	**0.7**	**71.9**	**36.4**	**1.1**	**78.9**	**40.2**	**1.4**	**86.9**	**44.6**
	[0.4-1.1]	[68.2-75.6]	[34.6-38.3]	[0.7-1.6]	[75.1-82.8]	[38.2-42.1]	[0.9-2]	[82.8-90.9]	[42.6-46.7]
ASR	**0.7**	**71.0**	**35.8**	**1.2**	**78.2**	**39.7**	**1.3**	**78.8**	**40.0**
	[0.4-1]	[67.3-74.6]	[34-37.7]	[0.7-1.6]	[74.3-82]	[37.7-41.6]	[0.8-1.7]	[75.1-82.6]	[38.1-41.9]

Table 39: Distribution of breast cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
EPIDERMOID CARCINOMA		0	0.0%	2	0.1%	1	0.1%	3	0.1%
ADENOCARCINOMA	Adenocarcinoma NOS	115	7.8%	180	11.0%	179	10.1%	474	9.7%
	Infiltrating Duct Carcinoma	946	64.5%	975	59.4%	1125	63.3%	3046	62.4%
	Lobular Carcinoma NOS	95	6.5%	157	9.6%	166	9.3%	418	8.6%
	Inflammatory Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Infiltrating Duct Mixed Or Lobular Mixed	15	1.0%	8	0.5%	6	0.3%	29	0.6%
	Mucinous Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Mucin Producing Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Tubular Adenocarcinoma	0	0.0%	0	0.0%	1	0.1%	1	0.0%
	Papillary Adenocarcinoma	4	0.3%	5	0.3%	2	0.1%	11	0.2%
	Paget Disease	1	0.1%	0	0.0%	3	0.2%	4	0.1%
	Other Adenocarcinoma	38	2.6%	39	2.4%	75	4.2%	152	3.1%
OTHER SPECIFIED CARCINOMA	Medullary Adenocarcinoma	3	0.2%	3	0.2%	2	0.1%	8	0.2%
	Other	0	0.0%	2	0.1%	0	0.0%	2	0.0%
SARCOMA AND OTHER SOFT TISSUE TUMOR	Hemangiosarcoma	0	0.0%	1	0.1%	3	0.2%	4	0.1%
	Other Sarcoma	6	0.4%	4	0.2%	6	0.3%	16	0.3%
UNSPECIFIED CARCINOMA NOS		60	4.1%	76	4.6%	67	3.8%	203	4.2%
PHYLLODES TUMOR MALIGNANT		2	0.1%	7	0.4%	7	0.4%	16	0.3%
MALIGNANT TUMOR NOS		181	12.3%	182	11.1%	133	7.5%	496	10.2%
TOTAL		1466	100.0%	1641	100.0%	1776	100.0%	4883	100.0%

Table 40: Distribution of cervical cancer by age group, Lebanon, 2005-2007

	2005	2006	2007
	F	F	F
Count			
n	82	76	100
Age			
Mean	52.7	55.0	54.6
Mean 95 % CI	[49.9-55.6]	[52.1-58]	[51.7-57.4]
Median	51	54	54
Age group (%)			
0-4y	0	0	0
5-9y	0	0	0
10-14y	0	0	0
15-19y	0	0	1
20-24y	0	0	0
25-29y	1	1	1
30-34y	4	1	3
35-39y	7	9	12
40-44y	20	11	7
45-49y	9	8	8
50-54y	16	17	17
55-59y	7	14	11
60-64y	13	8	10
65-69y	6	12	9
70-74y	9	7	9
75+y	4	5	6
Unsp.	5	7	6
Total	100	100	100

Table 41: Incidence of cervical cancer, Lebanon 2003-2007

	Crude incidence rate	Age-standardized rate
Year	**Female**	**Female**
2003	4.5	5.0
2004	4.7	4.7
2005	4.1	4.0
2006	3.7	3.7
2007	5.0	4.5

Table 42: Age-specific, crude and age-standardized incidence rates for cervical cancer, Lebanon, 2005-2007

Age group	2005 F	2006 F	2007 F
0-4y	0.0	0.0	0.0
5-9y	0.0	0.0	0.0
10-14y	0.0	0.0	0.0
15-19y	0.0	0.0	0.6
20-24y	0.0	0.0	0.0
25-29y	0.6	0.6	0.6
30-34y	2.0	0.7	2.0
35-39y	4.0	4.6	8.8
40-44y	11.4	6.0	5.0
45-49y	6.4	5.4	7.6
50-54y	15.8	15.6	18.2
55-59y	7.9	15.5	15.1
60-64y	16.6	8.2	13.9
65-69y	8.3	16.3	14.9
70-74y	15.8	11.1	18.2
75+y	6.2	8.2	9.0
Crude Rate	**4.1**	**3.7**	**5.0**
	[3.2-4.9]	[2.9-4.5]	[4-5.9]
ASR	**4.0**	**3.7**	**4.5**
	[3.1-4.9]	[2.9-4.5]	[3.6-5.4]

Table 43: Distribution of cervical cancer by histological group, Lebanon, 2005-2007

Group	Sub-Group	2005 n & %		2006 n & %		2007 n & %		2005-2007 n & %	
EPIDERMOID CARCINOMA	Squamous Cell Carcinoma	51	62.2%	37	48.7%	62	62.0%	150	58.1%
	Squamous Cell Keratinizing	0	0.0%	0	0.0%	1	1.0%	1	0.4%
	Squamous Cell Non Keratinizing	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Squamous Cell Micro Invasive	1	1.2%	0	0.0%	0	0.0%	1	0.4%
	Other Epidermoid Carcinomas	3	3.7%	0	0.0%	0	0.0%	3	1.2%
ADENOCARCINOMA	Adenocarcinoma NOS	14	17.1%	24	31.6%	16	16.0%	54	20.9%
	Adenocarcinoma Squamous	0	0.0%	1	1.3%	0	0.0%	1	0.4%
	Other Adenocarcinoma	2	2.4%	1	1.3%	4	4.0%	7	2.7%
OTHER CARCINOMA	Other Specified Carcinoma	0	0.0%	1	1.3%	1	1.0%	2	0.8%
	Unspecified Carcinoma	8	9.8%	8	10.5%	8	8.0%	24	9.3%
SARCOMA		1	1.2%	2	2.6%	4	4.0%	7	2.7%
OTHER SPECIFIC TYPES		2	2.4%	1	1.3%	4	4.0%	7	2.7%
UNSPECIFIED		0	0.0%	1	1.3%	0	0.0%	1	0.4%
TOTAL		82	100.0%	76	100.0%	100	100.0%	258	100.0%

Table 44: Distribution of ovary cancer by age group, Lebanon, 2005-2007

	2005	2006	2007
	F	F	F
Count			
n	182	153	187
Age			
Mean	56.8	56.4	54.5
Mean 95 % CI	[54.6-59]	[53.8-59.1]	[52.2-56.8]
Median	58	57	56
Age group (%)			
0-4y	0	0	0
5-9y	0	0	0
10-14y	1	1	1
15-19y	1	1	1
20-24y	3	2	3
25-29y	2	3	4
30-34y	1	1	3
35-39y	3	3	3
40-44y	7	8	14
45-49y	10	8	6
50-54y	10	11	12
55-59y	14	18	12
60-64y	15	7	10
65-69y	9	8	10
70-74y	9	8	8
75+y	11	13	11
Unsp.	5	7	3
Total	100	100	100

Table 45: Incidence of ovary cancer, Lebanon 2003-2007

	Crude incidence rate	Age-standardized rate
Year	**Female**	**Female**
2003	4.9	5.1
2004	6.7	6.7
2005	9.0	9.0
2006	7.5	7.4
2007	9.3	8.3

Table 46: Age-specific, crude and age-standardized incidence rates for ovary cancer, Lebanon, 2005-2007

Age group	2005 F	2006 F	2007 F
0-4y	0.0	0.0	0.0
5-9y	0.0	0.0	0.0
10-14y	0.5	0.5	0.6
15-19y	0.5	1.0	0.6
20-24y	2.6	1.5	2.7
25-29y	2.4	3.0	4.8
30-34y	1.3	1.3	3.3
35-39y	4.0	2.6	4.1
40-44y	8.7	9.3	19.3
45-49y	18.4	12.7	10.1
50-54y	21.5	20.0	23.3
55-59y	34.0	37.4	30.3
60-64y	40.1	15.0	24.0
65-69y	28.2	22.9	29.8
70-74y	38.4	29.0	27.3
75+y	43.5	44.9	31.6
Crude Rate	9.0	7.5	9.3
	[7.7-10.3]	[6.3-8.6]	[8-10.6]
ASR	**9.0**	**7.4**	**8.3**
	[7.7-10.3]	[6.2-8.5]	[7.1-9.5]

Table 47: Distribution of ovary cancer by histological group, Lebanon, 2005-2007

Group	Sub-Group	2005 n & %		2006 n & %		2007 n & %		2005-2007 n & %	
EPIDERMOID CARCINOMA		1	0.5%	2	1.3%	1	0.5%	4	0.8%
ADENOCARCINOMA	Adenocarcinoma NOS	78	42.9%	49	32.0%	70	37.4%	197	37.7%
	Papillary Adenocarcinoma NOS	3	1.6%	1	0.7%	1	0.5%	5	1.0%
	Clear Cell Adenocarcinoma	1	0.5%	2	1.3%	3	1.6%	6	1.1%
	Endometroid Carcinoma	3	1.6%	2	1.3%	11	5.9%	16	3.1%
	Cystadenocarcinoma	10	5.5%	3	2.0%	6	3.2%	19	3.6%
	Serous Cystadenocarcinoma	26	14.3%	26	17.0%	25	13.4%	77	14.8%
	Papillary Serous Cystadenocarcinoma	7	3.8%	21	13.7%	19	10.2%	47	9.0%
	Mucinous Cystadenocarcinoma	11	6.0%	5	3.3%	12	6.4%	28	5.4%
	Mucinous Adenocarcinoma	2	1.1%	1	0.7%	4	2.1%	7	1.3%
	Mucin Producing Adenocarcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Adenocarcinoma	2	1.1%	2	1.3%	0	0.0%	4	0.8%
OTHER CARCINOMA	Stromal Cell Tumor	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Specific Carcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Unspecified Carcinoma	30	16.5%	32	20.9%	25	13.4%	87	16.7%
OTHER SPECIFIED TUMOR		5	2.7%	7	4.6%	10	5.3%	22	4.2%
MALIGNANT TUMOR NOS		3	1.6%	0	0.0%	0	0.0%	3	0.6%
TOTAL		182	100.0%	153	100.0%	187	100.0%	522	100.0%

Table 48: Distribution of prostate cancer by age group, Lebanon, 2005-2007

	2005	2006	2007
	M	M	M
Count			
n	607	744	841
Age			
Mean	69.5	70.5	70.2
Mean 95 % CI	[68.8-70.3]	[69.8-71.2]	[69.6-70.9]
Median	70	71	71
Age group (%)			
0-4y	0	0	0
5-9y	0	0	0
10-14y	0	0	0
15-19y	0	0	0
20-24y	0	0	0
25-29y	0	0	0
30-34y	0	0	0
35-39y	0	0	0
40-44y	0	0	0
45-49y	1	1	1
50-54y	2	3	4
55-59y	7	7	6
60-64y	13	10	12
65-69y	21	19	16
70-74y	20	16	21
75+y	28	35	31
Unsp.	7	9	10
Total	100	100	100

Table 49: Incidence of prostate cancer, Lebanon 2003-2007

	Crude incidence rate	Age-standardized rate
Year	**Male**	**Male**
2003	32.9	29.9
2004	28.2	27.6
2005	30.3	29.1
2006	36.6	34.7
2007	42.8	34.1

Table 50: Age-specific, crude and age-standardized incidence rates for prostate cancer, Lebanon, 2005-2007

	2005	2006	2007
Age group	**M**	**M**	**M**
0-4y	0.0	0.0	0.0
5-9y	0.0	0.0	0.0
10-14y	0.0	0.0	0.0
15-19y	0.5	0.0	0.0
20-24y	0.0	0.0	0.0
25-29y	0.0	0.0	0.6
30-34y	0.0	0.7	0.0
35-39y	0.8	0.8	0.8
40-44y	2.5	0.8	2.8
45-49y	5.1	8.0	7.9
50-54y	17.0	25.6	38.9
55-59y	63.9	79.8	79.8
60-64y	127.4	128.6	163.2
65-69y	230.4	249.9	228.7
70-74y	273.5	273.5	354.8
75+y	379.1	575.7	386.3
Crude Rate	**30.3**	**36.6**	**42.8**
	[27.9-32.7]	[34-39.2]	[39.9-45.7]
ASR	**29.1**	**34.7**	**34.1**
	[26.7-31.4]	[32.2-37.2]	[31.7-36.5]

Table 51: Distribution of kidney cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	83	28	111	85	38	123	99	43	142
%	75%	25%	100%	69%	31%	100%	70%	30%	100%
Age									
Mean	58.8	46.4	55.5	56.2	52.7	55.2	57.9	57.6	57.8
Mean 95 % CI	[54.9-62.6]	[37-55.8]	[51.7-59.4]	[52.4-60]	[44.6-60.7]	[51.6-58.7]	[54.4-61.4]	[51.3-64]	[54.7-60.9]
Median	64	55	62	61	56	61	62	62	62
Age group (%)									
0-4y	4	14	6	4	8	5	3	5	4
5-9y	1	0	1	0	0	0	0	2	1
10-14y	0	7	2	0	8	2	0	0	0
15-19y	0	0	0	0	0	0	0	0	0
20-24y	1	0	1	1	0	1	1	2	1
25-29y	0	7	2	2	0	2	1	0	1
30-34y	0	0	0	1	0	1	2	5	3
35-39y	4	4	4	8	5	7	2	0	1
40-44y	2	4	3	7	5	7	8	5	7
45-49y	14	4	12	5	3	4	9	7	8
50-54y	1	7	3	5	16	8	9	9	9
55-59y	6	11	7	11	3	8	5	12	7
60-64y	14	11	14	16	3	12	14	7	12
65-69y	22	18	21	9	13	11	14	9	13
70-74y	16	7	14	15	13	15	11	14	12
75+y	10	7	9	11	16	12	13	21	15
Unsp.	5	0	4	5	8	6	7	2	6
Total	100	100	100	100	100	100	100	100	100

Table 52: Incidence of kidney cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	3.8	2.1		6.2	2.2	
2004	3.1	1.9		3.1	1.9	
2005	4.1	1.4	2.8	4.3	1.5	2.9
2006	4.2	1.9	3.0	4.3	1.9	3.1
2007	5.0	2.1	3.6	4.9	1.9	3.4

Table 53: Age-specific, crude and age-standardized incidence rates for kidney cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	1.8	2.7	2.2	1.7	2.0	1.9	2.1	1.5	1.8
5-9y	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.3
10-14y	0.0	1.0	0.5	0.0	1.5	0.7	0.0	0.0	0.0
15-19y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20-24y	0.5	0.0	0.3	0.5	0.0	0.2	0.5	0.5	0.5
25-29y	0.0	1.2	0.6	1.3	0.0	0.6	0.6	0.0	0.3
30-34y	0.0	0.0	0.0	0.7	0.0	0.3	1.4	1.3	1.4
35-39y	2.4	0.7	1.5	5.5	1.3	3.6	1.7	0.0	0.8
40-44y	1.7	0.7	1.1	4.9	1.3	2.9	8.3	1.4	4.4
45-49y	13.2	0.9	6.8	4.0	0.9	2.4	9.9	2.5	5.9
50-54y	1.1	2.3	1.7	4.5	7.8	6.1	11.4	4.1	7.5
55-59y	7.1	3.9	5.4	12.6	1.3	6.7	7.0	6.3	7.3
60-64y	20.2	4.1	11.7	23.0	1.4	11.5	22.3	3.8	12.3
65-69y	31.5	8.3	19.9	13.1	8.2	11.4	23.7	6.0	14.6
70-74y	29.0	4.5	17.3	28.6	11.1	20.2	21.7	10.9	16.3
75+y	16.6	4.1	10.4	18.4	14.3	16.3	18.9	13.5	16.4
Crude Rate	**4.1**	**1.4**	**2.8**	**4.2**	**1.9**	**3.0**	**5.0**	**2.1**	**3.6**
	[3.3-5]	[0.9-1.9]	[2.2-3.3]	[3.3-5.1]	[1.3-2.4]	[2.5-3.5]	[4-6]	[1.5-2.8]	[3-4.2]
ASR	**4.3**	**1.5**	**2.9**	**4.3**	**1.9**	**3.1**	**4.9**	**1.9**	**3.4**
	[3.4-5.3]	[0.9-2.1]	[2.4-3.5]	[3.4-5.3]	[1.3-2.5]	[2.5-3.7]	[3.9-5.9]	[1.3-2.5]	[2.8-4]

Table 54: Distribution of kidney cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
CARCINOMA	Squamous And Transitionnel Cell Carcinoma	10	9.0%	8	6.5%	11	7.7%	29	7.7%
	Renal Cell Carcinoma	78	70.3%	95	77.2%	111	78.2%	284	75.5%
	Other Specified Carcinoma	1	0.9%	0	0.0%	1	0.7%	2	0.5%
	Unspecified Carcinoma	8	7.2%	8	6.5%	9	6.3%	25	6.6%
OTHER SPECIFIED MALIGNANT TUMOR	Nephroblastoma	9	8.1%	6	4.9%	4	2.8%	19	5.1%
	Sarcoma	4	3.6%	3	2.4%	3	2.1%	10	2.7%
	Other Specified Tumor	0	0.0%	1	0.8%	2	1.4%	3	0.8%
UNSPECIFIED		1	0.9%	2	1.6%	1	0.7%	4	1.1%
TOTAL		111	100.0%	123	100.0%	142	100.0%	376	100.0%

Table 55: Distribution of bladder cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	558	130	689	595	130	726	736	174	910
%	81%	19%	100%	82%	18%	100%	81%	19%	100%
Age									
Mean	66.0	63.7	65.6	67.4	68.1	67.5	67.0	65.7	66.8
Mean 95 % CI	[64.9-67.1]	[61.2-66.2]	[64.6-66.6]	[66.4-68.4]	[65.9-70.2]	[66.6-68.4]	[66.1-67.9]	[63.6-67.8]	[66-67.6]
Median	68	65	67	69	70	69	68	68	68
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	0	0	0
15-19y	0	0	0	0	0	0	0	0	0
20-24y	0	0	0	0	0	0	0	0	0
25-29y	0	1	0	0	0	0	0	0	0
30-34y	0	2	0	0	1	0	1	1	1
35-39y	1	2	1	1	0	0	1	2	1
40-44y	3	5	3	3	2	2	1	2	2
45-49y	4	6	4	3	5	3	4	6	5
50-54y	6	8	7	6	8	6	7	11	8
55-59y	9	8	9	8	7	8	9	7	9
60-64y	12	10	12	11	12	11	13	9	12
65-69y	16	10	15	18	12	17	14	11	14
70-74y	13	12	13	15	17	16	15	14	15
75+y	24	23	24	26	31	27	27	25	26
Unsp.	11	15	12	8	6	8	7	11	8
Total	100	100	100	100	100	100	100	100	100

Table 56: Incidence of bladder cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	31.9	5.8		29.5	6.3	
2004	28.7	5.5		28.1	5.5	
2005	27.9	6.4	17.1	27.7	6.2	17.0
2006	29.3	6.3	17.8	28.6	6.1	17.4
2007	37.4	8.7	22.9	32.1	7.2	19.6

Table 57: Age-specific, crude and age-standardized incidence rates for bladder cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.0	0.0	0.0	0.5	0.0	0.2	0.5	0.0	0.3
20-24y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25-29y	0.7	0.6	0.6	1.3	0.0	0.6	0.0	0.0	0.0
30-34y	0.0	1.3	0.7	1.4	0.7	1.0	2.8	0.7	1.7
35-39y	6.4	1.3	3.7	2.4	0.0	1.1	4.2	3.4	3.8
40-44y	13.3	4.7	8.5	13.9	1.3	7.3	10.2	3.6	6.1
45-49y	26.4	8.3	16.9	18.0	5.4	11.9	33.6	9.3	20.9
50-54y	46.3	13.6	29.4	43.4	12.2	27.8	66.3	21.3	43.0
55-59y	83.8	17.0	48.4	71.4	12.9	40.9	102.1	17.7	57.7
60-64y	116.5	20.7	66.5	110.2	23.1	64.1	151.4	22.8	81.9
65-69y	162.4	24.9	93.6	196.0	27.8	111.9	178.2	34.2	104.2
70-74y	174.0	40.7	110.3	204.1	51.2	132.1	220.9	50.9	136.0
75+y	308.7	72.5	190.6	345.0	87.8	215.4	285.0	73.7	185.0
Crude Rate	**27.9**	**6.4**	**17.1**	**29.3**	**6.3**	**17.8**	**37.4**	**8.7**	**22.9**
	[25.5-30.2]	[5.3-7.5]	[15.8-18.4]	[26.9-31.6]	[5.3-7.4]	[16.5-19.1]	[34.7-40.2]	[7.4-9.9]	[21.4-24.4]
ASR	**27.7**	**6.2**	**17.0**	**28.6**	**6.1**	**17.4**	**32.1**	**7.2**	**19.6**
	[25.4-30]	[5.2-7.3]	[15.7-18.3]	[26.3-31]	[5.1-7.2]	[16.1-18.7]	[29.7-34.5]	[6.1-8.3]	[18.3-21]

Table 58: Distribution of bladder cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
CARCINOMA	Squamous Cell Carcinoma	7	1.0%	9	1.2%	7	0.8%	23	1.0%
	Transitionnel Cell Carcinoma	640	92.9%	668	92.0%	844	92.7%	2152	92.6%
	Adenocarcinoma	13	1.9%	8	1.1%	14	1.5%	35	1.5%
	Other Specified Carcinoma	3	0.4%	5	0.7%	13	1.4%	21	0.9%
	Unspecified Carcinoma	12	1.7%	12	1.7%	20	2.2%	44	1.9%
SARCOMA		3	0.4%	4	0.6%	2	0.2%	9	0.4%
OTHER SPECIFIED MALIGNANT		0	0.0%	0	0.0%	0	0.0%	0	0.0%
UNSPECIFIED		11	1.6%	20	2.8%	10	1.1%	41	1.8%
TOTAL		689	100.0%	726	100.0%	910	100.0%	2325	100.0%

Table 59: Distribution of CNS cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	90	85	175	84	50	134	115	78	193
%	51%	49%	100%	63%	37%	100%	60%	40%	100%
Age									
Mean	39.3	38.1	38.7	42.2	42.1	42.2	41.7	45.8	43.4
Mean 95 % CI	[34.2-44.3]	[32.8-43.4]	[35.1-42.4]	[37.5-46.9]	[36.8-47.4]	[38.6-45.7]	[37.8-45.6]	[41.2-50.4]	[40.4-46.4]
Median	40	36	37.5	47	46	47	43	47	44.5
Age group (%)									
0-4y	7	12	9	6	0	4	6	0	4
5-9y	9	8	9	6	8	7	3	5	4
10-14y	9	1	5	4	4	4	6	8	7
15-19y	2	7	5	4	6	4	3	3	3
20-24y	1	4	2	5	4	4	4	5	5
25-29y	6	6	6	6	4	5	3	5	4
30-34y	7	7	7	5	4	4	5	3	4
35-39y	6	9	7	4	2	3	7	13	9
40-44y	7	5	6	5	10	7	13	5	10
45-49y	7	2	5	10	16	12	10	8	9
50-54y	4	4	4	8	8	8	6	4	5
55-59y	8	7	7	11	14	12	8	8	8
60-64y	6	4	5	13	6	10	5	9	7
65-69y	6	12	9	8	8	8	8	12	9
70-74y	9	6	7	1	2	1	3	8	5
75+y	4	5	5	5	0	3	5	5	5
Unsp.	4	2	3	1	4	2	3	1	3
Total	100	100	100	100	100	100	100	100	100

Table 60: Incidence of CNS cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	5.7	3.3		5.9	3.4	
2004	5.5	4.0		5.4	4.0	
2005	4.5	4.2	4.4	4.6	4.4	4.5
2006	4.1	2.4	3.3	4.4	2.5	3.5
2007	5.9	3.9	4.9	6.0	3.6	4.8

Table 61: Age-specific, crude and age-standardized incidence rates for CNS cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	3.6	6.7	5.3	2.9	0.0	1.6	4.8	0.0	2.5
5-9y	4.2	4.0	4.4	2.6	2.3	2.4	2.3	2.4	2.4
10-14y	3.8	0.5	2.2	1.4	1.0	1.2	3.6	3.3	3.5
15-19y	1.0	3.1	2.0	1.4	1.5	1.5	1.5	1.1	1.3
20-24y	0.5	1.6	1.0	1.9	1.0	1.5	2.5	2.1	2.3
25-29y	3.3	3.0	3.1	3.2	1.2	2.2	1.9	2.4	2.2
30-34y	4.1	4.0	4.1	2.7	1.3	2.0	4.2	1.3	2.7
35-39y	4.0	5.4	4.8	2.4	0.7	1.4	6.7	6.8	6.8
40-44y	5.0	2.7	3.7	3.3	3.3	3.3	14.8	2.9	8.1
45-49y	6.1	1.8	3.9	8.0	7.3	7.6	11.9	5.1	8.6
50-54y	4.5	3.4	4.0	7.8	4.5	6.1	8.0	3.0	5.4
55-59y	9.9	7.9	8.9	12.6	9.0	10.7	12.6	7.6	9.9
60-64y	7.8	4.1	5.8	16.8	4.1	10.1	8.9	8.8	8.9
65-69y	8.3	16.6	12.4	11.4	6.5	9.0	14.2	13.4	13.8
70-74y	16.6	11.3	14.1	2.0	2.2	2.1	7.2	10.9	9.1
75+y	8.3	8.3	8.3	8.2	0.0	4.1	8.1	6.0	7.1
Crude Rate	**4.5**	**4.2**	**4.4**	**4.1**	**2.4**	**3.3**	**5.9**	**3.9**	**4.9**
	[3.6-5.4]	[3.3-5.1]	[3.7-5]	[3.2-5]	[1.8-3.1]	[2.7-3.8]	[4.8-6.9]	[3-4.7]	[4.2-5.5]
ASR	**4.6**	**4.4**	**4.5**	**4.4**	**2.5**	**3.5**	**6.0**	**3.6**	**4.8**
	[3.6-5.6]	[3.4-5.3]	[3.8-5.2]	[3.5-5.4]	[1.8-3.1]	[2.9-4]	[4.9-7.1]	[2.8-4.4]	[4.1-5.5]

Table 62: Distribution of CNS cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
TUMORS OF NEUROEPITHELIAL TISSUE	Astrocytic Tumors	76	43.4%	60	44.8%	100	51.8%	236	50.6%
	Oligodendroglial Tumors	18	10.3%	24	17.9%	22	11.4%	64	13.7%
	Oligoastrocytic Tumors	10	5.7%	4	3.0%	9	4.7%	23	4.9%
	Ependymal Tumors	8	4.6%	5	3.7%	11	5.7%	24	5.2%
	Choroid Plexus Tumors	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Neuroepithelial Tumors	22	12.6%	19	14.2%	11	5.7%	52	11.2%
	Neuronal And Mixed Neuronal Glial Tumors	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Tumors of the Pineal Region	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Embryonal Tumors	22	12.6%	5	3.7%	9	4.7%	36	7.7%
TUMORS OF CRANIAL AND PARASPINAL NERVES	Schwannoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Neurofibroma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Perineurioma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
TUMORS OF THE MENINGES	Tumors of Meningothelial Cells	11	6.3%	5	3.7%	11	5.7%	27	5.8%
	Mesenchymal Tumors	1	0.6%	2	1.5%	1	0.5%	4	0.9%
	Primary Melanocytic Lesions	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Other Neoplasms Related to the Meninges	0	0.0%	0	0.0%	0	0.0%	0	0.0%
GERM CELL TUMORS		1	0.6%	0	0.0%	1	0.5%	2	0.4%
TUMORS OF THE SELLAR REGION		0	0.0%	0	0.0%	1	0.5%	1	0.2%
OTHER SPECIFIED TUMORS		1	0.6%	2	1.5%	4	2.1%	7	1.5%
UNSPECIFIED		5	2.9%	8	6.0%	13	6.7%	26	5.6%
TOTAL		175	100.0%	134	100.0%	193	100.0%	466	100.0%

Table 63: Distribution of thyroid cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	32	110	142	36	142	178	57	154	212
%	23%	77%	100%	20%	80%	100%	27%	73%	100%
Age									
Mean	47.4	44.5	45.1	44.8	45.2	45.1	46.9	46.0	46.2
Mean 95 % CI	[41.1-53.7]	[41.4-47.6]	[42.3-47.9]	[38.2-51.3]	[42.5-47.8]	[42.6-47.6]	[42.4-51.5]	[43.4-48.6]	[43.9-48.4]
Median	42	43	43	42.5	43	43	45.5	43	44
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	2	1	0	1	1	0	0	0
10-14y	3	0	1	0	0	0	4	1	2
15-19y	0	0	0	8	1	3	4	3	3
20-24y	0	7	6	8	3	4	2	3	2
25-29y	3	7	6	6	8	8	5	8	7
30-34y	13	10	11	3	12	10	5	6	6
35-39y	13	14	13	8	11	11	12	14	14
40-44y	19	9	11	19	12	13	16	15	15
45-49y	6	11	10	8	10	10	16	9	11
50-54y	6	9	8	0	9	7	9	8	8
55-59y	6	9	8	3	4	3	4	5	5
60-64y	3	2	2	6	8	7	9	8	8
65-69y	6	5	5	6	4	4	4	5	4
70-74y	6	5	5	11	6	7	2	5	4
75+y	6	4	4	3	3	3	9	5	6
Unsp.	9	7	8	11	9	10	2	5	4
Total	100	100	100	100	100	100	100	100	100

Table 64: Incidence of thyroid cancer, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	**Male**	**Female**	**Both**	**Male**	**Female**	**Both**
2003	1.7	4.0		1.7	4.2	
2004	1.8	5.6		1.8	5.6	
2005	1.6	5.4	3.5	1.6	5.2	3.4
2006	1.8	6.9	4.4	1.7	6.6	4.2
2007	2.9	7.7	5.3	2.9	6.9	4.9

Table 65: Age-specific, crude and age-standardized incidence rates for thyroid cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5-9y	0.0	1.2	0.6	0.0	0.6	0.3	0.0	0.0	0.0
10-14y	0.5	0.0	0.2	0.0	0.0	0.0	1.0	1.1	1.1
15-19y	0.0	0.0	0.0	1.4	1.0	1.5	1.0	2.8	1.8
20-24y	0.0	4.7	2.3	1.4	2.0	2.0	0.5	2.1	1.3
25-29y	0.7	5.5	3.1	1.3	7.8	4.7	1.9	7.8	5.0
30-34y	2.8	8.1	5.4	0.7	12.6	6.7	2.1	6.0	4.4
35-39y	3.2	10.8	7.7	2.4	11.9	7.6	5.9	15.6	11.3
40-44y	5.8	7.4	6.3	6.5	12.6	9.9	8.3	17.2	13.3
45-49y	2.0	12.0	7.2	3.0	13.6	9.0	8.9	12.6	10.9
50-54y	2.3	12.4	7.3	0.0	15.6	7.8	5.7	14.2	10.2
55-59y	2.8	14.4	8.9	1.4	7.7	4.7	2.8	10.1	6.6
60-64y	1.6	2.8	2.2	3.1	16.3	10.1	7.4	16.4	12.3
65-69y	3.3	8.3	6.6	3.3	9.8	6.5	3.2	10.4	6.9
70-74y	4.1	11.3	8.6	10.2	20.0	13.8	1.8	12.7	7.3
75+y	4.1	8.3	7.3	2.0	8.2	6.1	6.8	12.0	10.0
Crude Rate	**1.6**	**5.4**	**3.5**	**1.8**	**6.9**	**4.4**	**2.9**	**7.7**	**5.3**
	[1-2.2]	[4.4-6.5]	[2.9-4.1]	[1.2-2.3]	[5.8-8.1]	[3.7-5]	[2.1-3.7]	[6.4-8.9]	[4.6-6]
ASR	**1.6**	**5.2**	**3.4**	**1.7**	**6.6**	**4.2**	**2.9**	**6.9**	**4.9**
	[1-2.1]	[4.2-6.1]	[2.8-3.9]	[1.2-2.3]	[5.5-7.7]	[3.5-4.8]	[2.1-3.7]	[5.8-8]	[4.2-5.6]

Table 66: Distribution of thyroid cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005**		**2006**		**2007**		**2005-2007**	
EPIDERMOID CARCINOMA		4	2.8%	1	0.6%	3	1.4%	8	1.5%
ADENOCARCINOMA	Papillary Adenocarcinoma	119	83.8%	152	85.4%	178	84.0%	449	84.4%
	Follicular Carcinoma	3	2.1%	4	2.2%	5	2.4%	12	2.3%
	Oxyphylic Carcinoma	2	1.4%	0	0.0%	1	0.5%	3	0.6%
	Other Adenocarcinoma	3	2.1%	2	1.1%	4	1.9%	9	1.7%
OTHER CARCINOMA	Medullary Carcinoma	2	1.4%	0	0.0%	4	1.9%	6	1.1%
	Other Specific Carcinoma	0	0.0%	0	0.0%	0	0.0%	0	0.0%
	Anaplastic Carcinoma	3	2.1%	3	1.7%	2	0.9%	8	1.5%
	Carcinoma NOS	4	2.8%	11	6.2%	11	5.2%	26	4.9%
OTHER SPECIFIC TYPES	Sarcoma and other Soft Tissue Tumors	0	0.0%	2	1.1%	0	0.0%	2	0.4%
	Other Types	0	0.0%	0	0.0%	0	0.0%	0	0.0%
UNSPECIFIED		2	1.4%	3	1.7%	4	1.9%	9	1.7%
TOTAL		142	100.0%	178	100.0%	212	100.0%	532	100.0%

Table 67: Distribution of leukemia by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	165	130	296	204	141	345	195	136	333
%	56%	44%	100%	59%	41%	100%	59%	41%	100%
Age									
Mean	45.8	41.0	43.8	43.7	49.4	46.1	44.4	43.5	44.0
Mean 95 % CI	[41.7-50]	[36.1-45.8]	[40.6-47]	[39.9-47.4]	[45.5-53.4]	[43.3-48.8]	[40.5-48.3]	[39.2-47.7]	[41.1-46.8]
Median	54	45	50	50	56	52	48	46	47
Age group (%)									
0-4y	5	14	9	9	6	8	8	7	8
5-9y	7	7	7	9	6	8	8	9	8
10-14y	8	5	7	4	4	4	5	6	5
15-19y	5	2	4	4	3	4	5	2	4
20-24y	4	3	3	3	1	2	5	4	5
25-29y	2	2	2	2	2	2	3	2	3
30-34y	1	8	4	3	0	2	4	3	4
35-39y	2	2	2	4	4	4	3	8	5
40-44y	5	3	4	3	9	6	5	5	5
45-49y	4	5	4	4	7	6	5	7	5
50-54y	5	7	6	8	5	7	5	6	5
55-59y	4	3	4	5	9	7	9	7	8
60-64y	10	5	8	7	9	8	3	7	5
65-69y	9	8	8	9	11	10	6	10	8
70-74y	13	7	10	7	11	9	7	9	8
75+y	10	12	10	12	11	12	17	8	13
Unsp.	5	8	6	4	2	3	3	1	2
Total	100	100	100	100	100	100	100	100	100

Table 68: Incidence of leukemia, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	9.5	5.6		9.3	6.3	
2004	8.4	8.2		5.3	5.3	
2005	8.2	6.4	7.3	8.3	6.9	7.6
2006	10.0	6.9	8.5	10.4	7.0	8.7
2007	9.9	6.8	8.3	9.5	6.6	8.1

Table 69: Age-specific, crude and age-standardized incidence rates for leukemia, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	4.7	13.4	9.1	11.7	5.3	8.7	11.8	6.8	9.4
5-9y	6.9	5.8	6.4	10.4	4.6	7.6	9.3	7.3	8.3
10-14y	7.0	3.0	5.1	3.7	2.9	3.6	5.1	4.4	4.8
15-19y	4.4	1.6	3.0	4.3	2.0	3.2	4.4	1.7	3.1
20-24y	2.9	2.1	2.8	2.9	1.0	2.0	4.9	3.2	4.1
25-29y	2.6	1.8	2.2	3.2	1.8	2.5	3.9	1.8	2.8
30-34y	0.7	6.7	3.7	4.8	0.0	2.3	5.7	2.7	4.1
35-39y	2.4	2.0	2.2	6.3	3.3	4.7	4.2	7.5	6.0
40-44y	8.3	2.7	5.2	4.9	8.6	6.9	9.3	5.0	6.9
45-49y	6.1	7.4	6.8	9.0	9.1	9.0	8.9	7.6	8.2
50-54y	9.0	10.2	10.2	18.9	7.8	13.4	11.4	8.1	9.7
55-59y	9.9	5.2	8.2	15.4	16.8	16.1	25.2	11.3	17.9
60-64y	28.0	8.3	17.5	23.0	16.3	19.5	8.9	11.4	10.2
65-69y	26.5	18.2	22.4	32.7	24.5	28.6	18.9	19.4	19.9
70-74y	47.7	22.6	35.7	32.7	35.6	34.1	25.3	21.8	23.6
75+y	35.2	33.1	34.2	53.1	32.7	42.9	45.9	16.5	32.0
Crude Rate	**8.2**	**6.4**	**7.3**	**10.0**	**6.9**	**8.5**	**9.9**	**6.8**	**8.3**
	[7-9.5]	[5.3-7.5]	[6.5-8.2]	[8.7-11.4]	[5.7-8]	[7.6-9.3]	[8.5-11.3]	[5.6-7.9]	[7.4-9.2]
ASR	**8.3**	**6.9**	**7.6**	**10.4**	**7.0**	**8.7**	**9.5**	**6.6**	**8.1**
	[7-9.6]	[5.7-8.1]	[6.7-8.5]	[8.9-11.8]	[5.8-8.2]	[7.8-9.6]	[8.1-10.9]	[5.5-7.8]	[7.2-9]

Table 70: Distribution of leukemia by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
ACUTE LYMPHOID LEUKEMIA	Burkitt Cell Leukemia	4	1.4%	2	0.6%	1	0.3%	7	0.7%
	Adult T Cell Leukemia Lymphoma HTLV1	1	0.3%	0	0.0%	0	0.0%	1	0.1%
	Prolymphocytic Leukemia	3	1.0%	0	0.0%	2	0.6%	5	0.5%
	Precursor Cell Lymphoblastic Leukemia	55	18.6%	85	24.6%	76	22.8%	216	22.2%
CHRONIC LYMPHOID LEUKEMIA		54	18.2%	71	20.6%	68	20.4%	193	19.8%
ACUTE MYELOID LEUKEMIA	Acute Myeloid Leukemia NOS	50	16.9%	54	15.7%	60	18.0%	164	16.8%
	Other Specified AML	25	8.4%	37	10.7%	35	10.5%	97	10.0%
	Therapy Related Acute Myeloid Leukemia	0	0.0%	0	0.0%	0	0.0%	0	0.0%
CHRONIC MYELOID LEUKEMIA		40	13.5%	60	17.4%	44	13.2%	144	14.8%
OTHER LEUKEMIA		10	3.4%	12	3.5%	13	3.9%	35	3.6%
UNSPECIFIED LEUKEMIA	Lymphoid Leukemia NOS	22	7.4%	4	1.2%	2	0.6%	28	2.9%
	Myeloid Leukemia NOS	4	1.4%	4	1.2%	1	0.3%	9	0.9%
	Leukemia NOS	28	9.5%	16	4.6%	31	9.3%	75	7.7%
TOTAL		296	100.0%	345	100.0%	333	100.0%	974	100.0%

Table 71: Distribution of lymphoma by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	357	303	660	362	302	666	369	319	691
%	54%	46%	100%	54%	45%	100%	53%	46%	100%
Age									
Mean	48.7	52.5	50.4	48.1	52.8	50.2	50.4	51.2	50.8
Mean 95 % CI	[46.4-51]	[50.1-54.8]	[48.8-52.1]	[46-50.3]	[50.4-55.2]	[48.6-51.8]	[48.2-52.6]	[49-53.4]	[49.3-52.4]
Median	52	56	53	49	56	53	54	54	54
Age group (%)									
0-4y	1	0	1	1	1	1	1	0	1
5-9y	1	1	1	1	1	1	2	1	1
10-14y	4	3	3	4	2	3	3	2	2
15-19y	5	4	4	4	4	4	4	3	4
20-24y	8	5	7	6	3	5	4	4	4
25-29y	3	5	4	5	7	6	5	5	5
30-34y	4	3	3	5	3	4	5	7	6
35-39y	5	6	5	5	2	4	4	5	4
40-44y	4	8	6	9	6	7	6	7	7
45-49y	6	6	6	7	6	7	7	5	6
50-54y	8	8	8	8	8	8	7	8	8
55-59y	8	7	7	7	9	8	8	10	9
60-64y	6	8	7	7	8	8	10	8	9
65-69y	10	9	9	5	10	7	10	8	9
70-74y	8	12	10	10	9	10	7	10	9
75+y	11	13	12	9	14	11	14	11	12
Unsp.	7	5	6	7	6	6	4	6	5
Total	100	100	100	100	100	100	100	100	100

Table 72: Incidence of lymphoma, Lebanon 2003-2007

	Crude incidence rate			Age-standardized rate		
Year	Male	Female	Both	Male	Female	Both
2003	13.9	9.8		13.9	9.9	
2004	18.1	13.5		17.7	13.4	
2005	17.8	15.0	16.4	17.6	14.3	15.9
2006	17.8	14.7	16.3	17.7	14.4	16.0
2007	18.8	15.9	17.3	17.6	14.0	15.8

Table 73: Age-specific, crude and age-standardized incidence rates for lymphoma, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	3.0	0.0	1.6	1.7	1.3	1.6	2.8	0.0	1.4
5-9y	2.6	1.2	1.9	1.6	2.3	1.9	3.5	1.8	3.0
10-14y	6.6	4.5	5.6	6.5	3.4	5.0	5.6	3.3	4.8
15-19y	9.3	6.2	7.8	8.2	6.1	7.2	7.7	6.1	7.0
20-24y	14.6	8.3	11.6	12.0	5.1	8.4	8.4	6.4	7.4
25-29y	8.5	9.1	8.5	12.2	13.1	12.7	12.3	10.2	10.9
30-34y	10.4	6.0	8.2	12.2	7.3	9.7	13.4	15.2	14.4
35-39y	16.0	12.1	13.9	15.8	4.6	10.1	13.4	10.9	11.6
40-44y	14.1	16.1	15.2	26.9	12.6	19.0	21.3	17.2	19.0
45-49y	25.4	16.6	20.8	29.0	17.2	22.8	24.7	14.3	19.1
50-54y	33.9	28.3	31.1	35.6	29.0	32.8	29.7	29.4	29.5
55-59y	41.2	28.8	34.7	40.6	38.7	39.6	40.6	44.1	42.4
60-64y	37.3	33.1	35.1	39.8	35.4	37.5	59.4	32.9	44.4
65-69y	63.0	46.4	54.7	32.7	52.3	42.5	59.9	38.7	49.0
70-74y	62.2	88.1	74.6	81.7	66.8	73.5	48.9	63.6	57.1
75+y	89.1	87.0	88.1	67.4	91.9	79.6	71.6	57.1	64.7
Crude Rate	**17.8**	**15.0**	**16.4**	**17.8**	**14.7**	**16.3**	**18.8**	**15.9**	**17.3**
	[16-19.7]	[13.3-16.7]	[15.2-17.7]	[16-19.6]	[13.1-16.4]	[15-17.5]	[16.9-20.7]	[14.1-17.6]	[16-18.6]
ASR	**17.6**	**14.3**	**15.9**	**17.7**	**14.4**	**16.0**	**17.6**	**14.0**	**15.8**
	[15.8-19.4]	[12.7-15.9]	[14.7-17.2]	[15.8-19.5]	[12.7-16]	[14.8-17.3]	[15.8-19.4]	[12.4-15.6]	[14.6-17]

Table 74: Distribution of lymphoma by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005 n & %**		**2006 n & %**		**2007 n & %**		**2005-2007 n & %**	
HODGKIN LYMPHOMA	Nodular Lymphocytic Predominance	1	0.2%	1	0.2%	1	0.1%	3	0.1%
	Classical Lymphocyte Rich	0	0.0%	1	0.2%	3	0.4%	4	0.2%
	Nodular Sclerosis	38	5.8%	51	7.7%	75	10.9%	164	8.1%
	Mixed Cellularity	10	1.5%	13	2.0%	10	1.4%	33	1.6%
	Lymphocytic Depletion	1	0.2%	1	0.2%	0	0.0%	2	0.1%
	Other Specified	0	0.0%	0	0.0%	2	0.3%	2	0.1%
	Unspecified	93	14.1%	71	10.7%	83	12.0%	247	12.2%
MATURE NON HODGKIN LYMPHOMA B CELL	Small B Lymphocytic	21	3.2%	18	2.7%	14	2.0%	53	2.6%
	Mantle Cell Lymphoma	6	0.9%	12	1.8%	11	1.6%	29	1.4%
	Large B Cell Lymphoma	152	23.0%	176	26.4%	164	23.7%	492	24.4%
	Burkitt Lymphoma	14	2.1%	14	2.1%	6	0.9%	34	1.7%
	Follicular Lymphoma	40	6.1%	52	7.8%	67	9.7%	159	7.9%
	Marginal Zone B Cell Lymphoma NOS	15	2.3%	16	2.4%	21	3.0%	52	2.6%
	Other	4	0.6%	7	1.1%	1	0.1%	12	0.6%
MATURE NON HODGKIN LYMPHOMA T AND	Mature T Cell Lymphoma	9	1.4%	13	2.0%	10	1.4%	32	1.6%
	Other	15	2.3%	30	4.5%	20	2.9%	65	3.2%
PRECURSOR CELL LYMPHOBLASTIC		3	0.5%	2	0.3%	4	0.6%	9	0.4%
LYMPHOMA NOS		236	35.8%	185	27.8%	172	24.9%	593	29.4%
OTHER TUMORS		2	0.3%	3	0.5%	27	3.9%	32	1.6%
TOTAL		660	100.0%	666	100.0%	691	100.0%	2017	100.0%

Table 75: Distribution of lymphoma by site, Lebanon, 2005-2007

	2005		2006		2007		2005-2007	
Site	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Lip / oral cavity and pharynx	13	2	14	2.1	19	2.7	46	2%
Digestive organs	76	11.5	69	10.4	83	12	228	11%
Respiratory and intrathoracic	34	5.2	27	4.1	32	4.6	93	5%
Bones / joints and cartilage	8	1.2	10	1.5	5	0.7	23	1%
Hematopoietic and reticulo	4	0.6	10	1.5	21	3	35	2%
Skin	24	3.6	26	3.9	35	5.1	85	4%
Peripheral nerve and autonomic	0	0	0	0	0	0	0	0%
Retroperitoneum and peritoneum	6	0.9	4	0.6	4	0.6	14	1%
Connective /subcutaneous /soft	8	1.2	14	2.1	5	0.7	27	1%
Breast	3	0.5	5	0.8	4	0.6	12	1%
Female genital organs	0	0	2	0.3	2	0.3	4	0%
Male genital organs	0	0	2	0.3	3	0.4	5	0%
Urinary tract	7	1.1	5	0.8	3	0.4	15	1%
Eye and CNS	11	1.7	11	1.7	7	1	29	1%
Thyroid and other endocrine	5	0.8	3	0.5	5	0.7	13	1%
Other and ill defined sites	2	0.3	4	0.6	3	0.4	9	0%
Lymph nodes	408	61.8	411	61.7	419	60.6	1238	61%
Unknown	51	7.7	49	7.4	41	5.9	141	7%
TOTAL	660	100	666	100	691	100	2017	100%

Table 76: Reported pediatric cases by main ICCC-3 groups (age<20) - Lebanon 2005-2007

ICCC main groups	2005	2006	2007	2005-2007	2005	2006	2007	2005-2007
	n				%			
I. Leukemia & myeloproliferative & myelodysplastic diseases	78	81	83	242	27%	28%	28%	28%
II. Lymphomas & reticuloendothelial neoplasms	63	59	56	178	22%	21%	19%	20%
III. CNS & miscellaneous intracranial & intraspinal neo.	46	26	30	102	16%	9%	10%	12%
IV. Neuroblastoma & other peripheral nervous cell tumor	7	6	5	18	2%	2%	2%	2%
V. Retinoblastoma	4	2	7	13	1%	1%	2%	1%
VI. Renal tumors	10	10	6	26	3%	3%	2%	3%
VII. Hepatic tumors	1	5	2	8	0%	2%	1%	1%
VIII. Malignant bone tumors	21	28	42	91	7%	10%	14%	10%
IX. Soft tissue & other extraosseous sarcomas	26	28	25	79	9%	10%	9%	9%
X. Germ cell & trophoblastic & neoplasms of gonads	7	13	8	28	2%	5%	3%	3%
XI. Other malignant epithelial neoplasms & melanomas	26	26	26	78	9%	9%	9%	9%
XII. Other & unspecified malignant neoplasms	3	3	4	10	1%	1%	1%	1%
All sites	292	287	294	873	100%	100%	100%	100%

Table 77: Reported pediatric cases by ICCC-3 subgroups (age<20) - Lebanon 2005-2007

Groups	Sub-groups	2005	2006	2007	2005-2007	2005	2006	2007	2005-2007
		n				%			
I. Leukemia & myeloproliferative & myelodysplastic diseases	a1. Lymphoid leukemias: precursor cell	34	60	57	151	1%	3%	2%	17%
	a2. Lymphoid leukemias: mature B-cell	5	2	0	7	0%	0%	0%	1%
	a3. Lymphoid leukemias: mature T-cell	0	0	0	0	0%	0%	0%	0%
	a4. Lymphoid leukemias: lymphoid leukemias NOS	10	0	0	10	0%	0%	0%	1%
	b. Acute myeloid leukemias	14	11	16	41	1%	0%	1%	5%
	c. Chronic myeloproliferative diseases	4	4	2	10	0%	0%	0%	1%
	d.Myelodysplastic synd & other meyoloproliferative disease	0	1	0	1	0%	0%	0%	0%
	e. Unspecified & other specified leukemias	11	3	8	22	0%	0%	0%	3%
II. Lymphomas & reticuloendothelial neoplasms	a. Hodgkin lymphomas	33	27	31	91	1%	1%	1%	10%
	b1. NHL: precursor cell	2	2	0	4	0%	0%	0%	0%
	b2. NHL: mature B-cell	6	7	4	17	0%	0%	0%	2%
	b3. NHL: mature T-cell & NK-cell	5	4	2	11	0%	0%	0%	1%
	b4. NHL: NOS	5	7	8	20	0%	0%	0%	2%
	c. Burkitt lymphoma	8	7	4	19	0%	0%	0%	2%
	d. Miscellaneous lymphoreticular neoplasms	1	1	4	6	0%	0%	0%	1%
	e. Unspecified lymphomas	3	4	3	10	0%	0%	0%	1%
III. CNS & miscellaneous intracranial & intraspinal neoplasms	a1. Ependymomas	4	1	2	7	0%	0%	0%	1%
	a2. Choroid plexus tumor	0	0	0	0	0%	0%	0%	0%
	b. Astrocytomas	19	16	18	53	1%	1%	1%	6%
	c1. Medulloblastomas	11	2	4	17	0%	0%	0%	2%
	c2. PNET	5	2	0	7	0%	0%	0%	1%
	c3. Medulloepithelioma	0	0	0	0	0%	0%	0%	0%
	c4. Atypical teratoid rhabdoid tumor	0	0	0	0	0%	0%	0%	0%
	d1. Oligodendrogliomas	1	2	2	5	0%	0%	0%	1%
	d2. Mixed & unspecified gliomas	3	2	4	9	0%	0%	0%	1%
	d3. Neuroepithelial glial tumors of uncertain origin	1	0	0	1	0%	0%	0%	0%
	e1. Pituitary adenomas & carcinomas	0	0	0	0	0%	0%	0%	0%
	e2. Tumors of cellar region	0	0	0	0	0%	0%	0%	0%
	e3. Pineal parenchymal tumors	0	0	0	0	0%	0%	0%	0%
	e4. Neuronal & mixed neuronal-glial tumors	0	0	0	0	0%	0%	0%	0%
	e5. Meningiomas	0	0	0	0	0%	0%	0%	0%
	f. Unspecified intracranial & intraspinal neoplasms	2	1	0	3	0%	0%	0%	0%

IV. Neuroblastoma & other peripheral nervous cell tumor	a. Neuroblastoma & ganglioneuroblastoma	7	6	5	18	0%	0%	0%	2%
	b. Other peripheral nervous cell tumors	0	0	0	0	0%	0%	0%	0%
V. Retinoblastoma	Retinoblastoma	4	2	7	13	0%	0%	0%	1%
VI. Renal tumors	a1. Nephroblastoma	10	7	4	21	0%	0%	0%	2%
	a2. Rhabdoid renal tumor	0	0	0	0	0%	0%	0%	0%
	a3. Kidney sarcomas	0	0	0	0	0%	0%	0%	0%
	a4. pNET of kidney	0	0	0	0	0%	0%	0%	0%
	b. Renal carcinomas	0	2	2	4	0%	0%	0%	0%
	c. Unspecified malignant renal tumors	0	1	0	1	0%	0%	0%	0%
VII. Hepatic tumors	a. Hepatoblastoma	0	3	0	3	0%	0%	0%	0%
	b. Hepatic carcinomas	1	1	2	4	0%	0%	0%	0%
	c. Unspecified malignant hepatic tumors	0	1	0	1	0%	0%	0%	0%
VIII. Malignant bone tumors	a. Osteosarcomas	10	11	17	38	0%	0%	1%	4%
	b. Chondrosarcomas	1	0	1	2	0%	0%	0%	0%
	c1. Ewing tumor & Askin tumor of bone	7	15	17	39	0%	1%	1%	4%
	c2. pNET of bone	0	0	0	0	0%	0%	0%	0%
	d1. Malignant fibrous neoplasms of bone	0	0	1	1	0%	0%	0%	0%
	d2. Malignant chordomas	0	0	0	0	0%	0%	0%	0%
	d3. Odontogenic malignant tumors	0	1	0	1	0%	0%	0%	0%
	d4. Miscellaneous malignant bone tumors	2	0	1	3	0%	0%	0%	0%
	e. Unspecified malignant bone tumors	1	1	5	7	0%	0%	0%	1%
IX. Soft tissue & other extraosseous sarcomas	a. Rhabdomyosarcomas	15	14	7	36	1%	1%	0%	4%
	b1. Fibroblastic & myofibroblastic tumors	0	0	1	1	0%	0%	0%	0%
	b2. Nerve sheath tumors	0	0	0	0	0%	0%	0%	0%
	b3. Other fibromatous	0	0	0	0	0%	0%	0%	0%
	c. Kaposi sarcoma	0	0	0	0	0%	0%	0%	0%
	d1. Ewing tumor & Askin tumor of soft tissue	4	2	0	6	0%	0%	0%	1%
	d2. pNET of soft tissue	0	0	0	0	0%	0%	0%	0%
	d3. Extrarenal rhabdoid tumor	0	0	0	0	0%	0%	0%	0%
	d4. Liposarcomas	0	0	1	1	0%	0%	0%	0%
	d5. Fibrohistiocytic tumors	0	3	0	3	0%	0%	0%	0%
	d6. Leiomyosarcoms	1	1	1	3	0%	0%	0%	0%
	d7. Synovial sarcomas	2	2	4	8	0%	0%	0%	1%
	d8. Blood vessel tumors	0	0	0	0	0%	0%	0%	0%
	d9. Osseous & chondromatous neoplasms of soft tissue	0	2	0	2	0%	0%	0%	0%
	d10. Alveolar soft parts sarcoma	0	0	0	0	0%	0%	0%	0%
	d11.Miscellaneous soft tissue sarcomas	0	0	0	0	0%	0%	0%	0%
	e. Unspecified soft tissue sarcomas	4	4	11	19	0%	0%	0%	2%

X. Germ cell & trophoblastic & neoplams of gonads	a1. Intracranial & intraspinal germinomas	0	1	1	2	0%	0%	0%	0%
	a2. Intracranial & intraspinal teratomas	1	0	0	1	0%	0%	0%	0%
	a3. Intracranial & intraspinal embryonal carcinomas	0	0	0	0	0%	0%	0%	0%
	a4. Intracranial & intraspinal yolk sac tumor	0	0	0	0	0%	0%	0%	0%
	a5. Intracranial & intraspinal choriocarcinoma	0	0	0	0	0%	0%	0%	0%
	a6. Intracranial & intraspinal tumors of mixed forms	0	0	0	0	0%	0%	0%	0%
	b1. Malignant germinomas of extracranial & extragonadal	0	1	0	1	0%	0%	0%	0%
	b2. Malignant teratomas of extracranial & extragonadal	0	0	0	0	0%	0%	0%	0%
	b3. Embryonal carcinomas of extracranial & extragonadal	0	0	0	0	0%	0%	0%	0%
	b4. Yolk sac tumor of extracranial & extragonadal sites	1	1	1	3	0%	0%	0%	0%
	b5. Choriocarcinomas of extracranial & extragonadal sites	0	0	0	0	0%	0%	0%	0%
	b6. Other & unspecified malignant mixed germ cell tumors of extr	0	0	0	0	0%	0%	0%	0%
	c1. Malignant gonadal germinomas	0	2	0	2	0%	0%	0%	0%
	c2. Malignant gonadal teratomas	0	0	1	1	0%	0%	0%	0%
	c3. Gonadal embryonal carcinomas	2	3	4	9	0%	0%	0%	1%
	c4. Gonadal yolk sac tumor	0	0	0	0	0%	0%	0%	0%
	c5. Gonadal choriocarcinoma	0	0	0	0	0%	0%	0%	0%
	c6. Malignant gonadal tumors of mixed forms	1	0	0	1	0%	0%	0%	0%
	c7. Malignant gonadal gonadoblastoma	0	0	0	0	0%	0%	0%	0%
	d. Gonadal carcinomas	2	4	1	7	0%	0%	0%	1%
	e. Other & unspecified malignant gonadal tumors	0	1	0	1	0%	0%	0%	0%

XI. Other malignant epithelial neoplasms & melanoma	a. Adrenocortical carcinomas	0	0	0	0	0%	0%	0%	0%
	b. Thyroid carcinomas	3	6	10	19	0%	0%	0%	2%
	c. Nasopharyngeal carcinomas	2	6	1	9	0%	0%	0%	1%
	d. Malignant melanomas	3	1	1	5	0%	0%	0%	1%
	e. Skin carcinomas	2	0	1	3	0%	0%	0%	0%
	f1. Carcinomas of salivary glands	2	1	1	4	0%	0%	0%	0%
	f2. Carcinomas of colon & rectum	1	2	3	6	0%	0%	0%	1%
	f3. Carcinomas of appendix	2	0	0	2	0%	0%	0%	0%
	f4. Carcinomas of lung	2	1	2	5	0%	0%	0%	1%
	f5. Carcinomas of thymus	0	1	0	1	0%	0%	0%	0%
	f6. Carcinomas of breast	2	1	1	4	0%	0%	0%	0%
	f7. Carcinomas of cervix uteri	0	0	0	0	0%	0%	0%	0%
	f8. Carcinomas of bladder	2	2	1	5	0%	0%	0%	1%
	f9. Carcinomas of eye	0	0	0	0	0%	0%	0%	0%
	f10. Carcinomas of other specified sites	5	5	4	14	0%	0%	0%	2%
	f11. Carcinomas of unspecified sites	0	0	1	1	0%	0%	0%	0%
XII. Other & unspecified malignant neoplasms	a1. Gastrointestinal stromal tumor	0	0	0	0	0%	0%	0%	0%
	a2. Pancreatoblastoma	0	0	0	0	0%	0%	0%	0%
	a3. Pulmonary blastoma & pleuropulmonary blastoma	0	0	1	1	0%	0%	0%	0%
	a4. Other complex mixed & stromal neoplasms	0	1	0	1	0%	0%	0%	0%
	a5. Mesothelioma	0	0	0	0	0%	0%	0%	0%
	a6. Other specified malignant tumors	0	0	0	0	0%	0%	0%	0%
	b. Other unspecified malignant tumors	3	2	3	8	0%	0%	0%	1%
All sites		2297	2293	2301	873	100%	100%	100%	100%

Table 78: Distribution of non-melanoma skin cancer by gender and age group, Lebanon, 2005-2007

	2005			2006			2007		
	M	F	Both	M	F	Both	M	F	Both
Count									
n	319	187	508	347	175	522	382	254	639
%	63%	37%	100%	66%	34%	100%	60%	40%	100%
Age									
Mean	68.5	64.5	67.0	69.0	63.0	67.1	68.8	65.1	67.3
Mean 95 % CI	[66.7-70.3]	[61.9-67.1]	[65.5-68.5]	[67.5-70.5]	[60.5-65.6]	[65.7-68.4]	[67.4-70.2]	[63.1-67.1]	[66.2-68.5]
Median	70	67	69	71	65	69	71	68	70
Age group (%)									
0-4y	0	0	0	0	0	0	0	0	0
5-9y	0	0	0	0	0	0	0	0	0
10-14y	0	0	0	0	0	0	0	0	0
15-19y	0	0	0	0	0	0	0	0	0
20-24y	0	0	0	0	0	0	0	0	0
25-29y	1	2	1	0	1	0	1	1	1
30-34y	1	2	1	1	3	2	0	1	0
35-39y	2	2	2	1	5	2	2	2	2
40-44y	1	5	3	0	4	2	1	4	3
45-49y	3	3	3	5	5	5	4	5	4
50-54y	3	5	4	6	6	6	5	7	6
55-59y	5	5	5	5	8	6	7	8	8
60-64y	9	7	8	9	7	8	7	7	7
65-69y	11	11	11	12	10	11	11	9	10
70-74y	11	9	10	13	9	11	13	13	13
75+y	29	25	28	33	26	31	33	26	31
Unsp.	24	25	25	14	17	15	15	16	15
Total	100	100	100	100	100	100	100	100	100

Table 79: Incidence of non-melanoma skin cancer, Lebanon 2005-2007

	Crude incidence rate			Age-standardized rate		
Year	**Male**	**Female**	**Both**	**Male**	**Female**	**Both**
2003						
2004						
2005	15.9	9.3	12.6	15.3	8.7	12.0
2006	17.1	8.5	12.8	16.4	8.1	12.2
2007	19.4	12.6	16.0	15.6	10.3	12.9

Table 80: Age-specific, crude and age-standardized incidence rates for non-melanoma skin cancer, Lebanon, 2005-2007

	2005			2006			2007		
Age group	**M**	**F**	**Both**	**M**	**F**	**Both**	**M**	**F**	**Both**
0-4y	0.6	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.4
5-9y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10-14y	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15-19y	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
20-24y	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.5	0.3
25-29y	2.6	2.4	2.5	0.0	0.6	0.3	1.3	2.4	1.9
30-34y	2.1	3.4	2.7	2.7	4.6	3.7	0.7	1.3	1.4
35-39y	5.6	3.4	4.4	3.2	6.6	4.7	5.9	4.8	5.3
40-44y	3.3	8.7	6.3	0.8	5.3	3.7	5.6	9.3	7.7
45-49y	11.2	7.4	9.2	20.0	10.0	14.7	17.8	11.8	14.6
50-54y	14.7	13.6	14.1	29.0	14.5	21.7	27.4	20.3	23.6
55-59y	28.4	15.7	21.8	28.0	21.9	24.8	44.8	31.5	37.8
60-64y	59.0	23.5	40.9	55.1	19.1	36.7	49.0	25.3	36.2
65-69y	79.6	44.8	61.3	81.7	34.3	58.0	80.4	41.7	60.5
70-74y	95.3	47.5	73.5	104.1	40.1	74.6	108.6	69.1	88.9
75+y	254.8	128.4	191.6	273.5	110.2	192.9	201.3	120.3	162.9
Crude Rate	**15.9**	**9.3**	**12.6**	**17.1**	**8.5**	**12.8**	**19.4**	**12.6**	**16.0**
	[14.2-17.7]	[7.9-10.6]	[11.5-13.7]	[15.3-18.9]	[7.3-9.8]	[11.7-13.9]	[17.5-21.4]	[11.1-14.2]	[14.8-17.2]
ASR	**15.3**	**8.7**	**12.0**	**16.4**	**8.1**	**12.2**	**15.6**	**10.3**	**12.9**
	[13.6-17]	[7.5-10]	[10.9-13.1]	[14.7-18.2]	[6.9-9.3]	[11.2-13.3]	[13.9-17.2]	[9-11.6]	[11.9-14]

Table 81: Distribution of non-melanoma skin cancer by histological group, Lebanon, 2005-2007

Group	**Sub-Group**	**2005**		**2006**		**2007**		**2005-2007**	
CARCINOMA	Squamous Cell Carcinoma	154	30.3%	174	33.3%	189	29.6%	517	31.0%
	Basal Cell Carcinoma	339	66.7%	327	62.6%	435	68.1%	1101	66.0%
	Other Specified Carcinoma	8	1.6%	9	1.7%	7	1.1%	24	1.4%
	Unspecified	6	1.2%	12	2.3%	7	1.1%	25	1.5%
UNSPECIFIED		1	0.2%	0	0.0%	1	0.2%	2	0.1%
TOTAL		508	100.0%	522	100.0%	639	100.0%	1669	100.0%

Table 82: Distribution of in-situ tumors by site and year, Lebanon, 2005-2007

	2005	2006	2007	2005-2007	2005	2006	2007	2005-2007
Sites	**n**				**%**			
Lip	0	0	0	0	0%	0%	0%	0%
Tongue	0	0	1	1	0%	0%	1%	0%
Mouth	0	0	0	0	0%	0%	0%	0%
Salivary glands	0	0	0	0	0%	0%	0%	0%
Tonsil	0	0	0	0	0%	0%	0%	0%
Other oropharynx	0	0	0	0	0%	0%	0%	0%
Nasopharynx	0	0	0	0	0%	0%	0%	0%
Hypopharynx	0	0	0	0	0%	0%	0%	0%
Pharynx unsp.	0	0	0	0	0%	0%	0%	0%
Oesophagus	0	1	0	1	0%	1%	0%	0%
Stomach	1	0	1	2	1%	0%	1%	1%
Small intestine	1	0	1	2	1%	0%	1%	1%
Colon	2	3	5	10	2%	3%	4%	3%
Rectum	1	2	1	4	1%	2%	1%	1%
Anus	0	1	0	1	0%	1%	0%	0%
Liver	0	1	0	1	0%	1%	0%	0%
Gallbladder etc.	0	1	1	2	0%	1%	1%	1%
Pancreas	1	0	0	1	1%	0%	0%	0%
Nose sinuses & etc.	0	0	0	0	0%	0%	0%	0%
Larynx	1	4	4	9	1%	3%	3%	3%
Trachea bronchus & lung	0	2	0	2	0%	2%	0%	1%
Other thoracic organs	0	0	0	0	0%	0%	0%	0%
Bone	1	0	0	1	1%	0%	0%	0%
Melanoma of skin	0	0	1	1	0%	0%	1%	0%
Other skin	8	15	15	38	10%	13%	12%	12%
Mesothelioma	0	0	0	0	0%	0%	0%	0%
Kaposi sarcoma	0	0	0	0	0%	0%	0%	0%
Connective & soft tissue	0	0	0	0	0%	0%	0%	0%
Breast	37	51	59	147	45%	43%	46%	45%
Vulva	2	0	2	4	2%	0%	2%	1%
Vagina	1	2	1	4	1%	2%	1%	1%
Cervix uteri	5	15	4	24	6%	13%	3%	7%
Corpus uteri	2	3	3	8	2%	3%	2%	2%
Uterus unsp.	0	0	0	0	0%	0%	0%	0%
Ovary	0	0	0	0	0%	0%	0%	0%
Other female genital	0	0	0	0	0%	0%	0%	0%
Placenta	0	0	0	0	0%	0%	0%	0%
Penis	1	0	0	1	1%	0%	0%	0%
Prostate	1	0	5	6	1%	0%	4%	2%
Testis	0	0	0	0	0%	0%	0%	0%
Other male genital	0	0	0	0	0%	0%	0%	0%
Kidney	0	0	1	1	0%	0%	1%	0%
Renal pelvis	0	0	0	0	0%	0%	0%	0%
Ureter	2	0	0	2	2%	0%	0%	1%
Bladder	14	15	18	47	17%	13%	14%	14%
Other urinary organs	0	0	0	0	0%	0%	0%	0%
Eye	0	1	0	1	0%	1%	0%	0%
Brain & nervous system	0	0	0	0	0%	0%	0%	0%
Thyroid	2	0	3	5	2%	0%	2%	2%
Adrenal gland	0	0	0	0	0%	0%	0%	0%
Other endocrine	0	0	0	0	0%	0%	0%	0%
Hodgkin disease	0	0	0	0	0%	0%	0%	0%
Non-Hodgkin lymphoma	0	0	0	0	0%	0%	0%	0%
Immunoproliferative dis.	0	0	0	0	0%	0%	0%	0%
Multiple myeloma	0	0	0	0	0%	0%	0%	0%
Lymphoid leukemia	0	0	0	0	0%	0%	0%	0%
Myeloid leukemia	0	0	0	0	0%	0%	0%	0%
Leukemia unsp.	0	0	0	0	0%	0%	0%	0%
Other & Unspecified	0	2	1	3	0%	2%	1%	1%
All sites, total	83	119	127	329	100%	100%	100%	100%
All sites, without C44*	75	104	112	291	90%	87%	88%	88%

Table 83: Incident cases (n) by primary site & age group, Lebanon, 2005

Primary site	All ages	Age group																	Gender			ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	Male	Female	Unsp.	
Lip	7	0	0	0	0	0	0	0	0	0	1	0	0	0	1	3	2	0	4	3	0	C00
Tongue	14	0	0	0	0	0	0	0	2	1	3	0	1	3	0	1	2	1	9	5	0	C01-C02
Mouth	19	0	0	0	0	0	0	0	0	1	2	3	2	2	0	3	5	1	9	10	0	C03-C06
Salivary glands	13	0	0	1	1	0	0	0	1	0	3	1	1	0	3	2	0	0	7	6	0	C07-C08
Tonsil	6	0	0	0	0	0	0	0	0	0	1	0	1	2	0	0	0	2	5	1	0	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	0	0	C10
Nasopharynx	27	0	0	2	1	0	1	1	0	5	4	3	2	2	2	1	2	1	21	6	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	3	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	2	1	0	C14
Oesophagus	24	0	0	0	0	0	0	1	1	0	0	1	4	4	1	4	6	2	17	7	0	C15
Stomach	229	0	0	0	0	0	1	3	12	15	13	20	23	21	31	36	36	18	124	105	0	C16
Small intestine	23	0	0	0	0	1	0	3	0	0	4	0	2	1	2	3	6	1	12	11	0	C17
Colon	464	0	0	0	2	5	5	10	11	24	23	34	42	64	57	65	86	36	254	210	0	C18
Rectum	119	0	0	1	0	3	1	3	6	9	5	6	14	17	14	11	19	10	64	55	0	C19-C20
Anus	11	0	1	0	0	0	0	0	0	0	1	1	0	2	2	2	2	0	6	5	0	C21
Liver	84	0	0	0	1	0	0	1	4	2	5	10	11	8	11	9	16	6	45	39	0	C22
Gallbladder etc.	59	0	0	0	0	0	0	0	0	1	4	5	4	2	9	11	16	7	29	30	0	C23-C24
Pancreas	143	0	0	1	1	1	1	1	2	6	10	18	10	19	24	15	21	13	70	73	0	C25
Nose sinuses & etc.	13	0	0	0	0	0	0	0	1	1	4	1	2	1	0	2	0	1	7	6	0	C30-C31
Larynx	118	0	0	0	0	0	1	0	3	3	9	9	10	24	17	22	15	5	97	21	0	C32
Trachea bronchus & lung	702	1	0	0	1	2	3	7	13	24	47	49	68	107	118	81	136	45	502	198	2	C33-C34
Other thoracic organs	64	1	0	0	0	1	4	3	1	3	3	5	5	5	10	3	14	6	41	23	0	C37-C38
Bone	81	1	3	11	7	3	2	11	6	3	5	5	3	2	4	3	7	5	53	28	0	C40-C41
Melanoma of skin	64	2	0	0	1	2	0	1	3	10	2	5	3	3	5	4	12	11	34	30	0	C43
Other skin	508	1	0	0	1	0	6	6	9	13	14	19	24	42	56	51	140	126	319	187	2	C44
Mesothelioma	12	0	0	0	0	0	0	0	2	1	2	1	1	1	1	0	3	0	10	2	0	C45
Kaposi sarcoma	6	0	0	0	0	0	0	0	2	0	0	0	1	0	0	1	1	1	6	0	0	C46
Connective & soft tissue	76	3	1	4	7	3	2	3	8	3	8	5	9	8	2	1	1	8	45	31	0	C47;C49
Breast	1466	0	0	0	3	1	15	45	106	215	181	208	148	143	125	99	103	74	15	1451	0	C50
Vulva	23	0	0	0	0	0	1	1	0	1	0	1	1	5	2	3	5	3	0	23	0	C51
Vagina	8	0	0	0	0	0	0	0	1	0	0	2	3	0	1	0	1	0	0	8	0	C52
Cervix uteri	82	0	0	0	0	0	1	3	6	16	7	13	6	11	5	7	3	4	0	82	0	C53
Corpus uteri	120	0	0	0	0	0	0	1	4	8	12	10	16	20	15	12	15	7	0	120	0	C54
Uterus unsp.	30	0	0	0	0	0	0	0	0	1	4	3	5	5	5	2	5	0	0	30	0	C55
Ovary	182	0	0	1	1	5	4	2	6	12	19	18	25	27	16	16	20	10	0	182	0	C56
Other female genital	4	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	1	0	0	4	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Penis	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	2	0	0	C60
Prostate	607	0	0	0	1	0	0	0	1	3	5	14	42	76	129	122	170	44	607	0	0	C61
Testis	62	0	1	0	3	6	7	23	8	3	3	2	1	1	0	1	1	2	62	0	0	C62
Other male genital	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	2	0	0	C63
Kidney	101	7	1	2	0	1	2	0	3	2	12	3	7	14	20	13	10	4	77	24	0	C64
Renal pelvis	10	0	0	0	0	0	0	0	1	1	1	0	1	1	3	2	0	0	6	4	0	C65
Ureter	4	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0	2	2	0	C66
Bladder	689	0	1	1	0	0	2	2	9	20	31	46	63	80	100	90	162	82	558	130	1	C67
Other urinary organs	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	3	0	0	C68
Eye	13	4	2	1	2	0	0	0	0	0	0	0	0	0	1	2	0	1	2	11	0	C69
Brain & nervous system	175	16	15	9	8	4	10	12	13	10	8	7	13	8	15	13	8	6	90	85	0	C70-C72
Thyroid	142	0	2	1	0	8	9	15	19	16	14	12	12	3	7	7	6	11	32	110	0	C73
Adrenal gland	6	3	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	2	4	0	C74
Other endocrine	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C75
Hodgkin disease	143	1	0	14	18	22	10	10	11	7	4	8	5	3	5	7	11	7	76	67	0	C81
Non-Hodgkin lymphoma	517	4	7	8	11	21	16	13	25	32	36	44	43	42	57	58	69	31	281	236	0	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	111	0	0	0	0	0	0	0	2	6	4	7	11	9	14	17	32	9	62	49	0	C90
Lymphoid leukemia	139	18	15	10	4	3	1	1	1	7	4	5	3	10	14	16	14	13	81	57	1	C91
Myeloid leukemia	129	5	2	7	7	5	6	7	5	6	9	8	7	13	9	12	15	6	68	61	0	C92-C94
Leukemia unsp.	28	3	4	3	0	2	0	3	0	0	0	4	1	1	2	3	2	0	16	12	0	C95
Other & Unspecified	224	2	4	1	2	4	2	4	8	20	17	26	13	23	15	22	38	23	102	122	0	OTHER
All sites, total	7914	72	59	78	83	103	115	197	317	512	545	644	669	840	932	860	1245	643	3941	3967	6	
All sites, without C44*	7406	71	59	78	82	103	109	191	308	499	531	625	645	798	876	809	1105	517	3622	3780	4	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 84: Incident cases (n) by primary site & age group, males, Lebanon, 2005

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	4	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	0	C00
Tongue	9	0	0	0	0	0	0	0	2	0	1	0	1	3	0	1	1	0	C01-C02
Mouth	9	0	0	0	0	0	0	0	0	0	2	2	1	0	0	2	2	0	C03-C06
Salivary glands	7	0	0	1	0	0	0	0	1	0	2	1	0	0	1	1	0	0	C07-C08
Tonsil	5	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	2	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	C10
Nasopharynx	21	0	0	1	1	0	0	1	0	4	3	3	1	2	1	1	2	1	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	C14
Oesophagus	17	0	0	0	0	0	0	0	1	0	0	1	2	2	0	4	5	2	C15
Stomach	124	0	0	0	0	0	0	1	4	7	3	11	11	13	24	19	23	8	C16
Small intestine	12	0	0	0	0	1	0	2	0	0	0	0	1	0	1	2	4	1	C17
Colon	254	0	0	0	1	1	3	6	5	13	11	22	21	35	36	34	46	20	C18
Rectum	64	0	0	1	0	3	1	1	5	2	2	3	10	7	8	4	11	6	C19-C20
Anus	6	0	0	0	0	0	0	0	0	0	1	1	0	1	1	2	0	0	C21
Liver	45	0	0	0	1	0	0	1	3	1	4	4	9	4	5	6	5	2	C22
Gallbladder etc.	29	0	0	0	0	0	0	0	0	1	2	3	2	1	5	4	7	4	C23-C24
Pancreas	70	0	0	0	0	0	0	1	2	3	6	9	5	11	10	8	11	4	C25
Nose & sinuses & etc.	7	0	0	0	0	0	0	0	0	1	3	1	1	1	0	0	0	0	C30-C31
Larynx	97	0	0	0	0	0	0	0	1	3	7	8	7	20	17	18	12	4	C32
Trachea bronchus & lung	502	1	0	0	1	2	1	4	6	16	33	32	46	70	92	67	101	30	C33-C34
Other thoracic organs	41	0	0	0	0	1	3	2	0	1	2	3	4	5	7	2	9	2	C37-C38
Bone	53	1	3	7	4	2	1	6	6	0	3	1	3	1	3	3	5	4	C40-C41
Melanoma of skin	34	1	0	0	0	1	0	1	1	3	2	3	0	0	2	3	8	9	C43
Other skin	319	1	0	0	1	0	3	2	5	3	8	10	15	29	36	35	93	78	C44
Mesothelioma	10	0	0	0	0	0	0	0	1	1	2	1	1	1	1	0	2	0	C45
Kaposi sarcoma	6	0	0	0	0	0	0	0	2	0	0	0	1	0	0	1	1	1	C46
Connective & soft tissue	45	1	1	2	6	2	1	1	4	2	4	2	7	5	1	1	1	4	C47;C49
Breast	15	0	0	0	0	0	0	0	0	3	0	1	1	1	2	4	3	0	C50
Penis	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	C60
Prostate	607	0	0	0	1	0	0	0	1	3	5	14	42	76	129	122	170	44	C61
Testis	62	0	1	0	3	6	7	23	8	3	3	2	1	1	0	1	1	2	C62
Other male genital	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	C63
Kidney	77	3	1	0	0	1	0	0	3	1	11	1	5	12	16	11	8	4	C64
Renal pelvis	6	0	0	0	0	0	0	0	0	1	1	0	0	0	2	2	0	0	C65
Ureter	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	C66
Bladder	558	0	1	1	0	0	1	0	7	14	23	36	52	67	87	75	132	62	C67
Other urinary organs	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	C68
Eye	2	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	90	6	8	8	2	1	5	6	5	6	6	4	7	5	5	8	4	4	C70-C72
Thyroid	32	0	0	1	0	0	1	4	4	6	2	2	2	1	2	2	2	3	C73
Adrenal gland	2	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C74
Other endocrine	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	76	1	0	7	10	11	6	5	7	4	2	3	3	2	3	4	4	4	C81
Non-Hodgkin lymphoma	281	4	5	6	8	17	6	9	12	12	21	25	24	20	32	24	36	20	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	62	0	0	0	0	0	0	0	1	4	3	3	6	4	8	8	17	8	C90
Lymphoid leukemia	81	6	10	8	4	2	1	1	1	5	1	3	3	7	6	11	7	5	C91
Myeloid leukemia	68	1	1	4	4	2	3	0	2	4	5	3	3	9	8	8	7	4	C92-C94
Leukemia unsp.	16	1	1	2	0	2	0	0	0	0	0	2	1	1	1	3	2	0	C95
Other & Unspecified	102	2	3	0	1	1	2	1	3	4	6	11	6	7	8	14	20	13	OTHER
All sites, total	3942	30	36	50	47	56	46	79	103	132	193	233	306	427	562	520	767	355	
All sites, without C44*	3623	29	36	50	46	56	43	77	98	129	185	223	291	398	526	485	674	277	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 85: Incident cases (n) by primary site & age group, females, Lebanon, 2005

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	C00
Tongue	5	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	1	1	C01-C02
Mouth	10	0	0	0	0	0	0	0	0	1	0	1	1	2	0	1	3	1	C03-C06
Salivary glands	6	0	0	0	1	0	0	0	0	0	1	0	1	0	2	1	0	0	C07-C08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	6	0	0	1	0	0	1	0	0	1	1	0	1	0	1	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C14
Oesophagus	7	0	0	0	0	0	0	1	0	0	0	0	2	2	1	0	1	0	C15
Stomach	105	0	0	0	0	0	1	2	8	8	10	9	12	8	7	17	13	10	C16
Small intestine	11	0	0	0	0	0	0	1	0	0	4	0	1	1	1	1	2	0	C17
Colon	210	0	0	0	1	4	2	4	6	11	12	12	21	29	21	31	40	16	C18
Rectum	55	0	0	0	0	0	0	2	1	7	3	3	4	10	6	7	8	4	C19-C20
Anus	5	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	C21
Liver	39	0	0	0	0	0	0	0	1	1	1	6	2	4	6	3	11	4	C22
Gallbladder etc.	30	0	0	0	0	0	0	0	0	0	2	2	2	1	4	7	9	3	C23-C24
Pancreas	73	0	0	1	1	1	1	0	0	3	4	9	5	8	14	7	10	9	C25
Nose & sinuses & etc.	6	0	0	0	0	0	0	0	1	0	1	0	1	0	0	2	0	1	C30-C31
Larynx	21	0	0	0	0	0	1	0	2	0	2	1	3	4	0	4	3	1	C32
Trachea bronchus & lung	198	0	0	0	0	0	2	2	7	8	14	17	21	37	26	14	35	15	C33-C34
Other thoracic organs	23	1	0	0	0	0	1	1	1	2	1	2	1	0	3	1	5	4	C37-C38
Bone	28	0	0	4	3	1	1	5	0	3	2	4	0	1	1	0	2	1	C40-C41
Melanoma of skin	30	1	0	0	1	1	0	0	2	7	0	2	3	3	3	1	4	2	C43
Other skin	187	0	0	0	0	0	3	4	4	10	6	9	9	13	20	16	47	46	C44
Mesothelioma	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	31	2	0	2	1	1	1	2	4	1	4	3	2	3	1	0	0	4	C47;C49
Breast	1451	0	0	0	3	1	15	45	106	212	181	207	147	142	123	95	100	74	C50
Vulva	23	0	0	0	0	0	1	1	0	1	0	1	1	5	2	3	5	3	C51
Vagina	8	0	0	0	0	0	0	0	1	0	0	2	3	0	1	0	1	0	C52
Cervix uteri	82	0	0	0	0	0	1	3	6	16	7	13	6	11	5	7	3	4	C53
Corpus uteri	120	0	0	0	0	0	0	1	4	8	12	10	16	20	15	12	15	7	C54
Uterus unsp.	30	0	0	0	0	0	0	0	0	1	4	3	5	5	5	2	5	0	C55
Ovary	182	0	0	1	1	5	4	2	6	12	19	18	25	27	16	16	20	10	C56
Other female genital	4	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	1	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	24	4	0	2	0	0	2	0	0	1	1	2	2	2	4	2	2	0	C64
Renal pelvis	4	0	0	0	0	0	0	0	1	0	0	0	1	1	1	0	0	0	C65
Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	C66
Bladder	130	0	0	0	0	0	1	2	2	6	8	10	11	13	13	15	30	19	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	11	4	1	0	2	0	0	0	0	0	0	0	0	0	1	2	0	1	C69
Brain & nervous system	85	10	7	1	6	3	5	6	8	4	2	3	6	3	10	5	4	2	C70-C72
Thyroid	110	0	2	0	0	8	8	11	15	10	12	10	10	2	5	5	4	8	C73
Adrenal gland	4	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	67	0	0	7	8	11	4	5	4	3	2	5	2	1	2	3	7	3	C81
Non-Hodgkin lymphoma	236	0	2	2	3	4	10	4	13	20	15	19	19	22	25	34	33	11	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	49	0	0	0	0	0	0	0	1	2	1	4	5	5	6	9	15	1	C90
Lymphoid leukemia	57	12	5	2	0	1	0	0	0	2	3	2	0	2	8	5	7	8	C91
Myeloid leukemia	61	4	1	3	3	3	3	7	3	2	4	5	4	4	1	4	8	2	C92-C94
Leukemia unsp.	12	2	3	1	0	0	0	3	0	0	0	2	0	0	1	0	0	0	C95
Other & Unspecified	122	0	1	1	1	3	0	3	5	16	11	15	7	16	7	8	18	10	OTHER
All sites, total	3967	42	23	28	35	47	69	117	214	380	352	411	362	412	370	342	478	285	
All sites, without C44*	3780	42	23	28	35	47	66	113	210	370	346	402	353	399	350	326	431	239	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 86: Relative proportions (%) of cases by primary site & age group, males, Lebanon, 2005

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0.2	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0	0	0	C01-C02
Mouth	0.2	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0.1	0.1	0	C03-C06
Salivary glands	0.2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	C07-C08
Tonsil	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C09
Other oropharynx	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.5	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0.1	0	0	0.1	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.4	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0.1	C15
Stomach	3.1	0	0	0	0	0	0	0	0.1	0.2	0.1	0.3	0.3	0.3	0.6	0.5	0.6	0.2	C16
Small intestine	0.3	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.1	0.1	0	C17
Colon	6.4	0	0	0	0	0	0.1	0.2	0.1	0.3	0.3	0.6	0.5	0.9	0.9	0.9	1.2	0.5	C18
Rectum	1.6	0	0	0	0	0.1	0	0	0.1	0.1	0.1	0.1	0.3	0.2	0.2	0.1	0.3	0.2	C19-C20
Anus	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C21
Liver	1.1	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	C22
Gallbladder etc.	0.7	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0.1	0.1	0.2	0.1	C23-C24
Pancreas	1.8	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.1	0.3	0.3	0.2	0.3	0.1	C25
Nose & sinuses & etc.	0.2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	C30-C31
Larynx	2.5	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.2	0.5	0.4	0.5	0.3	0.1	C32
Trachea bronchus & lung	12.7	0	0	0	0	0.1	0	0.1	0.2	0.4	0.8	0.8	1.2	1.8	2.3	1.7	2.6	0.8	C33-C34
Other thoracic organs	1	0	0	0	0	0	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	C37-C38
Bone	1.3	0	0.1	0.2	0.1	0.1	0	0.2	0.2	0	0.1	0	0.1	0	0.1	0.1	0.1	0.1	C40-C41
Melanoma of skin	0.9	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0	0.1	0.1	0.2	0.2	C43
Other skin	8.1	0	0	0	0	0	0.1	0.1	0.1	0.1	0.2	0.3	0.4	0.7	0.9	0.9	2.4	2	C44
Mesothelioma	0.3	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.1	0	C45
Kaposi sarcoma	0.2	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1.1	0	0	0.1	0.2	0.1	0	0	0.1	0.1	0.1	0.1	0.2	0.1	0	0	0	0.1	C47;C49
Breast	0.4	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0.1	0.1	0	C50
Penis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C60
Prostate	15.4	0	0	0	0	0	0	0	0	0.1	0.1	0.4	1.1	1.9	3.3	3.1	4.3	1.1	C61
Testis	1.6	0	0	0	0.1	0.2	0.2	0.6	0.2	0.1	0.1	0.1	0	0	0	0	0	0.1	C62
Other male genital	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	2	0.1	0	0	0	0	0	0	0.1	0	0.3	0	0.1	0.3	0.4	0.3	0.2	0.1	C64
Renal pelvis	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C65
Ureter	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	14.2	0	0	0	0	0	0	0	0.2	0.4	0.6	0.9	1.3	1.7	2.2	1.9	3.3	1.6	C67
Other urinary organs	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C68
Eye	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	2.3	0.2	0.2	0.2	0.1	0	0.1	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.2	0.1	0.1	C70-C72
Thyroid	0.8	0	0	0	0	0	0	0.1	0.1	0.2	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	C73
Adrenal gland	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.9	0	0	0.2	0.3	0.3	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	C81
Non-Hodgkin lymphoma	7.1	0.1	0.1	0.2	0.2	0.4	0.2	0.2	0.3	0.3	0.5	0.6	0.6	0.5	0.8	0.6	0.9	0.5	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.6	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.4	0.2	C90
Lymphoid leukemia	2.1	0.2	0.3	0.2	0.1	0.1	0	0	0	0.1	0	0.1	0.1	0.2	0.2	0.3	0.2	0.1	C91
Myeloid leukemia	1.7	0	0	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	C92-C94
Leukemia unsp.	0.4	0	0	0.1	0	0.1	0	0	0	0	0	0.1	0	0	0	0.1	0.1	0	C95
Other & Unspecified	2.6	0.1	0.1	0	0	0	0.1	0	0.1	0.1	0.2	0.3	0.2	0.2	0.2	0.4	0.5	0.3	OTHER
All sites, total	100	0.8	0.9	1.3	1.2	1.4	1.2	2	2.6	3.3	4.9	5.9	7.8	10.8	14.3	13.1	19.5	9	
All sites but C44	91.9	0.7	0.9	1.3	1.2	1.4	1.1	2	2.5	3.3	4.7	5.7	7.4	10.1	13.3	12.3	17.1	7	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 87: Relative proportions (%) of cases by primary site & age group, females, Lebanon, 2005

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C00
Tongue	0.1	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	C01-C02
Mouth	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	C03-C06
Salivary glands	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.2	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	C15
Stomach	2.6	0	0	0	0	0	0	0.1	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.4	0.3	0.3	C16
Small intestine	0.3	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.1	0	C17
Colon	5.3	0	0	0	0	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.5	0.7	0.5	0.8	1	0.4	C18
Rectum	1.4	0	0	0	0	0	0	0.1	0	0.2	0.1	0.1	0.1	0.3	0.2	0.2	0.2	0.1	C19-C20
Anus	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C21
Liver	1	0	0	0	0	0	0	0	0	0	0	0.2	0.1	0.1	0.2	0.1	0.3	0.1	C22
Gallbladder etc.	0.8	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0.1	0.2	0.2	0.1	C23-C24
Pancreas	1.8	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.1	0.2	0.4	0.2	0.3	0.2	C25
Nose & sinuses & etc.	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C30-C31
Larynx	0.5	0	0	0	0	0	0	0	0.1	0	0.1	0	0.1	0.1	0	0.1	0.1	0	C32
Trachea bronchus & lung	5	0	0	0	0	0	0.1	0.1	0.2	0.2	0.4	0.4	0.5	0.9	0.7	0.4	0.9	0.4	C33-C34
Other thoracic organs	0.6	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0.1	0	0.1	0.1	C37-C38
Bone	0.7	0	0	0.1	0.1	0	0	0.1	0	0.1	0.1	0.1	0	0	0	0	0.1	0	C40-C41
Melanoma of skin	0.8	0	0	0	0	0	0	0	0.1	0.2	0	0.1	0.1	0.1	0.1	0	0.1	0.1	C43
Other skin	4.7	0	0	0	0	0	0.1	0.1	0.1	0.3	0.2	0.2	0.2	0.3	0.5	0.4	1.2	1.2	C44
Mesothelioma	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	0.8	0.1	0	0.1	0	0	0	0.1	0.1	0	0.1	0.1	0.1	0.1	0	0	0	0.1	C47;C49
Breast	36.6	0	0	0	0.1	0	0.4	1.1	2.7	5.3	4.6	5.2	3.7	3.6	3.1	2.4	2.5	1.9	C50
Vulva	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	C51
Vagina	0.2	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	C52
Cervix uteri	2.1	0	0	0	0	0	0	0.1	0.2	0.4	0.2	0.3	0.2	0.3	0.1	0.2	0.1	0.1	C53
Corpus uteri	3	0	0	0	0	0	0	0	0.1	0.2	0.3	0.3	0.4	0.5	0.4	0.3	0.4	0.2	C54
Uterus unsp.	0.8	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	C55
Ovary	4.6	0	0	0	0	0.1	0.1	0.1	0.2	0.3	0.5	0.5	0.6	0.7	0.4	0.4	0.5	0.3	C56
Other female genital	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0.6	0.1	0	0.1	0	0	0.1	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0	C64
Renal pelvis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C66
Bladder	3.3	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.8	0.5	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.3	0.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	C69
Brain & nervous system	2.1	0.3	0.2	0	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.3	0.1	0.1	0.1	C70-C72
Thyroid	2.8	0	0.1	0	0	0.2	0.2	0.3	0.4	0.3	0.3	0.3	0.3	0.1	0.1	0.1	0.1	0.2	C73
Adrenal gland	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.7	0	0	0.2	0.2	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.1	0.2	0.1	C81
Non-Hodgkin lymphoma	5.9	0	0.1	0.1	0.1	0.1	0.3	0.1	0.3	0.5	0.4	0.5	0.5	0.6	0.6	0.9	0.8	0.3	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.2	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.1	0.2	0.2	0.4	0	C90
Lymphoid leukemia	1.4	0.3	0.1	0.1	0	0	0	0	0	0.1	0.1	0.1	0	0.1	0.2	0.1	0.2	0.2	C91
Myeloid leukemia	1.5	0.1	0	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.2	0.1	C92-C94
Leukemia unsp.	0.3	0.1	0.1	0	0	0	0	0.1	0	0	0	0.1	0	0	0	0	0	0	C95
Other & Unspecified	3.1	0	0	0	0	0.1	0	0.1	0.1	0.4	0.3	0.4	0.2	0.4	0.2	0.2	0.5	0.3	OTHER
All sites, total	100	1.1	0.6	0.7	0.9	1.2	1.7	2.9	5.4	9.6	8.9	10	9.1	10	9.3	8.6	12	7.2	
All sites but C44	95.3	1.1	0.6	0.7	0.9	1.2	1.7	2.8	5.3	9.3	8.7	10	8.9	10	8.8	8.2	11	6	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 88: Annual incidence rates per 100000 by primary site & age group, males, Lebanon, 2005

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.2	0.2	0	0	0	0	0	0	0	0	0	1	0	0	0	1.7	2.1	2.1	C00
Tongue	0.5	0.4	0	0	0	0	0	0	0	1.6	0	1	0	1.4	4.7	0	2.1	2.1	C01-C02
Mouth	0.5	0.4	0	0	0	0	0	0	0	0	0	2	2.3	1.4	0	0	4.1	4.1	C03-C06
Salivary glands	0.4	0.3	0	0	0.5	0	0	0	0	0.8	0	2	1.1	0	0	1.7	2.1	0	C07-C08
Tonsil	0.3	0.2	0	0	0	0	0	0	0	0	0	2	0	2.8	3.1	0	0	0	C09
Other oropharynx	0.1	0.1	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	2.1	C10
Nasopharynx	1.1	1	0	0	0.5	0.5	0	0	0.7	0	3.3	3	3.4	1.4	3.1	1.7	2.1	4.1	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0.1	0.1	0	0	0	0	0	0	0	0	0	0	1.1	0	1.6	0	0	0	C14
Oesophagus	0.8	0.8	0	0	0	0	0	0	0	0.8	0	0	1.1	2.8	3.1	0	10.4	12.4	C15
Stomach	6.2	6.2	0	0	0	0	0	0	0.7	3.2	5.8	3	13.6	17	22	43.1	41.4	51.8	C16
Small intestine	0.5	0.6	0	0	0	0	0.5	0	1.4	0	0	0	0	1.4	0	1.7	4.1	8.3	C17
Colon	12.8	12.7	0	0	0	0.5	0.5	2	4.8	4	11.6	12.2	27.1	32.7	59	64.6	76.7	103.6	C18
Rectum	3.2	3.2	0	0	0.5	0	1.5	0.7	0.7	4.8	1.7	2	3.4	15.6	12	14.9	8.3	24.9	C19-C20
Anus	0.3	0.3	0	0	0	0	0	0	0	0	0	1	1.1	0	1.6	1.7	4.1	0	C21
Liver	2.3	2.2	0	0	0	0.5	0	0	0.7	2.4	0.8	4.1	4.5	12.8	6.2	8.3	12.4	10.4	C22
Gallbladder etc.	1.4	1.4	0	0	0	0	0	0	0	0	0.8	2	3.4	2.8	1.6	9.9	10.4	16.6	C23-C24
Pancreas	3.6	3.5	0	0	0	0	0	0	0.7	1.6	2.5	6.1	11.3	7.1	19	18.2	16.6	24.9	C25
Nose & sinuses & etc.	0.4	0.3	0	0	0	0	0	0	0	0	0.8	3	1.1	1.4	1.6	0	0	0	C30-C31
Larynx	5	4.8	0	0	0	0	0	0	0	0.8	2.5	7.1	9	9.9	33	29.8	39.4	26.9	C32
Trachea bronchus & lung	25.3	25.1	0.6	0	0	0.5	1	0.7	2.8	4.8	14.1	35.5	38.4	69.6	115	162.4	147.1	221.7	C33-C34
Other thoracic organs	2.1	2	0	0	0	0	0.5	2	1.4	0	0.8	2	3.4	5.7	7.8	11.6	4.1	18.6	C37-C38
Bone	2.5	2.6	0.6	1.6	3.8	1.9	1	0.7	4.1	4.8	0	3	1.1	4.3	1.6	5	6.2	10.4	C40-C41
Melanoma of skin	1.6	1.7	0.6	0	0	0	0.5	0	0.7	0.8	3.3	3	4.5	0	0	5	8.3	22.8	C43
Other skin	15.3	15.9	0.6	0	0	0.5	0	2.6	2.1	5.6	3.3	11.2	14.7	28.4	59	79.6	95.3	254.8	C44
Mesothelioma	0.5	0.5	0	0	0	0	0	0	0	0.8	0.8	2	1.1	1.4	1.6	1.7	0	4.1	C45
Kaposi sarcoma	0.3	0.3	0	0	0	0	0	0	0	1.6	0	0	0	1.4	0	0	2.1	2.1	C46
Connective & soft tissue	2.3	2.2	0.6	0.5	0.9	3.4	1	0.7	0.7	3.2	1.7	4.1	2.3	11.4	7.8	1.7	2.1	2.1	C47;C49
Breast	0.7	0.7	0	0	0	0	0	0	0	0	2.5	0	1.1	1.4	1.6	3.3	8.3	6.2	C50
Penis	0.1	0.1	0	0	0	0	0	0	0	0	0	1	0	0	1.6	0	0	0	C60
Prostate	29.1	30.3	0	0	0	0.5	0	0	0	0.8	2.5	5.1	17	63.9	127	230.4	273.5	379.1	C61
Testis	2.9	3.1	0	0.5	0	1.5	2.9	4.6	16.6	6.4	2.5	3	2.3	1.4	1.6	0	2.1	2.1	C62
Other male genital	0.1	0.1	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	2.1	C63
Kidney	4	3.8	1.8	0.5	0	0	0.5	0	0	2.4	0.8	12.2	1.1	7.1	20	28.2	24.9	16.6	C64
Renal pelvis	0.3	0.3	0	0	0	0	0	0	0	0	0.8	1	0	0	0	3.3	4.1	0	C65
Ureter	0.1	0.1	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0	2.1	C66
Bladder	27.7	27.9	0	0.5	0.5	0	0	0.7	0	6.4	13.3	26.4	46.3	83.8	117	162.4	174	308.7	C67
Other urinary organs	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.1	2.1	C68
Eye	0.1	0.1	0	0.5	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	4.6	4.5	3.6	4.2	3.8	1	0.5	3.3	4.1	4	5	6.1	4.5	9.9	7.8	8.3	16.6	8.3	C70-C72
Thyroid	1.6	1.6	0	0	0.5	0	0	0.7	2.8	3.2	5.8	2	2.3	2.8	1.6	3.3	4.1	4.1	C73
Adrenal gland	0.1	0.1	0.6	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	C74
Other endocrine	0.1	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	3.5	3.8	0.6	0	3.3	5.4	5.8	3.9	3.5	5.6	3.3	2	3.4	4.3	3.1	5	8.3	8.3	C81
Non-Hodgkin lymphoma	14.1	14	2.4	2.6	2.8	4.4	8.8	3.9	6.9	10.4	10.8	23.3	30.5	36.9	34	56.4	53.9	80.8	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	3	3.1	0	0	0	0	0	0	0	0.8	4.1	3	3.4	9.9	7.8	14.9	18.6	41.4	C90
Lymphoid leukemia	4.1	4	3.6	5.8	4.2	1.9	1	0.7	0.7	0.8	4.1	1	3.4	4.3	11	9.9	24.9	14.5	C91
Myeloid leukemia	3.4	3.4	0.6	0.5	1.9	1.9	1	2	0	1.6	3.3	5.1	3.4	4.3	16	14.9	18.6	14.5	C92-C94
Leukemia unsp.	0.8	0.8	0.6	0.5	0.9	0	1	0	0	0	0	0	2.3	1.4	1.6	1.7	6.2	4.1	C95
Other & Unspecified	5.1	5.1	1.2	1.6	0	0.5	0.5	1.3	0.7	2.4	4.1	7.1	14.7	9.9	12	14.9	33.1	47.7	OTHER
All sites, total	195.1	196.7	18.9	20.1	24.9	25.3	29.2	32.7	58.7	89.8	119	213	288	477	729	1023	1181	1778	
All sites but C44	179.8	180.8	18.3	20.1	24.9	24.9	29.2	30.1	56.6	84.2	116	202	274	449	670	943.1	1086	1523	

** C44 refers to non-melanoma skin cancer.*

In-situ cancers are not included.

Table 89: Annual incidence rates per 100000 by primary site & age group, females, Lebanon, 2005

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.5	2.1	C00
Tongue	0.2	0.2	0	0	0	0	0	0	0	0	0.7	2.8	0	0	0	0	0	2.1	C01-C02
Mouth	0.5	0.5	0	0	0	0	0	0	0	0	0.7	0	1.1	1.3	2.8	0	2.3	6.2	C03-C06
Salivary glands	0.3	0.3	0	0	0	0.5	0	0	0	0	0	0.9	0	1.3	0	3.3	2.3	0	C07-C08
Tonsil	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.3	0.3	0	0	0.5	0	0	0.6	0	0	0.7	0.9	0	1.3	0	1.7	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	C14
Oesophagus	0.3	0.3	0	0	0	0	0	0	0.7	0	0	0	0	2.6	2.8	1.7	0	2.1	C15
Stomach	5	5.2	0	0	0	0	0	0.6	1.3	6	6	10.1	11.3	17	12	13.3	42.9	29	C16
Small intestine	0.6	0.5	0	0	0	0	0	0	0.7	0	0	3.7	0	1.3	1.4	1.7	2.3	4.1	C17
Colon	10.1	10.4	0	0	0	0.5	2.1	1.2	2.7	4	8.1	12	14.7	30.1	43	38.1	76.8	89.1	C18
Rectum	2.6	2.7	0	0	0	0	0	0	1.3	0.7	5.4	2.8	3.4	5.2	15	9.9	18.1	18.6	C19-C20
Anus	0.3	0.2	0	0.6	0	0	0	0	0	0	0	0	0	0	1.4	1.7	0	4.1	C21
Liver	1.9	1.9	0	0	0	0	0	0	0	0.7	0.7	0.9	7.9	2.6	5.5	11.6	6.8	24.9	C22
Gallbladder etc.	1.4	1.5	0	0	0	0	0	0	0	0	0	1.8	2.3	2.6	1.4	6.6	18.1	20.7	C23-C24
Pancreas	3.6	3.6	0	0	0.5	0.5	0.5	0.6	0	0	2	4.6	11.3	7.9	12	26.5	18.1	22.8	C25
Nose & sinuses & etc.	0.3	0.3	0	0	0	0	0	0	0	0.7	0	0.9	0	1.3	0	0	4.5	0	C30-C31
Larynx	1	1	0	0	0	0	0	0.6	0	1.3	0	1.8	1.1	3.9	5.5	0	9	6.2	C32
Trachea bronchus & lung	9.8	9.8	0	0	0	0	0	1.2	1.3	5.4	6	13.8	20.3	30.1	55	46.4	33.9	78.7	C33-C34
Other thoracic organs	1.1	1.1	0.7	0	0	0	0	0.6	0.7	0.7	1.3	0.9	2.3	1.3	0	6.6	2.3	12.4	C37-C38
Bone	1.3	1.4	0	0	2	1.6	0.5	0.6	3.4	0	2	1.8	4.5	0	1.4	1.7	0	4.1	C40-C41
Melanoma of skin	1.4	1.5	0.7	0	0	0.5	0.5	0	0	1.3	5.4	0	2.3	3.9	4.1	5	2.3	8.3	C43
Other skin	8.7	9.3	0	0	0	0	0	2.4	3.4	3.4	8.7	7.4	13.6	15.7	24	44.8	47.5	128.4	C44
Mesothelioma	0.1	0.1	0	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	2.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1.6	1.5	1.3	0	1	0.5	0.5	0.6	1.3	3.4	0.7	4.6	3.4	2.6	4.1	1.7	0	0	C47;C49
Breast	71	71.9	0	0	0	1.6	0.5	9.7	32	75	150	176	246	203	207	216	226	217.5	C50
Vulva	1.1	1.1	0	0	0	0	0	0.6	0.7	0	0.7	0	1.1	1.3	8.3	3.3	6.8	12.4	C51
Vagina	0.4	0.4	0	0	0	0	0	0	0	0.7	0	0	2.3	3.9	0	1.7	0	2.1	C52
Cervix uteri	4	4.1	0	0	0	0	0	0.6	2	4	11	6.4	15.8	7.9	17	8.3	15.8	6.2	C53
Corpus uteri	6	5.9	0	0	0	0	0	0	0.7	2.7	5.4	12	12.4	22.2	29	26.5	29.4	33.1	C54
Uterus unsp.	1.5	1.5	0	0	0	0	0	0	0	0	0.7	3.7	3.4	6.5	6.9	8.3	4.5	10.4	C55
Ovary	9	9	0	0	0.5	0.5	2.6	2.4	1.3	4	8.7	18.4	21.5	34	40	28.2	38.4	43.5	C56
Other female genital	0.2	0.2	0	0	0	0	0	0.6	0	0.7	0	0	0	0	1.4	0	0	2.1	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	1.3	1.2	2.7	0	1	0	0	1.2	0	0	0.7	0.9	2.3	2.6	2.8	6.6	4.5	4.1	C64
Renal pelvis	0.2	0.2	0	0	0	0	0	0	0	0.7	0	0	0	1.3	1.4	1.7	0	0	C65
Ureter	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.1	C66
Bladder	6.2	6.4	0	0	0	0	0	0.6	1.3	1.3	4.7	8.3	13.6	17	21	24.9	40.7	72.5	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.7	0.5	2.7	0.6	0	1	0	0	0	0	0	0	0	0	0	1.7	4.5	0	C69
Brain & nervous system	4.4	4.2	6.7	4	0.5	3.1	1.6	3	4	5.4	2.7	1.8	3.4	7.9	4.1	16.6	11.3	8.3	C70-C72
Thyroid	5.2	5.4	0	1.2	0	0	4.7	5.5	8.1	11	7.4	12	12.4	14.4	2.8	8.3	11.3	8.3	C73
Adrenal gland	0.3	0.2	1.3	0	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	3	3.3	0	0	3.5	4.1	6.2	2.4	3.4	2.7	2	1.8	5.7	2.6	1.4	3.3	6.8	14.5	C81
Non-Hodgkin lymphoma	11.3	11.7	0	1.2	1	1.6	2.1	6.1	2.7	9.4	14	14.7	22.6	26.2	32	43.1	81.4	72.5	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	2.3	2.4	0	0	0	0	0	0	0	0.7	1.3	0.9	4.5	6.5	6.9	9.9	20.3	31.1	C90
Lymphoid leukemia	3.2	2.8	9.4	3.5	1	0	0.5	0	0	0	1.3	2.8	2.3	0	2.8	14.9	13.6	16.6	C91
Myeloid leukemia	3	3	2.7	0.6	1.5	1.6	1.6	1.8	4.7	2	1.3	3.7	5.7	5.2	5.5	1.7	9	16.6	C92-C94
Leukemia unsp.	0.7	0.6	1.3	1.7	0.5	0	0	0	2	0	0	0	2.3	0	0	1.7	0	0	C95
Other & Unspecified	5.9	6	0	0.6	0.5	0.5	1.6	0	2	3.4	11	11	18.1	10.5	24	13.3	20.3	41.4	OTHER
All sites, total	193.4	196.5	30	14	15	19	26	45	84	153	274	347	497	508	612	665	839	1090	
All sites but C44	184.7	187.2	30	14	15	19	26	42	81	150	265	340	484	492	588	620	791	961.3	

** C44 refers to non-melanoma skin cancer.*
In-situ cancers are not included.

Table 90: Incident cases (n) by primary site & age group, Lebanon, 2006

Primary site	All ages	Age group																	Gender			ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	Male	Female	Unsp.	
Lip	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	4	0	5	2	0	C00
Tongue	28	1	0	0	0	1	0	2	3	0	3	3	3	4	3	1	2	2	19	9	0	C01-C02
Mouth	25	0	0	0	1	1	0	0	0	3	3	1	2	2	5	2	4	1	9	16	0	C03-C06
Salivary glands	23	1	0	0	1	0	1	0	2	2	1	2	0	3	0	4	2	4	17	6	0	C07-C08
Tonsil	6	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	2	0	1	5	0	C09
Other oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	2	2	0	C10
Nasopharynx	35	0	0	3	4	0	0	0	2	2	7	3	4	5	1	0	0	4	27	8	0	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	C12-C13
Pharynx unsp.	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	0	4	0	0	C14
Oesophagus	32	0	0	0	0	0	0	0	1	2	2	0	0	5	3	9	6	4	22	10	0	C15
Stomach	210	0	0	0	1	0	2	4	8	6	16	12	16	19	36	31	48	11	129	81	0	C16
Small intestine	35	1	0	1	1	1	0	2	1	4	2	0	4	2	4	4	4	4	15	20	0	C17
Colon	499	0	0	0	1	0	4	11	8	18	26	34	54	49	64	51	137	42	266	233	0	C18
Rectum	147	0	0	0	1	1	1	0	8	6	10	14	13	18	21	15	26	13	83	64	0	C19-C20
Anus	10	0	0	0	0	0	0	0	0	1	1	1	1	1	0	2	3	0	5	5	0	C21
Liver	97	4	1	0	0	1	0	2	3	2	6	9	19	4	18	9	13	6	52	45	0	C22
Gallbladder etc.	56	0	0	0	0	0	0	0	0	0	2	5	4	3	8	15	16	3	22	34	0	C23-C24
Pancreas	132	0	0	0	1	0	0	1	7	5	9	8	11	17	23	25	15	10	72	60	0	C25
Nose sinuses & etc.	10	1	0	1	0	0	0	0	0	0	1	3	1	0	1	2	0	0	9	1	0	C30-C31
Larynx	140	0	0	0	0	0	0	0	2	3	10	15	18	19	23	22	21	7	118	22	0	C32
Trachea bronchus & lung	823	0	0	0	1	2	3	7	7	26	40	61	101	121	148	112	136	58	582	241	0	C33-C34
Other thoracic organs	37	1	1	0	1	1	3	0	1	1	1	2	3	5	1	4	6	6	26	11	0	C37-C38
Bone	75	1	2	13	15	5	4	6	0	3	2	3	3	3	4	2	6	3	41	34	0	C40-C41
Melanoma of skin	72	0	0	1	0	2	2	6	2	5	6	7	6	2	9	6	13	5	32	40	0	C43
Other skin	522	0	0	0	0	1	1	9	11	8	26	33	31	43	60	59	160	80	347	175	0	C44
Mesothelioma	13	0	0	0	0	0	0	0	1	1	2	1	0	2	2	1	2	1	10	3	0	C45
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	1	1	0	2	0	0	1	1	0	5	1	0	C46
Connective & soft tissue	84	3	5	2	5	2	6	3	8	11	4	6	4	2	9	6	7	1	43	40	1	C47;C49
Breast	1641	0	0	1	2	3	14	39	125	199	239	193	196	164	143	103	138	82	23	1617	1	C50
Vulva	27	0	0	0	0	0	0	0	0	0	0	4	2	5	3	3	9	1	0	27	0	C51
Vagina	7	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	3	0	0	7	0	C52
Cervix uteri	76	0	0	0	0	0	1	1	7	8	6	13	11	6	9	5	4	5	0	76	0	C53
Corpus uteri	147	0	0	0	0	0	0	3	6	7	10	18	28	21	20	12	16	6	0	147	0	C54
Uterus unsp.	17	0	0	0	0	0	0	0	2	1	3	0	1	1	6	0	2	1	0	17	0	C55
Ovary	153	0	0	1	2	3	5	2	4	13	13	17	27	10	13	12	20	11	0	153	0	C56
Other female genital	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Penis	6	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	3	1	6	0	0	C60
Prostate	744	0	0	0	0	0	0	1	1	1	7	21	52	77	140	122	257	65	744	0	0	C61
Testis	49	2	0	1	3	10	7	7	6	4	3	0	2	0	0	0	1	3	49	0	0	C62
Other male genital	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C63
Kidney	116	6	0	3	0	1	2	1	9	8	4	10	8	14	13	17	13	7	79	37	0	C64
Renal pelvis	7	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1	2	0	6	1	0	C65
Ureter	6	0	0	0	0	0	0	0	1	0	0	0	0	2	1	0	2	0	4	2	0	C66
Bladder	726	0	0	0	2	0	2	3	3	18	23	46	56	82	126	114	195	56	595	130	1	C67
Other urinary organs	7	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	2	0	6	1	0	C68
Eye	8	2	0	1	0	0	0	0	0	0	1	2	1	0	0	0	1	0	5	3	0	C69
Brain & nervous system	134	5	9	5	6	6	7	6	4	9	16	11	16	14	11	2	4	3	84	50	0	C70-C72
Thyroid	178	0	1	0	5	7	14	18	19	24	17	13	6	13	7	12	5	17	36	142	0	C73
Adrenal gland	7	0	0	0	0	0	0	0	1	0	1	1	1	0	0	1	1	1	5	2	0	C74
Other endocrine	3	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	1	0	C75
Hodgkin disease	138	0	1	9	17	18	19	9	5	7	9	11	5	4	5	6	6	7	84	54	0	C81
Non-Hodgkin lymphoma	528	5	6	11	10	14	21	18	21	42	36	44	50	46	44	59	67	34	278	248	2	C82-C85;C96
Immunoproliferative dis.	4	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	2	2	0	C88
Multiple myeloma	95	0	0	0	0	0	0	0	3	5	8	7	11	9	16	11	15	10	47	48	0	C90
Lymphoid leukemia	162	22	25	8	6	3	4	1	4	2	5	8	5	12	16	13	19	9	105	57	0	C91
Myeloid leukemia	167	5	1	5	7	4	4	6	9	15	14	12	17	14	15	16	21	2	91	76	0	C92-C94
Leukemia unsp.	16	0	1	1	0	1	0	0	0	2	0	3	2	0	3	2	1	0	8	8	0	C95
Other & Unspecified	187	5	3	2	3	4	2	3	8	4	11	19	22	20	14	21	27	19	88	99	0	OTHER
All sites, total	8491	65	56	71	97	92	130	171	313	479	610	679	825	852	1056	921	1469	605	4312	4174	5	
All sites, without C44*	7969	65	56	71	97	91	129	162	302	471	584	646	794	809	996	862	1309	525	3965	3999	5	

** C44 refers to non melanoma skin cancer*

In-situ cancers are not included.

Table 91: Incident cases (n) by primary site & age group, males, Lebanon, 2006

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	5	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	0	C00
Tongue	19	1	0	0	0	0	0	2	0	0	1	3	2	4	2	1	1	2	C01-C02
Mouth	9	0	0	0	1	0	0	0	0	0	1	0	2	0	2	1	2	0	C03-C06
Salivary glands	17	1	0	0	1	0	0	0	0	2	1	2	0	1	0	3	2	4	C07-C08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	C10
Nasopharynx	27	0	0	1	4	0	0	0	2	1	3	3	4	5	1	0	0	3	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C12-C13
Pharynx unsp.	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	0	C14
Oesophagus	22	0	0	0	0	0	0	0	0	0	2	0	0	4	2	9	2	3	C15
Stomach	129	0	0	0	0	0	1	0	3	6	12	7	9	18	22	20	26	5	C16
Small intestine	15	0	0	1	0	0	0	1	0	2	0	0	1	2	2	2	2	2	C17
Colon	266	0	0	0	0	0	3	3	5	11	13	17	30	25	32	23	84	20	C18
Rectum	83	0	0	0	1	0	1	0	2	5	4	8	4	8	17	7	18	8	C19-C20
Anus	5	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	2	0	C21
Liver	52	1	0	0	0	0	0	2	2	0	4	6	12	4	7	6	6	2	C22
Gallbladder etc.	22	0	0	0	0	0	0	0	0	0	1	1	0	1	5	5	7	2	C23-C24
Pancreas	72	0	0	0	0	0	0	1	4	3	6	3	4	12	11	12	9	7	C25
Nose & sinuses & etc.	9	1	0	0	0	0	0	0	0	0	1	3	1	0	1	2	0	0	C30-C31
Larynx	118	0	0	0	0	0	0	0	2	1	8	13	13	15	20	21	19	6	C32
Trachea bronchus & lung	582	0	0	0	1	2	1	3	4	13	22	45	76	89	103	88	97	38	C33-C34
Other thoracic organs	26	1	0	0	1	1	3	0	1	1	1	1	2	4	1	3	2	4	C37-C38
Bone	41	0	2	5	5	3	3	5	0	2	2	1	3	2	2	0	4	2	C40-C41
Melanoma of skin	32	0	0	1	0	1	1	3	1	1	2	2	5	0	4	2	6	3	C43
Other skin	347	0	0	0	0	1	0	3	3	1	17	22	17	31	43	44	115	50	C44
Mesothelioma	10	0	0	0	0	0	0	0	0	1	2	1	0	1	2	1	2	0	C45
Kaposi sarcoma	5	0	0	0	0	0	0	0	0	1	1	0	2	0	0	0	1	0	C46
Connective & soft tissue	43	2	3	0	2	1	2	1	6	5	2	3	4	1	3	4	3	1	C47;C49
Breast	23	0	0	0	1	0	0	0	2	3	2	2	1	3	4	2	3	0	C50
Penis	6	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	3	1	C60
Prostate	744	0	0	0	0	0	0	1	1	1	7	21	52	77	140	122	257	65	C61
Testis	49	2	0	1	3	10	7	7	6	4	3	0	2	0	0	0	1	3	C62
Other male genital	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	79	3	0	0	0	1	2	1	7	6	3	4	8	13	8	12	7	4	C64
Renal pelvis	6	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	2	0	C65
Ureter	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	C66
Bladder	595	0	0	0	1	0	2	2	3	16	17	36	47	66	110	92	155	48	C67
Other urinary organs	6	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	2	0	C68
Eye	5	0	0	1	0	0	0	0	0	0	1	1	1	0	0	0	1	0	C69
Brain & nervous system	84	5	5	3	3	4	5	4	3	4	8	7	9	11	7	1	4	1	C70-C72
Thyroid	36	0	0	0	3	3	2	1	3	7	3	0	1	2	2	4	1	4	C73
Adrenal gland	5	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	1	1	C74
Other endocrine	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	84	0	1	7	13	9	9	4	5	5	5	8	4	0	1	5	4	4	C81
Non-Hodgkin lymphoma	278	3	2	6	3	14	9	13	14	26	22	22	23	24	18	32	27	20	C82-C85;C96
Immunoproliferative dis.	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	C88
Multiple myeloma	47	0	0	0	0	0	0	0	0	3	7	5	4	4	9	4	7	4	C90
Lymphoid leukemia	105	14	17	5	4	3	3	1	4	1	3	6	2	8	9	6	13	6	C91
Myeloid leukemia	91	5	1	3	5	2	2	6	4	5	6	7	7	6	10	8	12	2	C92-C94
Leukemia unsp.	8	0	1	0	0	1	0	0	0	0	0	3	2	0	0	1	0	0	C95
Other & Unspecified	88	1	1	0	2	3	1	1	5	1	5	8	8	11	8	11	13	9	OTHER
All sites, total	4312	40	33	36	55	59	58	65	93	138	200	274	366	457	616	560	928	334	
All sites, without C44*	3965	40	33	36	55	58	58	62	90	137	183	252	349	426	573	516	813	284	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 92: Incident cases (n) by primary site & age group, females, Lebanon, 2006

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	C00
Tongue	9	0	0	0	0	1	0	0	3	0	2	0	1	0	1	0	1	0	C01-C02
Mouth	16	0	0	0	0	1	0	0	0	3	2	1	0	2	3	1	2	1	C03-C06
Salivary glands	6	0	0	0	0	0	1	0	2	0	0	0	0	2	0	1	0	0	C07-C08
Tonsil	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	2	0	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	C10
Nasopharynx	8	0	0	2	0	0	0	0	0	1	4	0	0	0	0	0	0	1	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	10	0	0	0	0	0	0	0	1	2	0	0	0	1	1	0	4	1	C15
Stomach	81	0	0	0	1	0	1	4	5	0	4	5	7	1	14	11	22	6	C16
Small intestine	20	1	0	0	1	1	0	1	1	2	2	0	3	0	2	2	2	2	C17
Colon	233	0	0	0	1	0	1	8	3	7	13	17	24	24	32	28	53	22	C18
Rectum	64	0	0	0	0	1	0	0	6	1	6	6	9	10	4	8	8	5	C19-C20
Anus	5	0	0	0	0	0	0	0	0	1	0	1	1	1	0	0	1	0	C21
Liver	45	3	1	0	0	1	0	0	1	2	2	3	7	0	11	3	7	4	C22
Gallbladder etc.	34	0	0	0	0	0	0	0	0	0	1	4	4	2	3	10	9	1	C23-C24
Pancreas	60	0	0	0	1	0	0	0	3	2	3	5	7	5	12	13	6	3	C25
Nose & sinuses & etc.	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-C31
Larynx	22	0	0	0	0	0	0	0	0	2	2	2	5	4	3	1	2	1	C32
Trachea bronchus & lung	241	0	0	0	0	0	2	4	3	13	18	16	25	32	45	24	39	20	C33-C34
Other thoracic organs	11	0	1	0	0	0	0	0	0	0	0	1	1	1	0	1	4	2	C37-C38
Bone	34	1	0	8	10	2	1	1	0	1	0	2	0	1	2	2	2	1	C40-C41
Melanoma of skin	40	0	0	0	0	1	1	3	1	4	4	5	1	2	5	4	7	2	C43
Other skin	175	0	0	0	0	0	1	6	8	7	9	11	14	12	17	15	45	30	C44
Mesothelioma	3	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	C45
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C46
Connective & soft tissue	40	1	2	2	3	1	4	2	2	6	2	3	0	1	6	2	3	0	C47;C49
Breast	1617	0	0	1	1	3	14	39	123	196	237	190	195	161	139	101	135	82	C50
Vulva	27	0	0	0	0	0	0	0	0	0	0	4	2	5	3	3	9	1	C51
Vagina	7	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	3	0	C52
Cervix uteri	76	0	0	0	0	0	1	1	7	8	6	13	11	6	9	5	4	5	C53
Corpus uteri	147	0	0	0	0	0	0	3	6	7	10	18	28	21	20	12	16	6	C54
Uterus unsp.	17	0	0	0	0	0	0	0	2	1	3	0	1	1	6	0	2	1	C55
Ovary	153	0	0	1	2	3	5	2	4	13	13	17	27	10	13	12	20	11	C56
Other female genital	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	37	3	0	3	0	0	0	0	2	2	1	6	0	1	5	5	6	3	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C65
Ureter	2	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	C66
Bladder	130	0	0	0	0	0	0	1	0	2	6	10	9	16	16	22	40	8	C67
Other urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C68
Eye	3	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C69
Brain & nervous system	50	0	4	2	3	2	2	2	1	5	8	4	7	3	4	1	0	2	C70-C72
Thyroid	142	0	1	0	2	4	12	17	16	17	14	13	5	11	5	8	4	13	C73
Adrenal gland	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C75
Hodgkin disease	54	0	0	2	4	9	10	5	0	2	4	3	1	4	4	1	2	3	C81
Non-Hodgkin lymphoma	248	2	4	5	7	0	11	5	7	16	14	22	27	21	26	27	40	14	C82-C85;C96
Immunoproliferative dis.	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	C88
Multiple myeloma	48	0	0	0	0	0	0	0	3	2	1	2	7	5	7	7	8	6	C90
Lymphoid leukemia	57	8	8	3	2	0	1	0	0	1	2	2	3	4	7	7	6	3	C91
Myeloid leukemia	76	0	0	2	2	2	2	0	5	10	8	5	10	8	5	8	9	0	C92-C94
Leukemia unsp.	8	0	0	1	0	0	0	0	0	2	0	0	0	0	3	1	1	0	C95
Other & Unspecified	99	4	2	2	1	1	1	2	3	3	6	11	14	9	6	10	14	10	OTHER
All sites, total	4174	25	23	35	41	33	71	106	220	341	410	404	459	394	440	361	540	271	
All sites, without C44*	3999	25	23	35	41	33	70	100	212	334	401	393	445	382	423	346	495	241	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 93: Relative proportions (%) of cases by primary site & age group, males, Lebanon, 2006

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0.4	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	C01-C02
Mouth	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-C06
Salivary glands	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.6	0	0	0	0.1	0	0	0	0	0	0.1	0.1	0.1	0.1	0	0	0	0.1	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.2	0	0.1	C15
Stomach	3	0	0	0	0	0	0	0	0.1	0.1	0.3	0.2	0.2	0.4	0.5	0.5	0.6	0.1	C16
Small intestine	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C17
Colon	6.2	0	0	0	0	0	0.1	0.1	0.1	0.3	0.3	0.4	0.7	0.6	0.7	0.5	1.9	0.5	C18
Rectum	1.9	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.1	0.2	0.4	0.2	0.4	0.2	C19-C20
Anus	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	1.2	0	0	0	0	0	0	0	0	0	0.1	0.1	0.3	0.1	0.2	0.1	0.1	0	C22
Gallbladder etc.	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0	C23-C24
Pancreas	1.7	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.3	0.3	0.3	0.2	0.2	C25
Nose & sinuses & etc.	0.2	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	C30-C31
Larynx	2.7	0	0	0	0	0	0	0	0	0	0.2	0.3	0.3	0.3	0.5	0.5	0.4	0.1	C32
Trachea bronchus & lung	13.5	0	0	0	0	0	0	0.1	0.1	0.3	0.5	1	1.8	2.1	2.4	2	2.2	0.9	C33-C34
Other thoracic organs	0.6	0	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0	0.1	0	0.1	C37-C38
Bone	1	0	0	0.1	0.1	0.1	0.1	0.1	0	0	0	0	0.1	0	0	0	0.1	0	C40-C41
Melanoma of skin	0.7	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0.1	0	0.1	0.1	C43
Other skin	8	0	0	0	0	0	0	0.1	0.1	0	0.4	0.5	0.4	0.7	1	1	2.7	1.2	C44
Mesothelioma	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1	0	0.1	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0	0.1	0.1	0.1	0	C47;C49
Breast	0.5	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0.1	0	0.1	0	C50
Penis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C60
Prostate	17.3	0	0	0	0	0	0	0	0	0	0.2	0.5	1.2	1.8	3.2	2.8	6	1.5	C61
Testis	1.1	0	0	0	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0	0	0	0	0	0	0.1	C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	1.8	0.1	0	0	0	0	0	0	0.2	0.1	0.1	0.1	0.2	0.3	0.2	0.3	0.2	0.1	C64
Renal pelvis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	13.8	0	0	0	0	0	0	0	0.1	0.4	0.4	0.8	1.1	1.5	2.6	2.1	3.6	1.1	C67
Other urinary organs	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	1.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.2	0	0.1	0	C70-C72
Thyroid	0.8	0	0	0	0.1	0.1	0	0	0.1	0.2	0.1	0	0	0	0	0.1	0	0.1	C73
Adrenal gland	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.9	0	0	0.2	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0	0	0.1	0.1	0.1	C81
Non-Hodgkin lymphoma	6.4	0.1	0	0.1	0.1	0.3	0.2	0.3	0.3	0.6	0.5	0.5	0.5	0.6	0.4	0.7	0.6	0.5	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.1	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.2	0.1	C90
Lymphoid leukemia	2.4	0.3	0.4	0.1	0.1	0.1	0.1	0	0.1	0	0.1	0.1	0	0.2	0.2	0.1	0.3	0.1	C91
Myeloid leukemia	2.1	0.1	0	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.2	0.3	0	C92-C94
Leukemia unsp.	0.2	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	C95
Other & Unspecified	2	0	0	0	0	0.1	0	0	0.1	0	0.1	0.2	0.2	0.3	0.2	0.3	0.3	0.2	OTHER
All sites, total	100	0.9	0.8	0.8	1.3	1.4	1.3	1.5	2.2	3.2	4.6	6.4	8.5	10.6	14.3	13	21.5	7.7	
All sites but C44	92	0.9	0.8	0.8	1.3	1.3	1.3	1.4	2.1	3.2	4.2	5.8	8.1	9.9	13.3	12	18.9	6.6	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 94: Relative proportions (%) of cases by primary site & age group, females, Lebanon, 2006

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0.2	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	C01-C02
Mouth	0.4	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0	0	C03-C06
Salivary glands	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-C08
Tonsil	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C15
Stomach	1.9	0	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0.2	0	0.3	0.3	0.5	0.1	C16
Small intestine	0.5	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	C17
Colon	5.6	0	0	0	0	0	0	0.2	0.1	0.2	0.3	0.4	0.6	0.6	0.8	0.7	1.3	0.5	C18
Rectum	1.5	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.2	0.2	0.1	0.2	0.2	0.1	C19-C20
Anus	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	1.1	0.1	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0.3	0.1	0.2	0.1	C22
Gallbladder etc.	0.8	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0.2	0.2	0	C23-C24
Pancreas	1.4	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.2	0.1	0.3	0.3	0.1	0.1	C25
Nose & sinuses & etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-C31
Larynx	0.5	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0	0	C32
Trachea bronchus & lung	5.8	0	0	0	0	0	0	0.1	0.1	0.3	0.4	0.4	0.6	0.8	1.1	0.6	0.9	0.5	C33-C34
Other thoracic organs	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C37-C38
Bone	0.8	0	0	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	C40-C41
Melanoma of skin	1	0	0	0	0	0	0	0.1	0	0.1	0.1	0.1	0	0	0.1	0.1	0.2	0	C43
Other skin	4.2	0	0	0	0	0	0	0.1	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4	1.1	0.7	C44
Mesothelioma	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1	0	0	0	0.1	0	0.1	0	0	0.1	0	0.1	0	0	0.1	0	0.1	0	C47;C49
Breast	38.7	0	0	0	0	0.1	0.3	0.9	2.9	4.7	5.7	4.6	4.7	3.9	3.3	2.4	3.2	2	C50
Vulva	0.6	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.1	0.2	0	C51
Vagina	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C52
Cervix uteri	1.8	0	0	0	0	0	0	0	0.2	0.2	0.1	0.3	0.3	0.1	0.2	0.1	0.1	0.1	C53
Corpus uteri	3.5	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.4	0.7	0.5	0.5	0.3	0.4	0.1	C54
Uterus unsp.	0.4	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0	0	0	C55
Ovary	3.7	0	0	0	0	0.1	0.1	0	0.1	0.3	0.3	0.4	0.6	0.2	0.3	0.3	0.5	0.3	C56
Other female genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0.9	0.1	0	0.1	0	0	0	0	0	0	0	0.1	0	0	0.1	0.1	0.1	0.1	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	3.1	0	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.4	0.4	0.5	1	0.2	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	1.2	0	0.1	0	0.1	0	0	0	0	0.1	0.2	0.1	0.2	0.1	0.1	0	0	0	C70-C72
Thyroid	3.4	0	0	0	0	0.1	0.3	0.4	0.4	0.4	0.3	0.3	0.1	0.3	0.1	0.2	0.1	0.3	C73
Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.3	0	0	0	0.1	0.2	0.2	0.1	0	0	0.1	0.1	0	0.1	0.1	0	0	0.1	C81
Non-Hodgkin lymphoma	5.9	0	0.1	0.1	0.2	0	0.3	0.1	0.2	0.4	0.3	0.5	0.6	0.5	0.6	0.6	1	0.3	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.1	0	0	0	0	0	0	0	0.1	0	0	0	0.2	0.1	0.2	0.2	0.2	0.1	C90
Lymphoid leukemia	1.4	0.2	0.2	0.1	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.1	0.1	C91
Myeloid leukemia	1.8	0	0	0	0	0	0	0	0.1	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0	C92-C94
Leukemia unsp.	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	C95
Other & Unspecified	2.4	0.1	0	0	0	0	0	0	0.1	0.1	0.1	0.3	0.3	0.2	0.1	0.2	0.3	0.2	OTHER
All sites, total	100	0.6	0.6	0.8	1	0.8	1.7	2.5	5.3	8.2	9.8	9.7	11	9.4	10.5	8.6	12.9	6.5	
All sites but C44	95.8	0.6	0.6	0.8	1	0.8	1.7	2.4	5.1	8	9.6	9.4	10.7	9.2	10.1	8.3	11.9	5.8	

** C44 refers to non melanoma skin cancer.*
In-situ cancers are not included.

Table 95: Annual incidence rates per 100000 by primary site & age group, males, Lebanon, 2006

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	0	1.5	3.3	0	4.1	C00
Tongue	1	0.9	0.6	0	0	0	0	0	1.4	0	0	1	3.3	2.8	6.1	3.3	2	2	C01-C02
Mouth	0.4	0.4	0	0	0	0.5	0	0	0	0	0	1	0	2.8	0	3.3	2	4.1	C03-C06
Salivary glands	0.8	0.8	0.6	0	0	0.5	0	0	0	0	2.4	1	3.3	0	1.5	0	8.2	6.1	C07-C08
Tonsil	0.1	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	C09
Other oropharynx	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	3.3	0	0	C10
Nasopharynx	1.4	1.3	0	0	0.5	2.4	0	0	0	1.6	0.8	3	3.3	7	9.2	1.6	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	C12-C13
Pharynx unsp.	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	2.8	0	1.6	0	2	C14
Oesophagus	1.1	1.1	0	0	0	0	0	0	0	0	0	2	0	0	7.7	3.3	20.4	4.1	C15
Stomach	6.4	6.3	0	0	0	0	0	0.6	0	2.4	4.9	12	7.8	13	29	37.6	42.9	55.1	C16
Small intestine	0.7	0.7	0	0	0.5	0	0	0	0.7	0	1.6	0	0	1.4	3.1	3.3	4.1	4.1	C17
Colon	12.9	13.1	0	0	0	0	0	1.9	2	4	9.8	14	20	45	41	57.2	51	186	C18
Rectum	4.1	4.1	0	0	0	0.5	0	0.6	0	1.6	4.9	4	10	5.6	14	31	16.3	40.8	C19-C20
Anus	0.2	0.2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	4.1	4.1	C21
Liver	2.7	2.6	0.6	0	0	0	0	0	1.4	1.6	0	4	6.7	17	6.1	11.4	12.2	12.2	C22
Gallbladder etc.	1	1.1	0	0	0	0	0	0	0	0	0	1	1.1	0	1.5	9.8	12.2	16.3	C23-C24
Pancreas	3.6	3.5	0	0	0	0	0	0	0.7	3.2	2.4	7	3.3	5.6	20	19.6	26.5	20.4	C25
Nose & sinuses & etc.	0.5	0.4	0.6	0	0	0	0	0	0	0	0	1	3.3	1.4	0	1.6	4.1	0	C30-C31
Larynx	5.9	5.8	0	0	0	0	0	0	0	1.6	0.8	8	16	20	25	34.3	44.9	40.8	C32
Trachea bronchus & lung	29.1	28.6	0	0	0	0.5	1	0.6	2	3.2	11	24	53	113	145	180	192	212	C33-C34
Other thoracic organs	1.3	1.3	0.6	0	0	0.5	0.5	2.6	0	0.8	0.8	1	1.1	2.8	7.7	1.6	8.2	4.1	C37-C38
Bone	1.9	2	0	1	2.3	2.4	1.4	1.9	3.4	0	1.6	2	1.1	4.2	3.1	3.3	0	8.2	C40-C41
Melanoma of skin	1.5	1.6	0	0	0.5	0	0.5	0.6	2	0.8	0.8	2	2.2	8.4	0	6.5	4.1	14.3	C43
Other skin	16.4	17.1	0	0	0	0	0.5	0	2.7	3.2	0.8	20	29	28	55	81.7	104	274	C44
Mesothelioma	0.5	0.5	0	0	0	0	0	0	0	0	0.8	2	1.1	0	1.5	3.3	2	4.1	C45
Kaposi sarcoma	0.3	0.2	0	0	0	0	0	0	0	0	0.8	1	0	2.8	0	0	0	2	C46
Connective & soft tissue	2.1	2.1	1.2	1.6	0	1	0.5	1.3	0.7	4.7	4.1	2	3.3	5.6	1.5	4.9	8.2	6.1	C47;C49
Breast	1.2	1.1	0	0	0	0.5	0	0	0	1.6	2.4	2	2.2	1.4	4.6	6.5	4.1	6.1	C50
Penis	0.3	0.3	0	0	0	0.5	0	0	0	0	0	0	0	0	0	1.6	0	8.2	C60
Prostate	34.7	36.6	0	0	0	0	0	0	0.7	0.8	0.8	8	26	80	129	250	274	576	C61
Testis	2.3	2.4	1.2	0	0.5	1.4	5.3	4.5	4.8	4.7	3.3	3	0	2.8	0	0	0	2	C62
Other male genital	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	4	3.9	1.7	0	0	0	0.5	1.3	0.7	5.5	4.9	3	4.5	11	21	13.1	26.5	14.3	C64
Renal pelvis	0.3	0.3	0	0	0	0	0	0	0	0	0	1	0	1.4	1.5	0	2	4.1	C65
Ureter	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	0	1.5	1.6	0	4.1	C66
Bladder	28.6	29.3	0	0	0	0.5	0	1.3	1.4	2.4	14	18	43	71	110	196	204	345	C67
Other urinary organs	0.3	0.3	0	0	0	0	0	0	0	0	0	0	1.1	0	3.1	0	2	4.1	C68
Eye	0.3	0.2	0	0	0.5	0	0	0	0	0	0	1	1.1	1.4	0	0	0	2	C69
Brain & nervous system	4.4	4.1	2.9	2.6	1.4	1.4	1.9	3.2	2.7	2.4	3.3	8	7.8	13	17	11.4	2	8.2	C70-C72
Thyroid	1.7	1.8	0	0	0	1.4	1.4	1.3	0.7	2.4	6.5	3	0	1.4	3.1	3.3	10.2	2	C73
Adrenal gland	0.2	0.2	0	0	0	0	0	0	0	0.8	0	0	1.1	0	0	0	2	2	C74
Other endocrine	0.1	0.1	0	0	0.5	0	0	0.6	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	3.9	4.1	0	0.5	3.2	6.7	4.3	5.8	2.7	4	4.1	5	8.9	5.6	0	1.6	10.2	8.2	C81
Non-Hodgkin lymphoma	13.8	13.7	1.7	1	2.8	1.4	7.2	6.4	9.5	12	23	24	27	35	40	31	69.4	59.2	C82-C85;C96
Immunoproliferative dis.	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	1.4	0	1.6	0	0	C88
Multiple myeloma	2.4	2.3	0	0	0	0	0	0	0	0	2.4	8	5.6	5.6	6.1	16.3	8.2	16.3	C90
Lymphoid leukemia	5.4	5.2	8.7	9.4	2.3	1.9	1.4	1.9	0.7	3.2	0.8	3	6.7	2.8	12	16.3	12.2	28.6	C91
Myeloid leukemia	4.5	4.5	2.9	0.5	1.4	2.4	1	1.3	4.1	3.2	4.1	6	7.8	9.8	9.2	16.3	16.3	24.5	C92-C94
Leukemia unsp.	0.4	0.4	0	0.5	0	0	0.5	0	0	0	0	0	3.3	2.8	0	0	2	0	C95
Other & Unspecified	4.4	4.3	0.6	0.5	0	1	1.4	0.6	0.7	4.7	0.8	6	10	13	18	14.7	24.5	28.6	OTHER
All sites, total	210.3	212.1	25	18	18	28	30	40	48	79	122	216	330	552	759	1091	1245	2072	
All sites but C44	193.9	195	25	18	18	28	30	40	45	76	121	196	301	524	704	1009	1141	1798	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 96: Annual incidence rates per 100000 by primary site & age group, females, Lebanon, 2006

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.1	C00
Tongue	0.4	0.4	0	0	0	0	1	0	0	2	0	1.8	0	1.3	0	1.6	0	2	C01-C02
Mouth	0.8	0.8	0	0	0	0	1	0	0	0	2	1.8	1.1	0	2.7	4.9	2.2	4.1	C03-C06
Salivary glands	0.3	0.3	0	0	0	0	0	1	0	1.3	0	0	0	0	2.7	0	2.2	0	C07-C08
Tonsil	0.2	0.2	0	0	0	0	0	0	0	0	0	0.9	0	0	1.4	0	2.2	4.1	C09
Other oropharynx	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	1.3	1.4	0	0	0	C10
Nasopharynx	0.4	0.4	0	0	1	0	0	0	0	0	0.7	4.5	0	0	0	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.4	0.5	0	0	0	0	0	0	0	0.7	1.3	0	0	0	1.4	1.6	0	8.2	C15
Stomach	3.7	4	0	0	0	1	0	1	3	3.3	0	3.6	5.6	10.3	1.4	24.5	26.7	49	C16
Small intestine	0.9	1	1	0	0	1	1	0	1	0.7	1.3	1.8	0	3.9	0	3.3	4.5	4.1	C17
Colon	11	11.4	0	0	0	1	0	1	6	2	5.3	12.7	21.2	34.8	36.7	57.2	69	120.4	C18
Rectum	3.1	3.1	0	0	0	0	1	0	0	4.6	0.7	6.4	7.8	12.9	15	6.5	20	18.4	C19-C20
Anus	0.2	0.2	0	0	0	0	0	0	0	0	0.7	0	1.1	1.3	1.4	0	0	2	C21
Liver	2.3	2.2	2	1	0	0	1	0	0	0.7	1.3	1.8	3.3	10.3	0	19.6	6.7	16.3	C22
Gallbladder etc.	1.6	1.7	0	0	0	0	0	0	0	0	0	0.9	4.5	5.2	2.7	4.9	22.3	18.4	C23-C24
Pancreas	2.9	2.9	0	0	0	1	0	0	0	2	1.3	2.7	5.6	9	6.8	21.2	31.2	12.2	C25
Nose & sinuses & etc.	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-C31
Larynx	1.1	1.1	0	0	0	0	0	0	0	0	1.3	1.8	2.2	6.4	5.4	4.9	2.2	4.1	C32
Trachea bronchus & lung	11.6	11.8	0	0	0	0	0	1	3	2	9.3	18.1	18.9	34.8	47.6	80	57.9	87.8	C33-C34
Other thoracic organs	0.5	0.5	0	1	0	0	0	0	0	0	0	0	1.1	1.3	1.4	0	2.2	10.2	C37-C38
Bone	1.6	1.7	1	0	4	5	1	1	1	0	0.7	0	2.2	0	1.4	3.3	4.5	4.1	C40-C41
Melanoma of skin	1.9	2	0	0	0	0	1	1	2	0.7	2.6	3.6	5.6	1.3	2.7	8.2	8.9	14.3	C43
Other skin	8.1	8.5	0	0	0	0	0	1	5	6.6	5.3	10	14.5	21.9	19.1	34.3	40.1	110.2	C44
Mesothelioma	0.1	0.1	0	0	0	0	0	0	0	1.3	0	0	0	0	2.7	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	C46
Connective & soft tissue	1.9	2	1	1	1	2	1	2	1	1.3	4	1.8	3.3	0	1.4	9.8	4.5	6.1	C47;C49
Breast	78.2	78.9	0	0	1	1	2	9	27	86	136.4	226.8	222.7	264.3	231.4	238.4	236.1	289.9	C50
Vulva	1.3	1.3	0	0	0	0	0	0	0	0	0	0	4.5	2.6	6.8	4.9	6.7	18.4	C51
Vagina	0.3	0.3	0	0	0	0	0	0	0	0	0	0	0	0	2.7	0	4.5	6.1	C52
Cervix uteri	3.7	3.7	0	0	0	0	0	1	1	4.6	6	5.4	15.6	15.5	8.2	16.3	11.1	8.2	C53
Corpus uteri	7.2	7.2	0	0	0	0	0	0	2	4	4.6	9.1	21.2	37.4	29.9	34.3	29	34.7	C54
Uterus unsp.	0.8	0.8	0	0	0	0	0	0	0	1.3	0.7	2.7	0	1.3	1.4	9.8	0	4.1	C55
Ovary	7.4	7.5	0	0	1	1	2	3	1	2.6	9.3	12.7	20	37.4	15	22.9	29	44.9	C56
Other female genital	0.1	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	1.8	1.8	2	0	2	0	0	0	0	1.3	1.3	0.9	7.8	0	1.4	8.2	11.1	14.3	C64
Renal pelvis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	0	C65
Ureter	0.1	0.1	0	0	0	0	0	0	0	0.7	0	0	0	0	1.4	0	0	0	C66
Bladder	6.1	6.3	0	0	0	0	0	0	1	0	1.3	5.4	12.2	12.9	23.1	27.8	51.2	87.8	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	C68
Eye	0.2	0.1	1	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	C69
Brain & nervous system	2.5	2.4	0	2	1	2	1	1	1	0.7	3.3	7.3	4.5	9	4.1	6.5	2.2	0	C70-C72
Thyroid	6.6	6.9	0	1	0	1	2	8	13	12	12.6	13.6	15.6	7.7	16.3	9.8	20	8.2	C73
Adrenal gland	0.1	0.1	0	0	0	0	0	0	0	0	0	0.9	0	1.3	0	0	0	0	C74
Other endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0.9	0	0	0	0	0	0	C75
Hodgkin disease	2.5	2.6	0	0	1	2	5	7	3	0	1.3	3.6	3.3	1.3	5.4	6.5	2.2	4.1	C81
Non-Hodgkin lymphoma	11.9	12.1	1	2	2	4	0	7	3	4.6	11.3	13.6	25.6	37.4	29.9	45.7	64.6	85.7	C82-C85;C96
Immunoproliferative dis.	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.4	1.6	0	0	C88
Multiple myeloma	2.3	2.3	0	0	0	0	0	0	0	2	1.3	0.9	2.2	10.3	8.2	13.1	17.8	18.4	C90
Lymphoid leukemia	3.1	2.8	5	5	2	1	0	1	0	0	0.7	1.8	2.2	3.9	5.4	11.4	15.6	12.2	C91
Myeloid leukemia	3.6	3.7	0	0	1	1	1	1	0	3.3	6.6	7.3	5.6	12.9	10.9	8.2	17.8	18.4	C92-C94
Leukemia unsp.	0.4	0.4	0	0	1	0	0	0	0	0	1.3	0	0	0	0	4.9	2.2	2	C95
Other & Unspecified	4.9	4.8	3	1	1	1	1	1	1	2	2	6.4	13.4	20.6	13.6	11.4	24.5	32.7	OTHER
All sites, total	200.5	203.7	18	14	18	22	18	45	76	156	239.7	395.6	479.9	631.8	572.9	770.8	861.8	1192	
All sites but C44	192.5	195.1	18	14	18	22	18	45	71	149	234.4	385.6	465.4	609.8	553.9	736.5	821.7	1082	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 97: Incident cases (n) by primary site & age group, Lebanon, 2007

Primary site	All ages	Age group																	Gender			ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	Male	Female	Unsp.	
Lip	11	0	0	0	0	0	1	0	1	1	0	0	1	2	0	1	4	0	7	4	0	C00
Tongue	30	0	0	0	0	0	0	0	2	1	3	5	3	8	2	1	3	2	17	13	0	C01-C02
Mouth	22	0	0	0	0	0	0	1	1	0	1	4	5	1	3	1	2	3	14	8	0	C03-C06
Salivary glands	17	0	1	1	0	0	0	1	1	0	2	2	2	0	3	4	0	0	12	5	0	C07-C08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	C09
Other oropharynx	5	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0	1	4	1	0	C10
Nasopharynx	18	0	0	0	1	1	0	0	0	4	6	0	3	0	0	3	0	0	14	4	0	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	C12-C13
Pharynx unsp.	2	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	C14
Oesophagus	28	0	0	0	0	0	0	1	0	4	3	1	1	4	1	5	7	1	17	11	0	C15
Stomach	276	0	0	0	1	3	9	4	6	11	19	22	23	24	34	37	58	25	144	130	2	C16
Small intestine	41	0	0	0	1	0	2	0	1	0	3	4	4	5	7	6	7	1	25	16	0	C17
Colon	536	0	0	0	2	3	7	9	8	15	31	39	50	71	67	72	132	30	307	229	0	C18
Rectum	144	0	0	0	1	4	1	4	9	6	7	17	18	18	11	13	30	5	76	67	1	C19-C20
Anus	14	0	0	0	1	0	0	0	0	0	0	2	1	2	0	1	2	4	1	7	7	0	C21
Liver	123	0	0	1	1	0	0	1	4	5	8	12	9	21	12	17	26	6	81	42	0	C22
Gallbladder etc.	81	0	0	0	0	0	0	0	2	1	5	2	10	7	11	13	26	4	31	50	0	C23-C24
Pancreas	118	0	0	0	0	0	0	0	2	6	7	13	13	20	19	20	13	5	57	61	0	C25
Nose sinuses & etc.	16	0	0	1	1	2	0	1	1	0	1	1	1	0	4	0	3	0	12	4	0	C30-C31
Larynx	156	0	0	0	0	0	0	0	0	7	9	14	26	20	25	19	27	9	131	25	0	C32
Trachea bronchus & lung	856	1	0	0	3	1	1	5	10	21	37	64	100	107	134	140	172	60	620	234	2	C33-C34
Other thoracic organs	56	1	0	0	1	2	1	2	3	3	9	2	4	4	3	6	11	4	31	25	0	C37-C38
Bone	105	4	6	12	20	11	4	7	3	2	7	2	7	3	3	5	5	4	62	43	0	C40-C41
Melanoma of skin	67	1	0	0	0	2	2	1	7	8	4	5	6	2	5	5	11	8	29	38	0	C43
Other skin	639	1	0	0	0	1	5	3	12	16	27	37	48	45	67	83	195	99	382	254	3	C44
Mesothelioma	14	0	0	0	0	1	0	0	0	0	0	1	1	3	4	2	1	0	1	12	2	0	C45
Kaposi sarcoma	6	0	0	0	0	0	0	0	1	0	1	1	1	0	1	0	1	0	6	0	0	C46
Connective & soft tissue	109	2	0	6	6	4	2	6	4	9	11	9	11	6	9	7	12	5	56	52	1	C47;C49
Breast	1776	0	1	1	0	3	7	51	113	228	243	235	208	175	139	138	150	84	28	1747	1	C50
Vulva	20	0	0	0	0	0	0	0	0	1	0	2	1	1	6	6	3	0	0	20	0	C51
Vagina	12	0	0	0	0	0	0	0	1	0	2	0	1	2	1	2	2	1	0	12	0	C52
Cervix uteri	100	0	0	0	1	0	1	3	12	7	8	17	11	10	9	9	6	6	0	100	0	C53
Corpus uteri	179	0	0	0	1	0	0	1	9	8	14	18	26	27	22	21	24	8	0	179	0	C54
Uterus unsp.	17	0	0	0	0	0	0	1	0	0	3	3	2	3	5	0	0	0	0	17	0	C55
Ovary	187	0	0	1	1	5	8	5	6	26	12	22	23	18	19	15	20	6	0	187	0	C56
Other female genital	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Penis	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3	0	0	C60
Prostate	841	0	0	0	0	0	1	0	1	3	7	31	51	99	131	177	258	82	841	0	0	C61
Testis	66	0	0	0	4	5	8	15	15	8	6	0	2	0	0	0	2	1	66	0	0	C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	132	5	1	0	0	2	1	4	2	10	12	13	10	15	16	14	19	8	89	43	0	C64
Renal pelvis	10	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	3	0	10	0	0	C65
Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	0	0	C66
Bladder	910	0	0	0	1	0	0	5	9	14	42	73	80	111	125	138	239	73	736	174	0	C67
Other urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	C68
Eye	10	6	0	1	0	1	0	0	0	0	0	2	0	0	0	0	0	0	5	5	0	C69
Brain & nervous system	193	7	8	13	5	9	7	8	18	19	18	10	15	13	18	10	10	5	115	78	0	C70-C72
Thyroid	212	0	0	4	7	5	15	13	29	32	23	18	10	17	9	8	13	9	57	154	1	C73
Adrenal gland	8	0	0	0	0	0	1	0	0	0	3	0	1	1	2	0	0	0	5	3	0	C74
Other endocrine	6	0	0	0	0	1	1	0	1	0	2	0	0	0	1	0	0	0	3	3	0	C75
Hodgkin disease	174	0	2	12	17	17	16	27	10	16	5	6	14	9	7	7	5	4	89	85	0	C81
Non-Hodgkin lymphoma	517	4	7	5	9	11	18	13	20	29	35	46	47	53	54	53	81	32	280	234	3	C82-C85;C96
Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	C88
Multiple myeloma	119	0	0	0	0	1	0	1	1	5	7	6	15	14	27	23	11	8	60	59	0	C90
Lymphoid leukemia	149	22	23	7	5	6	1	2	3	2	4	5	14	8	11	9	22	5	87	60	2	C91
Myeloid leukemia	153	4	2	9	4	9	8	8	12	13	12	11	9	6	11	15	20	0	92	61	0	C92-C94
Leukemia unsp.	31	0	2	2	3	1	0	2	1	2	2	2	3	1	3	3	2	2	16	15	0	C95
Other & Unspecified	229	3	1	3	2	4	4	2	9	16	15	23	14	17	29	21	47	19	109	119	1	OTHER
All sites, total	9552	62	54	79	99	115	132	207	350	559	681	801	910	979	1072	1136	1687	629	4853	4682	17	
All sites, without C44*	8913	61	54	79	99	114	127	204	338	543	654	764	862	934	1005	1053	1492	530	4471	4428	14	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 98: Incident cases (n) by primary site & age group, males, Lebanon, 2007

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	7	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	3	0	C00
Tongue	17	0	0	0	0	0	0	0	1	1	0	3	2	4	1	1	3	1	C01-C02
Mouth	14	0	0	0	0	0	0	1	1	0	0	3	3	0	3	0	2	1	C03-C06
Salivary glands	12	0	1	1	0	0	0	1	0	0	1	1	2	0	3	2	0	0	C07-C08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C09
Other oropharynx	4	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	1	C10
Nasopharynx	14	0	0	0	1	0	0	0	0	4	6	0	1	0	0	2	0	0	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	C12-C13
Pharynx unsp.	2	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	C14
Oesophagus	17	0	0	0	0	0	0	1	0	3	2	1	0	2	1	4	3	0	C15
Stomach	144	0	0	0	1	0	4	1	1	4	9	7	12	16	20	24	30	15	C16
Small intestine	25	0	0	0	1	0	1	0	1	0	2	3	3	3	4	2	5	0	C17
Colon	307	0	0	0	1	2	2	7	5	7	15	21	31	38	41	49	76	12	C18
Rectum	76	0	0	0	1	2	1	3	3	0	3	8	10	10	6	5	22	2	C19-C20
Anus	7	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	3	0	C21
Liver	81	0	0	1	1	0	0	1	4	1	3	10	6	13	8	8	21	4	C22
Gallbladder etc.	31	0	0	0	0	0	0	0	0	1	2	0	4	2	6	6	10	0	C23-C24
Pancreas	57	0	0	0	0	0	0	0	2	5	5	7	6	11	8	9	1	3	C25
Nose & sinuses & etc.	12	0	0	1	1	1	0	0	0	0	1	1	1	0	3	0	3	0	C30-C31
Larynx	131	0	0	0	0	0	0	0	0	5	8	12	19	15	23	17	26	6	C32
Trachea bronchus & lung	620	1	0	0	1	1	1	4	2	9	28	39	71	78	112	102	130	41	C33-C34
Other thoracic organs	31	0	0	0	1	2	1	2	0	1	4	2	1	0	3	4	6	4	C37-C38
Bone	62	2	3	9	11	9	2	5	2	1	3	1	3	3	2	2	2	2	C40-C41
Melanoma of skin	29	0	0	0	0	1	2	0	3	1	2	2	4	2	4	3	2	3	C43
Other skin	382	0	0	0	0	0	2	1	6	5	15	20	27	28	43	51	127	57	C44
Mesothelioma	12	0	0	0	0	1	0	0	0	0	0	0	3	4	2	1	0	1	C45
Kaposi sarcoma	6	0	0	0	0	0	0	0	1	0	1	1	1	0	1	0	1	0	C46
Connective & soft tissue	56	1	0	1	2	3	2	4	3	3	7	6	4	1	5	5	6	3	C47;C49
Breast	28	0	0	1	0	0	0	0	0	0	1	3	3	3	5	3	7	2	C50
Penis	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	C60
Prostate	841	0	0	0	0	0	1	0	1	3	7	31	51	99	131	177	258	82	C61
Testis	66	0	0	0	4	5	8	15	15	8	6	0	2	0	0	0	2	1	C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	89	3	0	0	0	1	1	2	2	8	9	9	5	12	12	8	10	7	C64
Renal pelvis	10	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	3	0	C65
Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	C66
Bladder	736	0	0	0	1	0	0	4	5	10	32	54	68	95	105	113	196	53	C67
Other urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C68
Eye	5	3	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	115	7	4	7	3	5	3	6	8	15	12	7	9	6	9	4	6	4	C70-C72
Thyroid	57	0	0	2	2	1	3	3	7	9	9	5	2	5	2	1	5	1	C73
Adrenal gland	5	0	0	0	0	0	1	0	0	0	1	0	0	1	2	0	0	0	C74
Other endocrine	3	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	C75
Hodgkin disease	89	0	2	6	10	9	7	14	4	9	4	4	5	5	5	1	1	3	C81
Non-Hodgkin lymphoma	280	4	4	5	5	7	11	4	11	13	20	21	23	33	31	25	50	13	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	60	0	0	0	0	0	0	0	1	1	4	2	2	8	7	12	12	6	5	C90
Lymphoid leukemia	87	12	13	5	3	4	0	2	0	2	3	3	9	3	5	3	16	4	C91
Myeloid leukemia	92	4	2	4	3	5	6	6	5	7	5	7	6	2	5	10	15	0	C92-C94
Leukemia unsp.	16	0	0	1	3	1	0	0	0	1	1	0	2	1	2	1	2	1	C95
Other & Unspecified	109	1	0	1	0	2	2	2	4	6	6	9	7	12	17	11	20	9	OTHER
All sites, total	4853	39	29	46	56	64	62	90	99	146	239	304	417	522	645	672	1080	343	
All sites, without C44*	4471	39	29	46	56	64	60	89	93	141	224	284	390	494	602	621	953	286	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 99: Incident cases (n) by primary site & age group, females, Lebanon, 2007

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	4	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	1	0	C00
Tongue	13	0	0	0	0	0	0	0	1	0	3	2	1	4	1	0	0	1	C01-C02
Mouth	8	0	0	0	0	0	0	0	0	0	1	1	2	1	0	1	0	2	C03-C06
Salivary glands	5	0	0	0	0	0	0	0	1	0	1	1	0	0	0	2	0	0	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	C10
Nasopharynx	4	0	0	0	0	1	0	0	0	0	0	0	2	0	0	1	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	11	0	0	0	0	0	0	0	0	1	1	0	1	2	0	1	4	1	C15
Stomach	130	0	0	0	0	3	5	3	5	7	10	15	11	8	14	13	27	9	C16
Small intestine	16	0	0	0	0	0	1	0	0	0	1	1	1	2	3	4	2	1	C17
Colon	229	0	0	0	1	1	5	2	3	8	16	18	19	33	26	23	56	18	C18
Rectum	67	0	0	0	0	2	0	1	6	6	4	9	8	8	5	8	7	3	C19-C20
Anus	7	0	0	0	1	0	0	0	0	0	1	0	1	0	0	2	1	1	C21
Liver	42	0	0	0	0	0	0	0	0	4	5	2	3	8	4	9	5	2	C22
Gallbladder etc.	50	0	0	0	0	0	0	0	2	0	3	2	6	5	5	7	16	4	C23-C24
Pancreas	61	0	0	0	0	0	0	0	0	1	2	6	7	9	11	11	12	2	C25
Nose & sinuses & etc.	4	0	0	0	0	1	0	1	1	0	0	0	0	0	1	0	0	0	C30-C31
Larynx	25	0	0	0	0	0	0	0	0	2	1	2	7	5	2	2	1	3	C32
Trachea bronchus & lung	234	0	0	0	2	0	0	1	8	12	9	25	29	28	22	38	42	18	C33-C34
Other thoracic organs	25	1	0	0	0	0	0	0	3	2	5	0	3	4	0	2	5	0	C37-C38
Bone	43	2	3	3	9	2	2	2	1	1	4	1	4	0	1	3	3	2	C40-C41
Melanoma of skin	38	1	0	0	0	1	0	1	4	7	2	3	2	0	1	2	9	5	C43
Other skin	254	1	0	0	0	1	3	2	6	11	12	17	21	17	24	32	67	40	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	52	1	0	5	4	1	0	2	1	6	4	3	7	5	4	2	6	1	C47;C49
Breast	1747	0	1	0	0	3	7	51	113	228	241	232	205	172	134	135	143	82	C50
Vulva	20	0	0	0	0	0	0	0	0	1	0	2	1	1	6	6	3	0	C51
Vagina	12	0	0	0	0	0	0	0	1	0	2	0	1	2	1	2	2	1	C52
Cervix uteri	100	0	0	0	1	0	1	3	12	7	8	17	11	10	9	9	6	6	C53
Corpus uteri	179	0	0	0	1	0	0	1	9	8	14	18	26	27	22	21	24	8	C54
Uterus unsp.	17	0	0	0	0	0	0	1	0	0	3	3	2	3	5	0	0	0	C55
Ovary	187	0	0	1	1	5	8	5	6	26	12	22	23	18	19	15	20	6	C56
Other female genital	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	43	2	1	0	0	1	0	2	0	2	3	4	5	3	4	6	9	1	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	174	0	0	0	0	0	0	1	4	4	10	19	12	16	20	25	43	20	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	5	3	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	C69
Brain & nervous system	78	0	4	6	2	4	4	2	10	4	6	3	6	7	9	6	4	1	C70-C72
Thyroid	154	0	0	2	5	4	12	9	22	23	14	13	8	12	7	7	8	8	C73
Adrenal gland	3	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	C74
Other endocrine	3	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	C75
Hodgkin disease	85	0	0	6	7	8	9	13	6	7	1	2	9	4	2	6	4	1	C81
Non-Hodgkin lymphoma	234	0	3	0	4	4	7	9	9	16	15	25	24	20	22	27	31	18	C82-C85;C96
Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	C88
Multiple myeloma	59	0	0	0	0	1	0	0	0	1	5	4	7	7	15	11	5	3	C90
Lymphoid leukemia	60	9	10	2	2	2	1	0	3	0	1	2	5	5	6	5	6	1	C91
Myeloid leukemia	61	0	0	5	1	4	2	2	7	6	7	4	3	4	6	5	5	0	C92-C94
Leukemia unsp.	15	0	2	1	0	0	0	2	1	1	1	2	1	0	1	2	0	1	C95
Other & Unspecified	119	2	1	2	2	2	2	0	5	10	9	14	7	5	12	10	27	9	OTHER
All sites, total	4682	22	25	33	43	51	70	116	251	413	441	497	493	456	426	462	604	279	
All sites, without C44*	4428	21	25	33	43	50	67	114	245	402	429	480	472	439	402	430	537	239	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 100: Relative proportions (%) of cases by primary site & age group, males, Lebanon, 2007

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C00
Tongue	0.4	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0.1	0	C01-C02
Mouth	0.3	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0	0	0	C03-C06
Salivary glands	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.3	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.4	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.1	0.1	0	C15
Stomach	3	0	0	0	0	0	0.1	0	0	0.1	0.2	0.1	0.2	0.3	0.4	0.5	0.6	0.3	C16
Small intestine	0.5	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0	0.1	0	C17
Colon	6.3	0	0	0	0	0	0	0.1	0.1	0.1	0.3	0.4	0.6	0.8	0.8	1	1.6	0.2	C18
Rectum	1.6	0	0	0	0	0	0	0.1	0.1	0	0.1	0.2	0.2	0.2	0.1	0.1	0.5	0	C19-C20
Anus	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C21
Liver	1.7	0	0	0	0	0	0	0	0.1	0	0.1	0.2	0.1	0.3	0.2	0.2	0.4	0.1	C22
Gallbladder etc.	0.6	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.2	0	C23-C24
Pancreas	1.2	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0	0.1	C25
Nose & sinuses & etc.	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	C30-C31
Larynx	2.7	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.4	0.3	0.5	0.4	0.5	0.1	C32
Trachea bronchus &	12.8	0	0	0	0	0	0	0.1	0	0.2	0.6	0.8	1.5	1.6	2.3	2.1	2.7	0.8	C33-C34
Other thoracic organs	0.6	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0.1	0.1	0.1	C37-C38
Bone	1.3	0	0.1	0.2	0.2	0.2	0	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0	C40-C41
Melanoma of skin	0.6	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0	0.1	0.1	0	0.1	C43
Other skin	7.9	0	0	0	0	0	0	0	0.1	0.1	0.3	0.4	0.6	0.6	0.9	1.1	2.6	1.2	C44
Mesothelioma	0.2	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	C45
Kaposi sarcoma	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1.2	0	0	0	0	0.1	0	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	C47;C49
Breast	0.6	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0	C50
Penis	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C60
Prostate	17.3	0	0	0	0	0	0	0	0	0.1	0.1	0.6	1.1	2	2.7	3.6	5.3	1.7	C61
Testis	1.4	0	0	0	0.1	0.1	0.2	0.3	0.3	0.2	0.1	0	0	0	0	0	0	0	C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	1.8	0.1	0	0	0	0	0	0	0	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.1	C64
Renal pelvis	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	15.2	0	0	0	0	0	0	0.1	0.1	0.2	0.7	1.1	1.4	2	2.2	2.3	4	1.1	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	2.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.1	C70-C72
Thyroid	1.2	0	0	0	0	0	0.1	0.1	0.1	0.2	0.2	0.1	0	0.1	0	0	0.1	0	C73
Adrenal gland	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.8	0	0	0.1	0.2	0.2	0.1	0.3	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0	0	0.1	C81
Non-Hodgkin	5.8	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.3	0.4	0.4	0.5	0.7	0.6	0.5	1	0.3	C82-C85;C96
Immunoproliferative	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.2	0	0	0	0	0	0	0	0	0.1	0	0	0.2	0.1	0.2	0.2	0.1	0.1	C90
Lymphoid leukemia	1.8	0.2	0.3	0.1	0.1	0.1	0	0	0	0	0.1	0.1	0.2	0.1	0.1	0.1	0.3	0.1	C91
Myeloid leukemia	1.9	0.1	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0.2	0.3	0	C92-C94
Leukemia unsp.	0.3	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Other & Unspecified	2.2	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.4	0.2	0.4	0.2	OTHER
All sites, total	100	0.8	0.6	0.9	1.2	1.3	1.3	1.9	2	3	4.9	6.3	8.6	10.8	13.3	13.8	22.3	7.1	
All sites but C44	92.1	0.8	0.6	0.9	1.2	1.3	1.2	1.8	1.9	2.9	4.6	5.9	8	10.2	12.4	12.8	19.6	5.9	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 101: Relative proportions (%) of cases by primary site & age group, females, Lebanon, 2007

Primary site	All ages	Age group																	ICD (10th)
		0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	Unsp.	
Lip	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00
Tongue	0.3	0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	0	C01-C02
Mouth	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C03-C06
Salivary glands	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	C15
Stomach	2.8	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.2	0.2	0.3	0.3	0.6	0.2	C16
Small intestine	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	C17
Colon	4.9	0	0	0	0	0	0.1	0	0.1	0.2	0.3	0.4	0.4	0.7	0.6	0.5	1.2	0.4	C18
Rectum	1.4	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.2	0.1	0.1	C19-C20
Anus	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	0.9	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0.2	0.1	0.2	0.1	0	C22
Gallbladder etc.	1.1	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.1	0.1	0.3	0.1	C23-C24
Pancreas	1.3	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.2	0.3	0	C25
Nose & sinuses & etc.	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-C31
Larynx	0.5	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0.1	C32
Trachea bronchus & lung	5	0	0	0	0	0	0	0	0.2	0.3	0.2	0.5	0.6	0.6	0.5	0.8	0.9	0.4	C33-C34
Other thoracic organs	0.5	0	0	0	0	0	0	0	0.1	0	0.1	0	0.1	0.1	0	0	0.1	0	C37-C38
Bone	0.9	0	0.1	0.1	0.2	0	0	0	0	0	0.1	0	0.1	0	0	0.1	0.1	0	C40-C41
Melanoma of skin	0.8	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0	0	0	0	0.2	0.1	C43
Other skin	5.4	0	0	0	0	0	0.1	0	0.1	0.2	0.3	0.4	0.4	0.4	0.5	0.7	1.4	0.9	C44
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	1.1	0	0	0.1	0.1	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0	C47;C49
Breast	37.3	0	0	0	0	0.1	0.1	1.1	2.4	4.9	5.1	5	4.4	3.7	2.9	2.9	3.1	1.8	C50
Vulva	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	C51
Vagina	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C52
Cervix uteri	2.1	0	0	0	0	0	0	0.1	0.3	0.1	0.2	0.4	0.2	0.2	0.2	0.2	0.1	0.1	C53
Corpus uteri	3.8	0	0	0	0	0	0	0	0.2	0.2	0.3	0.4	0.6	0.6	0.5	0.4	0.5	0.2	C54
Uterus unsp.	0.4	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0	0	0	C55
Ovary	4	0	0	0	0	0.1	0.2	0.1	0.1	0.6	0.3	0.5	0.5	0.4	0.4	0.3	0.4	0.1	C56
Other female genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	0.9	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	3.7	0	0	0	0	0	0	0	0.1	0.1	0.2	0.4	0.3	0.3	0.4	0.5	0.9	0.4	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	1.7	0	0.1	0.1	0	0.1	0.1	0	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0	C70-C72
Thyroid	3.3	0	0	0	0.1	0.1	0.3	0.2	0.5	0.5	0.3	0.3	0.2	0.3	0.1	0.1	0.2	0.2	C73
Adrenal gland	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	1.8	0	0	0.1	0.1	0.2	0.2	0.3	0.1	0.1	0	0	0.2	0.1	0	0.1	0.1	0	C81
Non-Hodgkin lymphoma	5	0	0.1	0	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.5	0.5	0.4	0.5	0.6	0.7	0.4	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	1.3	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.3	0.2	0.1	0.1	C90
Lymphoid leukemia	1.3	0.2	0.2	0	0	0	0	0	0.1	0	0	0	0.1	0.1	0.1	0.1	0.1	0	C91
Myeloid leukemia	1.3	0	0	0.1	0	0.1	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	C92-C94
Leukemia unsp.	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C95
Other & Unspecified	2.5	0	0	0	0	0	0	0	0.1	0.2	0.2	0.3	0.1	0.1	0.3	0.2	0.6	0.2	OTHER
All sites, total	100	0.5	0.5	0.7	0.9	1.1	1.5	2.5	5.4	8.8	9.4	10.6	10.5	9.7	9.1	9.9	12.9	6	
All sites but C44	94.6	0.4	0.5	0.7	0.9	1.1	1.4	2.4	5.2	8.6	9.2	10.3	10.1	9.4	8.6	9.2	11.5	5.1	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 102: Relative proportions (%) of cases by primary site & age group, females, Lebanon, 2007

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.3	0.4	0	0	0	0	0	0	0	0.8	0	0	0	1.4	1.5	0	1.8	4.1	C00
Tongue	0.8	0.9	0	0	0	0	0	0	0	0.8	0.9	0	3.4	2.8	5.9	1.6	1.8	4.1	C01-C02
Mouth	0.7	0.7	0	0	0	0	0	0	0.7	0.8	0	0	3.4	4.2	0	4.7	0	2.7	C03-C06
Salivary glands	0.6	0.6	0	0.6	0.5	0	0	0	0.7	0	0	1	1.1	2.8	0	4.7	3.6	0	C07-C08
Tonsil	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	C09
Other oropharynx	0.2	0.2	0	0	0	0	0	0	0	0	0	1	0	1.4	1.5	0	0	0	C10
Nasopharynx	0.8	0.7	0	0	0	0.5	0	0	0	0	3.7	5.9	0	1.4	0	0	3.6	0	C11
Hypopharynx	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	0	C12-C13
Pharynx unsp.	0.1	0.1	0.7	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	C14
Oesophagus	0.8	0.9	0	0	0	0	0	0	0.7	0	2.8	2	1.1	0	3	1.6	7.2	4.1	C15
Stomach	6.4	7.3	0	0	0	0.5	0	2.6	0.7	0.8	3.7	9.9	9.1	18.2	26.7	34.7	48.9	44.6	C16
Small intestine	1.2	1.3	0	0	0	0.5	0	0.6	0	0.8	0	2	3.4	4.2	4.5	6.3	3.6	6.8	C17
Colon	13.5	15.6	0	0	0	0.5	1	1.3	5	4.2	6.5	15.8	25.1	44.8	59.4	67.8	92.3	106.7	C18
Rectum	3.4	3.9	0	0	0	0.5	1	0.6	2.1	2.5	0	3	9.1	14	14.8	9.5	9.1	31.1	C19-C20
Anus	0.3	0.4	0	0	0	0	0	0	0	0	0	1	1.1	1.4	0	1.6	0	4.1	C21
Liver	3.7	4.1	0	0	0.5	0.5	0	0	0.7	3.3	0.9	3	12.6	8.4	20.8	12.6	14.5	29.7	C22
Gallbladder etc.	1.3	1.6	0	0	0	0	0	0	0	0	0.9	2	0	5.6	3	9.5	10.9	13.5	C23-C24
Pancreas	3	2.9	0	0	0	0	0	0	0	1.7	4.6	4.9	8	8.4	17.8	12.6	18.1	1.4	C25
Nose & sinuses & etc.	0.5	0.6	0	0	0.5	0.5	0.5	0	0	0	0	1	1.1	1.4	0	4.7	0	4.1	C30-C31
Larynx	6.1	6.7	0	0	0	0	0	0	0	0	4.6	7.9	14.9	28	23.7	37.9	32.6	36.5	C32
Trachea bronchus & lung	27.8	31.5	0.7	0	0	0.5	0.5	0.6	2.8	1.7	9.3	29.6	48	106	125	189.3	197.3	187.8	C33-C34
Other thoracic organs	1.3	1.6	0	0	0	0.5	1	0.6	1.4	0	0.9	4.9	2.3	1.4	0	4.7	9.1	9.5	C37-C38
Bone	3	3.2	1.4	1.7	4.6	5.3	4.4	1.3	3.5	1.7	0.9	3	1.1	4.2	4.5	3.2	3.6	2.7	C40-C41
Melanoma of skin	1.4	1.5	0	0	0	0	0.5	1.3	0	2.5	0.9	2	2.3	5.6	3	6.3	5.4	2.7	C43
Other skin	15.6	19.4	0	0	0	0	0	1.3	0.7	5.9	5.6	17.8	27.4	44.8	49	80.4	108.6	201.3	C44
Mesothelioma	0.6	0.6	0	0	0	0	0.5	0	0	0	0	0	0	4.2	5.9	3.2	1.8	0	C45
Kaposi sarcoma	0.3	0.3	0	0	0	0	0	0	0	0.8	0	1	1.1	1.4	0	1.6	0	1.4	C46
Connective & soft tissue	2.7	2.8	0.7	0	0.5	1	1.5	1.3	2.8	2.5	2.8	6.9	6.9	5.6	1.5	7.9	9.1	8.1	C47;C49
Breast	1.3	1.4	0	0	0.5	0	0	0	0	0	0	1	3.4	4.2	4.5	7.9	5.4	10.8	C50
Penis	0.1	0.2	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	2.7	C60
Prostate	34.1	42.8	0	0	0	0	0	0.6	0	0.8	2.8	7.9	38.9	79.8	163	228.7	354.8	386.3	C61
Testis	3.2	3.4	0	0	0	1.9	2.5	5.2	10.6	12.6	7.4	5.9	0	2.8	0	0	0	2.7	C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	4.5	4.5	2.1	0	0	0	0.5	0.6	1.4	1.7	8.3	9.9	11.4	7	19.3	20.5	16.3	14.9	C64
Renal pelvis	0.4	0.5	0	0	0	0	0	0	0	0	0	0	0	0	3	3.2	5.4	4.1	C65
Ureter	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	1.8	0	C66
Bladder	32.1	37.4	0	0	0	0.5	0	0	2.8	4.2	10.2	33.6	66.3	102	151	178.2	220.9	285	C67
Other urinary organs	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.8	0	C68
Eye	0.3	0.3	2.1	0	0.5	0	0.5	0	0	0	0	0	0	0	0	0	0	0	C69
Brain & nervous system	6	5.9	4.8	2.3	3.6	1.5	2.5	1.9	4.2	6.7	14.8	11.9	8	12.6	8.9	14.2	7.2	8.1	C70-C72
Thyroid	2.9	2.9	0	0	1	1	0.5	1.9	2.1	5.9	8.3	8.9	5.7	2.8	7.4	3.2	1.8	6.8	C73
Adrenal gland	0.3	0.3	0	0	0	0	0	0.6	0	0	0	1	0	0	1.5	3.2	0	0	C74
Other endocrine	0.1	0.2	0	0	0	0	0.5	0.6	0	0	0	1	0	0	0	0	0	0	C75
Hodgkin disease	4.3	4.5	0	1.2	3.1	4.8	4.4	4.5	9.9	3.3	8.3	4	4.6	7	7.4	7.9	1.8	1.4	C81
Non-Hodgkin lymphoma	13.3	14.2	2.8	2.3	2.6	2.4	3.5	7.7	2.8	10	13	20.8	25.1	33.6	51.9	52	47.1	70.2	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	2.8	3.1	0	0	0	0	0	0	0.7	0.8	3.7	2	2.3	12.6	11.9	20.5	23.5	9.5	C90
Lymphoid leukemia	4.5	4.4	9	8.1	2.6	1.5	2	0	1.4	0	1.9	3	3.4	12.6	4.5	7.9	5.4	23	C91
Myeloid leukemia	4.3	4.7	2.8	1.2	2	1.5	2.5	3.9	4.2	4.2	6.5	4.9	8	8.4	3	7.9	18.1	20.3	C92-C94
Leukemia unsp.	0.7	0.8	0	0	0.5	1.5	0.5	0	0	0	0.9	1	0	2.8	1.5	3.2	1.8	2.7	C95
Other & Unspecified	5.1	5.5	0.7	0	0.5	0	1	1.3	1.4	3.3	6.5	6.9	11.4	11.2	19.3	30	21.7	29.7	OTHER
All sites, total	216.9	246.9	28.4	17.5	24.5	28.1	33	42	66.5	87	143	252	373	627	836	1099	1320	1586	
All sites but C44	201.4	227.4	28.4	17.5	24.5	28.1	33	40.7	65.8	81.2	137	234	345	582	787	1019	1211	1385	

** C44 refers to non melanoma skin cancer.*

In-situ cancers are not included.

Table 103: Annual incidence rates per 100000 by primary site & age group, males, Lebanon, 2007

Primary site	ASR	Crude rate	Age-specific rate																ICD (10th)
			0-4y	5-9y	10-14y	15-19y	20-24y	25-29y	30-34y	35-39y	40-44y	45-49y	50-54y	55-59y	60-64y	65-69y	70-74y	75+y	
Lip	0.2	0.2	0	0	0	0	0	0.6	0	0	0.7	0	0	0	1.3	0	0	1.5	C00
Tongue	0.6	0.6	0	0	0	0	0	0	0	0.7	0	2.5	2	1.3	5.1	1.5	0	0	C01-C02
Mouth	0.4	0.4	0	0	0	0	0	0	0	0	0	0.8	1	3.8	1.3	0	1.8	0	C03-C06
Salivary glands	0.2	0.2	0	0	0	0	0	0	0	0.7	0	0.8	1	0	0	0	3.6	0	C07-C08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	0	C10
Nasopharynx	0.2	0.2	0	0	0	0	0.5	0	0	0	0	0	0	2.5	0	0	1.8	0	C11
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C12-C13
Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14
Oesophagus	0.4	0.5	0	0	0	0	0	0	0	0	0.7	0.8	0	1.3	2.5	0	1.8	6	C15
Stomach	5.5	6.5	0	0	0	0	1.6	3	2	3.4	5.7	9.3	16.2	15.1	11.4	22.3	25.4	43.6	C16
Small intestine	0.7	0.8	0	0	0	0	0	0.6	0	0	0	0.8	1	1.3	2.5	4.5	7.3	3	C17
Colon	9.7	11.4	0	0	0	0.6	0.5	3	1.3	2	6.4	14.3	20.3	26.5	45.5	41.7	45.4	91.7	C18
Rectum	3	3.3	0	0	0	0	1.1	0	0.7	4.1	4.3	3.4	9.1	10.1	10.1	7.4	14.5	10.5	C19-C20
Anus	0.3	0.3	0	0	0	0.6	0	0	0	0	0	0.8	0	1.3	0	0	3.6	1.5	C21
Liver	1.8	2.1	0	0	0	0	0	0	0	0	2.9	4.2	2	3.8	10.1	6	16.4	7.5	C22
Gallbladder etc.	2	2.5	0	0	0	0	0	0	0	1.4	0	2.5	2	8.8	6.3	7.4	14.5	25.6	C23-C24
Pancreas	2.6	3	0	0	0	0	0	0	0	0	0.7	1.7	6.1	8.8	11.4	16.4	20	18	C25
Nose & sinuses & etc.	0.2	0.2	0	0	0	0	0.5	0	0.7	0.7	0	0	0	0	0	1.5	0	0	C30-C31
Larynx	1.2	1.2	0	0	0	0	0	0	0	0	1.4	0.8	2	10.1	7.6	3	3.6	1.5	C32
Trachea bronchus & lung	10	11.6	0	0	0	1.1	0	0	0.7	6.1	9.3	8.4	27.3	39.1	37.9	35.7	74.5	69.2	C33-C34
Other thoracic organs	1.1	1.2	0.8	0	0	0	0	0	0	2	1.4	4.2	0	3.8	5.1	0	3.6	7.5	C37-C38
Bone	2.1	2.1	1.5	1.8	1.7	5	1.1	1.2	1.3	0.7	0.7	3.4	1	5	0	1.5	5.5	4.5	C40-C41
Melanoma of skin	1.6	1.9	0.8	0	0	0	0.5	0	0.7	3.4	5.7	1.7	3	2.5	0	1.5	3.6	15	C43
Other skin	10.3	12.6	0.8	0	0	0	0.5	2.4	1.3	4.8	9.3	11.8	20.3	31.5	25.3	41.7	69.1	120	C44
Mesothelioma	0.1	0.1	0	0	0	0	0	0	0	0	0	0.8	1	0	0	0	0	0	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective & soft tissue	2.4	2.6	0.8	0	2.8	2.2	0.5	0	1.3	0.7	4.3	3.4	3	8.8	6.3	6	3.6	9	C47;C49
Breast	78.8	86.9	0	0.6	0	0	1.6	4.2	36	80.9	171	213	246	271	228	210	258	226	C50
Vulva	0.8	1	0	0	0	0	0	0	0	0	0.7	0	2	1.3	1.3	8.9	10.9	4.5	C51
Vagina	0.5	0.6	0	0	0	0	0	0	0	0.7	0	1.7	0	1.3	2.5	1.5	3.6	3	C52
Cervix uteri	4.5	5	0	0	0	0.6	0	0.6	2	8.8	5	7.6	18.2	15.1	13.9	14.9	18.2	9	C53
Corpus uteri	7.9	8.9	0	0	0	0.6	0	0	0.7	6.1	5.7	12.6	19.2	34	35.4	34.2	40	37.6	C54
Uterus unsp.	0.8	0.8	0	0	0	0	0	0	0.7	0	0	2.5	3	2.5	3.8	7.4	0	0	C55
Ovary	8.3	9.3	0	0	0.6	0.6	2.7	4.8	3.3	4.1	19.3	10.1	23.3	30.3	24	29.8	27.3	31.6	C56
Other female genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.8	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	1.9	2.1	1.5	0.6	0	0	0.5	0	1.3	0	1.4	2.5	4.1	6.3	3.8	6	10.9	13.5	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	7.2	8.7	0	0	0	0	0	0	0.7	3.4	3.6	9.3	21.3	17.7	22.8	34.2	50.9	73.7	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	0.4	0.2	2.3	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	C69
Brain & nervous system	3.6	3.9	0	2.4	3.3	1.1	2.1	2.4	1.3	6.8	2.9	5.1	3	7.6	8.8	13.4	10.9	6	C70-C72
Thyroid	6.9	7.7	0	0	1.1	2.8	2.1	7.8	6	15.6	17.2	12.6	14.2	10.1	16.4	10.4	12.7	12	C73
Adrenal gland	0.1	0.1	0	0	0	0	0	0	0	0	0	1.7	0	1.3	0	0	0	0	C74
Other endocrine	0.1	0.1	0	0	0	0	0	0	0	0.7	0	0.8	0	0	0	1.5	0	0	C75
Hodgkin disease	3.8	4.2	0	0	3.3	3.9	4.3	5.4	8.6	4.1	5	0.8	2	11.3	5.1	3	10.9	6	C81
Non-Hodgkin lymphoma	10.2	11.6	0	1.8	0	2.2	2.1	4.8	6.6	6.8	12.2	13.5	27.3	32.8	27.8	35.7	52.7	51.1	C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0	C88
Multiple myeloma	2.6	2.9	0	0	0	0	0.5	0	0	0	0.7	4.2	4.1	8.8	8.8	23.8	21.8	7.5	C90
Lymphoid leukemia	3.2	3	6.8	6.1	1.1	1.1	1.1	0.6	0	2	0	0.8	2	6.3	6.3	8.9	9.1	9	C91
Myeloid leukemia	2.7	3	0	0	2.8	0.6	2.1	1.2	1.3	4.8	4.3	5.9	4.1	3.8	5.1	8.9	9.1	7.5	C92-C94
Leukemia unsp.	0.7	0.7	0	1.2	0.6	0	0	0	1.3	0.7	0.7	0.8	2	1.3	0	1.5	3.6	0	C95
Other & Unspecified	5.1	5.9	1.5	0.6	1.1	1.1	1.1	1.2	0	3.4	7.9	8.4	15.2	10.1	6.3	19.4	20	43.6	OTHER
All sites, total	206.9	232.8	17	16	19	25	28	44	81	180	313	394	535	661	613	676	898	982	
All sites but C44	196.6	220.2	17	16	19	25	28	42	80	175	304	382	514	629	588	634	829	862	

** C44 refers to non melanoma skin cancer.*
In-situ cancers are not included.

ASR	Age Standardized Rate
CAS	Central Administration for Statistics
CI	Confidence Interval
CR	Crude Rate
DDC	Drug Dispensary Center
EMR	Eastern Mediterranean Region
ESP	Epidemiology Surveillance Program
IARC	International Agency for Research on Cancer
ICCC-3	International Classification of Childhood Cancer – 3rd edition
ICD-10	International Classification on Diseases – 10th revision
ICD-O-3	International Classification for Diseases on Oncology – 3rd edition
MOPH	Ministry of Public Health
NCR	National Cancer Registry
NHL	Non-Hodgkin Lymphoma
UNRWA	the United Nations Relief and Works Agency for Palestine Refugees in the Near East
WHO	World Health Organization

References

Adib S, Daniel J, Issa Gh. Cancer in Lebanon 2004 with an update of Cancer 2003. Lebanese Ministry of Public Health / National Cancer Registry, 2008

Bray F. Chapter 8. Age-Standardization. In the eighth volume in the "Cancer Incidence in Five Continents Vol. VIII". IARC Scientific Publication No. 155.
Available online: www.iarc.fr/en/publications/pdfs-online/epi/sp155/ci5v8-chap8.pdf

Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 17th July 2013

Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology, third edition. WHO. 2000

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer Statistics. CA: a cancer Journal for Clinicians 2011; 61:69-90

Jensen OM, Parkin DM, Maclennan R, Muir CS and Skeet RG. Cancer registration: Principles and methods. IARC Scientific Publications No. 95. Lyon, France 1991

Salim El, Moore MA, AL-Lawati JA, Al-Sayyad J, Bazawir A, Bener A, Corbex M, El-Saghir N, Habib OS, Maziak W, Mokhtar HC, Seif-Eldin IA, Sobue T. Cancer epidemiology and control in the Arab World – past, present and future. Asian Pacific J Can Prev 2009; 10: 3-16

Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer 2005;103:1457-67

الجمهورية اللبنانية
وزارة لصحة العامة
الوزير

رقم المحفوظات: 1/204–2/4
بيروت في 23 تموز 2002

قرار رقم 1/511
يتعلق بالزامية الابلاغ عن اية حالة سرطانية

ان وزير الصحة العامة

بناء على المرسوم رقم 4336 تاريخ 26 تشرين الاول 2000

بناء على المرسوم رقم 8377 تاريخ 30 كانون الاول 1961 (تنظيم وزارة الصحة العامة)

بناء على ضرورات المصلحة العامة وبعد اطلاق السجل الوطني للسرطان وحرصا على تغطية جميع الحالات السرطانية في لبنان من خلال المصادر المختصة

بناء على اقتراح مدير عام الصحة

يقرر ما يلي:

المادة الاولى: يطلب الى كافة الاطباء الاختصاصيين في مجال امراض: (التورم الخبيث - الدم – الباثولوجيا – وعلم الانسجة – امراض التورم الخبيث عند الاطفال – التشخيص الشعاعي والعلاج بالاشعة) عند اكتشاف اية حالة سرطانية ضرورة الابلاغ عنها اعتبارا من 1 كانون الثاني 2002.

المادة الثانية: تعتمد الاستمارة المرفقة بالقرار للابلاغ عن حالات السرطان والخاصة بالسجل الوطني للسرطان.

المادة الثالثة: يطلب من نقابتي اطباء لبنان (بيروت والشمال) متابعة تنفيذ القرار و اتخاذ الاجراءات المناسبة بحق الاطباء المتخلفين عن تطبيقه.

المادة الرابعة: تعدل استمارة الابلاغ بقرار من وزير الصحة العامة.

المادة الخامسة: يبلغ القرار حيث تدعو الحاجة.

وزير الصحة العامة

سليمان فرنجية

الجمهورية اللبنانية
وزارة الصحة العامة
الوزير

رقم المحوظات: 5/4 – 1/202
بيروت في 12 نيسان 2013

قرار رقم 1/410
يتعلق بالابلاغ عن حالات مرض السرطان (الورم الخبيث) المشخصة حديثا

ان وزير الصحة العامة،
بناء على المرسوم رقم 5818 تاريخ 13 حزيران 2011 (تشكيل الحكومية).
وحيثان مرض السرطان يشكل ثاني سبب من اسباب الوفيات في لبنان،
وحيث ان مكافحة مرض السرطان يتطلب معطيات دقيقة حول المرض وتوزيع الحالات حسب الخصائص الديموغرافية والوبائية والخصائص الطبية ومقارنة نسب الحدوث،
وحيث ان هذه المعلومات لا يمكن الحصول عليها الا عبر تعزيز السجل الوطني للسرطان،
وحيث ان سجل السرطان الوطني يرتكز على الابلاغ من قبل الاطباء والمستشفيات ومختبرات الانسجة ومختبرات الدم،

يقرر ما يلي:

المادة الاولى: يطلب من كافة الاطباء الاختصاصيينالعاملين على الاراضي اللبنانية، والذين يقومون بتشخيص وعلاج مرض السرطان، بالابلاغ عن اي حالة مرض السرطان تم تشخيصها في السنة الى وزارة الصحة العامة / برنامج الترصد الوبائي / السجل الوطني للسرطان.

المادة الثانية: تعرف الحالة كالتالي: اي حالة تم تشخيصها خلال العام مخبريا ورم خبيث. تشمل التعريف حالات الورم in-situ ، كما تشمل حالات سرطان الجلد non-melanoma skin cancer.

المادة الثالثة: يتم الابلاغ عن الحالات الفردية عبر ملء الاستمارة المرفقة. تشمل الابلاغات المرضى اللبنانيين وغير اللبنانيين.

المادة الرابعة: ترسل الاستمارات الى فريق برنامج الترصد الوبائي في المحافظة في كل من محافظات الشمال، البقاع، الجنوب والنبطية. اما في محافظتي جبل لبنان وبيروت، فترسل الاستمارات مباشرة الى الوحدة المركزية للترصد الوبائي.

المادة الخامسة: الابلاغ اسمي nominative. ويتم اعتماد الاسم الثلاثي عند الولادة. الابلاغ الاسمي يسمح بالكشف عن الحالات المتكررة ليتم سحبها من التحليل الوبائي. كما تقوم وزارة الصحة العامة بضمانة السرية المهنية والطبية. وتطبق السرية على اسم المريض، اسم الطبيب واسم المستشفى / المختبر.

المادة السادسة: يطلب من المستشفيات الحكومية والخاصة العاملة على الاراضي اللبنانية تسمية ضابط اتصال لسجل السرطان. يقوم ضابط الاتصال بالتنسيق مع الاطباء والمختبرات واالارشيف الطبي بغية جمع الاستمارات والتاكيد من تعبئتها وارسالها الى وزارة الصحة العامة. تقوم المستشفى بابلاغ وزارة الصحة العامة عن اسم ضابط الاتصال وطريقة التواصل معه.

المادة السابعة: تقوم وزارة الصحة العامة بنشر المعطيات على موقع وزارة الصحة العامة على الانترنت:
www.moph.gov.lb (→prevention, → surveillance, → cancer)
or moph.gov.lb/prevention/surveillance/pages/cancer.aspx

المادة الثامنة: يبلغ هذا القرار حيث تدعو الحاجة%

وزير الصحة العامة
علي حسن خليل

الجمهورية اللبنانية
وزارة لصحة العامة
الوزير

رقم المحفوظات: 1/9–2/4
بيروت في 21 تشرين الاول 2009

قرار رقم 1/994
تعديل لجنة السجل الوطني للسرطان

ان وزير الصحة العامة

بناء على المرسوم رقم 18 تاريخ 11 تموز 2008.

بناء على المرسوم رقم 8377 تاريخ 30 كانون الاول 1961 وتعديلاته (تنظيم وزارة الصحة العامة).

بناء على قرار رقم 1/511 تاريخ 23 تموز 2003 (الزامية الابلاغ عن اية حالة سرطانية).

بناء على ضرورات المصلحة العامة وبهدف متابعة اعمال السجل الموحد لجمع المعلومات المتعلقة بالامراض السرطانية في لبنان،

بناء على اقتراح مدير وزارة عام الصحة،

يقرر ما يلي:

المادة الاولى: تعدل اللجنة المؤلفة بموجب القرار رقم 1/230 تاريخ 4 تموز 2005 لتصبح على الشكل التالي:

– الدكتور وليد عمار	رئيسا
– الدكتور علي شمس الدين اختصاصي أمراض سرطان	نائب رئيس
– الدكتور اسعد خوري مدير الوقاية الصحية	عضوا
– رئيس الجمعية اللبنانية لأطباء التورم الخبيث	عضوا
– مندوب عن منظمة الصحة العالمية	عضوا
– مندوب عن الاتحاد اللبناني ضد السرطان	عضوا
– مندوب عن الجمعية اللبنانية للباتولوجيا	عضوا
– مندوب عن الجمعية اللبنانية لأمراض الدم	عضوا
– مندوب عن الجمعية اللبنانية للوبائيات	عضوا
– الدكتورة ندى غصن رئيسة دائرة الترصد الوبائي	عضوا مقررا
– الدكتورة فاديا الياس اختصاصيأامراض سرطانية	عضوا
– الدكتورة رشا حمرة رئيسة دائرة التثقيف والارشاد الصحي بالانابة	عضوا

وتستعين اللجنة لتسيير اعمالها بمن تراه مناسبا من اصحاب الخبرات في هذا المجال.

المادة الثانية: تبقى المواد الاخرى الواردة في القرار 1/230 دون تعديل.

المادة الثالثة: يبلغ هذا القرار حيث تدعو الحاجة.

وزير الصحة العامة

د. محمد جواد خليفة

Republic of Lebanon
Ministry of Public Health
Drugs Committee/ESU
MPH12-3

الجمهورية اللبنانية
وزارة الصحة العامة
لجنة الأدوية/ وحدة الترصد الوبائي

Antineoplastic Drugs / National Cancer Registry

NCR ID[1]: Karantina ID:

Patient Information

اسم المريض: _____ اسم الاب: _____ اسم الام: _____ الشهرة عند الولادة: _____
شهرة الزوج: _____ الجنس: ☐ذكر ☐ انثى تاريخ الولادة: _____ رقم السجل: _____
محل الولادة:
البلد: _____ القضاء: _____ البلدة: _____
عنوان السكن الدائم:
البلد: _____ القضاء: _____ البلدة: _____ هاتف: _____
الجنسية: _____ الاقامة في لبنان: ☐مقيم☐زائر☐لاجئ

Tumor Registry Information

Primary site (text): _____ **Date first diagnosis:_ _ / _ _ / _ _ _ _**
ICD-10: C _ _ . _ ICDO3-topo: C _ _ .._
Laterality: ☐ Right ☐ Left ☐ Bilateral ☐ Not applicable ☐ Unspecified
Pathology (text): _____ ICDO3-Morphology: M_ _ _ _ / _
Pathology Center: _____ Pathologist : _____
Classification: **TNM**[2]:T _ N_ M _ **Stage**[3]: _ _ **Grade**: _ _ _ _ Other Staging: _ _ _ _
Type of report: ☐ New case
☐ Known case
For known case: ☐ Relapse →☐ Local ☐ Regional ☐ Distal
☐ Progression
☐ Change of treatment

Treatment

Finality of treatment: ☐ Palliative ☐ Other
Prior Chemotherapy Treatment: ☐ No ☐ Yes[4] Specify: _____
Type of treatment planned:

Surgery:	☐ No	☐ Yes
Chemotherapy[5]:	☐ No	☐ Yes
Radiotherapy:	☐ No	☐ Yes
Targeted therapy:	☐ No	☐ Yes
Immunotherapy:	☐ No	☐ Yes
Hormone therapy:	☐ No	☐ Yes

Physician Information

Physician Name: _____ LOP Registration No.: _____
Specialty: _____ Telephone: _____

Date: Signature & stamp:

(1) For reporting to National Cancer Registry, form is sent to Epidemiological Surveillance Program (fax:01-610920, email: esumoh@moph.gov.lb)
(2) TNM classification is based on pathology results.
(3) Documented evidence should be submitted for stage IV.
(4) Copy of Drugs Dispensing Center Patient Card should be submitted (if applicable).
(5) If neoadjuvant chemotherapy, please specify date of treatment.

Documents to be submitted: ☐Physician's prescription (dosage &schedule); ☐Detailedmedical report; ☐Pathology report (solid tumor); ☐Laboratory report (blood tumor).

N.B.: This form must be completed by the Doctor. All Documents should be attached. All attached reports and studies should be original and official. Written enquiries are only accepted: attached to the medical file or sent by e-mail: drugs@moph.gov.lb